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ABSTRACT 
Sarah Schweitzer Cohen: Select Environmental and Genetic Determinants of Adiponectin 
and Obesity in Black and White Women 
(Under the direction of Marilie D. Gammon) 
 
Using interview data and blood samples collected at baseline from the Southern Community 
Cohort Study, this cross-sectional study examined serum adiponectin levels in relation to 
select environmental and behavioral factors.  Several single nucleotide polymorphisms 
(SNPs) in three adiponectin-related genes (ADIPOQ, ADIPOR1, and ADIPOR2) were also 
examined in relation to adiponectin and body mass index (BMI).  Multivariate linear 
regression models were used to evaluate the association between adiponectin and BMI 
separately for white and black women.  Prediction models for adiponectin for black and 
white women were also developed using multiple linear regression.  Associations between 
SNPs in ADIPOQ, ADIPOR1, and ADIPOR2 in relation to adiponectin and BMI were 
examined in linear regression models with adjustment for age and percentage of African 
ancestry to account for population stratification.  Black women were found to have lower 
adiponectin levels compared with whites even after adjustment for body mass index (BMI).  
These results expand upon previous studies that were limited by small sample sizes or narrow 
age and body size ranges and demonstrate that racial differences in adiponectin exist across 
the spectrum of BMI.  In the examination of predictors of adiponectin beyond BMI, the 
factors age, HDL-cholesterol, and hypertension were found to be strong correlates of 
adiponectin in both race groups.  In the genetic analyses, one SNP (rs17366568) in ADIPOQ 
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was found to be significantly associated with adiponectin in white women but not in black 
women.  This finding confirms results from two recent genome-wide association studies in 
European whites by demonstrating significant differences in adiponectin levels across 
genotypes of SNP rs17366568 and expands the current literature by examining this SNP in 
black women for the first time.  No significant associations were observed between any of 
the SNPs in the three adiponectin-related genes and BMI.  Observed racial differences in 
adiponectin and its correlates from this study will be utilized in future studies of diseases 
potentially affected by adiponectin such as cancer, cardiovascular disease, and type 2 
diabetes.  In addition, the development of lifestyle interventions as well as therapeutics that 
increase adiponectin levels for the purpose of disease prevention may be guided by results of 
this study. 
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 CHAPTER 1: BACKGROUND 
 
Brief introduction to background and specific aims 
The rapid increase in the prevalence of obesity in the United States in the past 30 years has 
many health implications.  Obesity is strongly associated with incidence and mortality of 
several common cancers including post-menopausal breast cancer, colorectal cancer and 
endometrial cancer (1). In addition, obesity is a major risk factor for coronary artery disease, 
type 2 diabetes, hypertension, and stroke (2).  Obesity patterns in the United States vary 
substantially by race with black women having a higher prevalence of obesity than white 
women (3).  Additionally, black women experience higher incidence and mortality for many 
common cancers (4) and cardiovascular disease (5).   
 The proteins known as adipokines are produced largely in adipose tissue and may 
play a differential role in the development of obesity in black compared to white women (6, 
7).  Several of these proteins were discovered relatively recently and remain largely 
unstudied in blacks.  The research presented here focused on adiponectin, an adipokine that 
holds great promise to elucidate links between race, obesity, and, ultimately, cancer and 
cardiovascular disease incidence and mortality (8, 9).  A better understanding of the role of 
adiponectin in relation to obesity and race will provide hypotheses to be tested in the future 
regarding the environmental and genetic determinants of obesity as they relate to disease risk 
in both black and white women. 
 Adiponectin was first characterized in the mid-1990s.  Since that time, several single 
nucleotide polymorphisms (SNPs) in the gene that encodes adiponectin (ADIPOQ) and the 
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genes encoding the adiponectin receptors (ADIPOR1 and ADIPOR2) have been identified 
and examined in association with measures of body size and other metabolic outcomes.  
However, few studies have included sufficient numbers of black subjects to assess whether 
the observed associations differ across racial groups. Adiponectin levels have also been 
shown to be negatively correlated with obesity, insulin resistance, and type 2 diabetes.  
Again, though, few studies have examined associations between blood levels of adiponectin 
and body size or metabolic disorders in black women.  This work was the first to characterize 
environmental factors (such as physical activity, energy and nutrient intake, reproductive 
factors, alcohol consumption, smoking, and co-morbid conditions) and genetic 
polymorphisms in ADIPOQ, ADIPOR1, and ADIPOR2 in relation to adiponectin levels and 
obesity in a large sample of healthy black and white women.    
 This research included cross-sectional analyses of baseline interview data and blood 
samples collected at enrollment into the Southern Community Cohort Study (SCCS) from 
2,000 black and white women.  The SCCS is a prospective cohort study designed to 
understand racial disparities in cancer incidence and mortality in the southeastern United 
States, particularly among understudied groups such as low-income and rural residents (10).  
The SCCS is ideal for examining environmental and genetic risk factors for adiponectin 
levels and obesity as they differ by race because a considerable amount of demographic and 
lifestyle data as well as blood samples were collected for a large number of black and white 
women from similar geographic and socioeconomic backgrounds.  A sample of 1,000 black 
and 1,000 white women, stratified by body mass index (BMI) and menopausal status, was 
selected from the SCCS study population to evaluate the specific aims of this study, which 
are outlined below.   
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Specific Aims 
Specific Aim 1: Determine whether adiponectin levels among black women as compared to 
white women are associated with BMI and environmental and behavioral factors including 
physical activity, energy and nutrient intake, alcohol consumption, smoking, reproductive 
factors, and co-morbid conditions. 
Specific Aim 2: Determine whether adiponectin levels among black women as compared to 
white women are associated with genetic polymorphisms in tag-SNPs in the ADIPOQ, 
ADIPOR1 and ADIPOR2 genes and, in exploratory analyses, interactions between 
environmental factors and genetic polymorphisms in the ADIPOQ, ADIPOR1 and ADIPOR2 
genes. 
Specific Aim 3: Determine whether BMI among black women as compared to white women 
are associated with genetic polymorphisms in tag-SNPs in the ADIPOQ, ADIPOR1 and 
ADIPOR2 genes; and in exploratory analyses, interactions between environmental factors 
and genetic polymorphisms in the ADIPOQ, ADIPOR1 and ADIPOR2 genes. 
Definition and measurement of obesity 
Obesity, defined at the most basic level, is simply an excess of accumulation of body fat (11).  
This excess results from an imbalance in energy consumption and expenditure, resulting in 
enlarged fat cells (also known as adipose cells) as well as an increase in the number of 
adipose cells (12).  The major sites for adipose tissue storage are both within the abdominal 
cavity (known as abdominal or visceral fat) and just under the skin (known as subcutaneous 
fat).  Visceral fat tends to accumulate with age and is more strongly associated with 
metabolic disorders and cardiovascular disease (13). 
There is little agreement on the best way to measure obesity accurately in either 
clinical settings or in large-scale research studies.  In epidemiologic studies, obesity is most 
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often measured by BMI because the component measures (height and weight) are easily 
obtained via self-report from study participants or from inexpensive and easy-to-use tools 
(11, 14).  BMI is calculated as the weight in kilograms divided by the square of height in 
meters.   Standard categories of BMI have been put forth by the World Health Organization 
and include underweight (BMI < 18.5 kg/m2), healthy weight (BMI 18.5-24.9 kg/m2), 
overweight (BMI 25.0-29.9 kg/m2), obesity class I (BMI 30.0-34.5 kg/m2), obesity class II 
(BMI 35.0-39.9 kg/m2) and obesity class III or extreme obesity (BMI > 40.0 kg/m2) (15).  
BMI has excellent validity as a measure of absolute fat mass adjusted for height (14), and the 
widely used, standardized cut-points established for BMI categories allow for ease of 
comparison across studies (15, 16).  However, the calculation of BMI includes a 
measurement of body weight which is made up of both lean body mass and fat tissue.  Thus, 
BMI is a less valid measure for percent body fat than other measures that account for 
differences in the proportion of each type of body tissue (14). 
Other measures to assess body composition include densitometry (under-water 
weighing) as well as newer techniques such as dual energy X-ray absorptiometry (DEXA), 
bioelectrical impedance analysis (BIA), and computed tomography (CT)/magnetic resonance 
imaging (MRI).  Densitometry requires that an individual be submerged in water.  By 
measuring the ratio of body weight measured in air and body weight measured under water, 
an estimate of the proportion of fat in the total body mass can be calculated (14).  DEXA 
uses an x-ray with low and high-energy peaks to distinguish fat mass, fat-free mass, and bone 
mineral mass in the whole body or by specific region (such as in the abdomen)  (14).  DEXA 
is not able to distinguish visceral fat from subcutaneous fat (17).  BIA involves sending a 
weak electrical current through the body and measuring its impedance by muscle tissue; 
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because muscle is composed mainly of water and fat tissue contains virtually no water, the 
impedance values can be used to estimate percentage body fat (14).  CT and MRI are 
considered to be the most accurate methods for assessing body composition including the 
quantification of visceral versus subcutaneous fat (17).  However, these three measures all 
require expensive equipment, specialized technicians, and can be time-consuming to perform 
on a large number of individuals, and thus are not widely used in epidemiologic research. 
Distribution of body fat, not just the total amount, has also been shown to be related 
to health risks.  While fat distribution can be measured using imaging tools such as DEXA 
and CT/MRT, waist circumference and waist-to-hip ratio (WHR) are also used to measure 
differences in fat tissue distribution and has been used frequently in epidemiologic studies 
because the required measurements are inexpensive and quick to obtain.  One limitation of 
these measures is that many factors can affect the measurement of waist and hip 
circumferences including the degree of training of the individual making the measure, the 
time of day, and timing of the most recent meal (14) 
In addition to the limitations of the measures of obesity described above, another 
level of complication arises when obesity is measured in individuals of different racial or 
ethnic backgrounds.  Reports in the literature are not entirely consistent but many studies 
have concluded that commonly used measures of obesity have different meanings for whites 
and blacks, likely due to differences in fat distribution.  Several studies report that for a 
similar waist circumference and BMI, blacks have less visceral fat than whites (13, 18).  For 
example, the hip circumferences of blacks have been found to be smaller than those in 
whites, resulting in an increased WHR for a given amount of central fat (11).  Evans et al. 
also reported that the relationship between BMI and percent fat measured by DEXA differs 
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by race with black women having lower body fatness than white women at the same BMI 
(19).  In contrast, Gallagher and colleagues found that BMI reflected the same level of 
fatness in black and white adults with BMI < 35 kg/m2 after age and sex adjustment (20).  
Differences also exist between blacks and whites with respect to fat-free body mass with 
blacks generally having more bone mineral density and body protein than whites (21). 
While tools such as under-water weighing, DEXA, and MRI are among the current gold 
standards for measuring body fatness, they are impractical in terms of cost and logistics for 
most large epidemiologic studies.  Ultimately, in a large study such as the Southern 
Community Cohort Study, the only cost-efficient approach to measuring body size is to use 
measurements that are readily obtained with minimal equipment and time such as self-
reported height and weight or interviewer measured height, weight, and perhaps waist and 
hip circumferences.  
Racial differences in obesity prevalence 
Based on measured height and weight data from the National Health and Nutrition 
Examination Surveys (NHANES), the prevalence of obesity among American adults began 
increasing rapidly in the late 1970s and early1980s (3).  The prevalence of obesity (defined 
as a body mass index [BMI] > 30 kg/m2) among women in NHANES from 1988-1994 was 
25.4% and increased to 33.4% in the NHANES data from 1999-2000 (22).  In the 2007-2008 
NHANES, the prevalence of obesity among women was 35.5%, representing a much slower 
increase than seen in the previous two decades (3).  In addition to the rapid rate of increase in 
the obesity prevalence among women overall in the past thirty years, there is strong variation 
in the prevalence of obesity by race.  NHANES data from 2007-2008 show that 33.0% of 
white women were obese compared to 49.6% of black women (3).  In relation to the 1988-
1994 estimates, this corresponds to a 10.1% prevalence increase for white women and an 
  7
11.4% increase for black women.   Differential increases in the prevalence of extreme obesity 
(BMI > 40 kg/m2) by race were even more pronounced with the prevalence increasing from 
3.4% to 6.4% among white women and from 7.9% to 14.2% among black women between 
the NHANES surveys covering 1998-1994 and 2007-2008 (3, 22). 
Environmental and behavioral determinants of obesity 
It is likely that genetic factors contribute to the ability of humans to store excess fat when 
food is abundant and to lose fat when food is scarce (23).  However, the recent increase in 
obesity among American women, as well as in other populations around the globe, is 
unlikely to be explained solely by genetics because it has happened over such a short period 
of time. Thus, individual-level behavioral and environmental factors are also thought to be 
strong contributors to obesity including physical activity levels, energy and nutrient intake, 
reproductive patterns, and socioeconomic status (24-27).  Population-level characteristics 
related to changes in occupations and infrastructure (such as changing modes of 
transportation) are also likely important influences on the development of obesity but are 
beyond the scope of this dissertation.   
Physical activity  
The modern environment does not require nor encourage physical activity for most adults 
(28).  The Centers for Disease Control and the American College of Sports Medicine 
recommend that adults engage in at least 150 minutes per week of moderate-intensity 
physical activity (29) but data from the Behavioral Risk Factor Surveillance System (BRFSS) 
finds that more than half of US adults do not meet PA recommendations based on activity 
patterns in three domains (household work, transportation, and discretionary/leisure time) 
(29, 30).  Many reasons are cited for the overall lack of physical activity among US adults 
including emotional barriers such as lack of time, lack of motivation, and lack of social 
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support as well as physical barriers such as lack of access to facilities and unsafe 
neighborhood conditions (31-33).   
Physical activity patterns by race have been extensively examined but there is inconsistency 
in the literature.  Many studies have found blacks are less physically active than whites (34-
36), in some cases, beginning as early as adolescence (37).  However, other studies have 
found no evidence for differences in physical activity levels across racial groups.  Using data 
from the Health and Retirement Study, He and Baker found that leisure-time physical activity 
did not differ between blacks and whites after adjustment for education and health status 
(38).  Similarly, Marshall and colleagues found that within strata of social class (including 
education, income, employment status, and marital status), there were few differences in the 
prevalence of physical inactivity between white and black women (39).   
Energy and nutrient intake  
Energy intake that exceeds the energy needs of the body has been shown in controlled studies 
to cause weight gain in the form of stored fat (40).  However, the role of particular dietary 
factors as determinants of obesity is much less clear.  Several methodological problems have 
been identified in studies of diet and obesity including short time periods of measurement, 
correlations between dietary factors and other determinants of obesity such as physical 
activity, and the validity and reliability of the tools used to measure dietary intakes (40).  
Despite these limitations, ecologic, observational, and intervention studies have identified 
links between obesity and the consumption of fats, high-fructose corn syrup, fast food, and 
snack foods (41-44). Recently, Drewnowski set forth a single explanation for these findings, 
namely that the consumption of low-cost foods which contain refined grains, added sugars, 
and added fats, explain the many links observed between weight gain and individual foods on 
a population level (45).  This hypothesis is consistent with the increased risk of overweight 
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and obesity among black women who are disproportionately of lower SES than white 
women.   
Reproductive factors  
There may also be important racial differences in reproductive factors that affect the 
prevalence of obesity.  While the role of parity in the development of obesity remains 
somewhat uncertain (46, 47), several studies have indicated that increasing parity is 
associated with an increase, albeit modest, in the risk of obesity (48-52).  In the few studies 
with sizable numbers of black women, it has been observed that black women appear to be 
more susceptible to weight gain following pregnancy than white women (53, 54).  For 
example, black women were found to retain more weight post-partum than white women at 
similar levels of gestational weight gain (53).  A recent analysis that stratified women by 
metropolitan status found that the effect of increased parity was significant only in black 
women living in metropolitan areas but not black women living in non-metropolitan areas 
(55).  A cross-sectional study using data from the Southern Community Cohort Study found 
a modest increase in the odds of obesity among both white and black women having five or 
more births compared to nulliparous women (56).  In addition, black women have more 
children on average than white women (57) and some studies have indicated that high levels 
of parity are most strongly associated with obesity (49, 50, 58).  Further, differences in the 
prevalence and length of breast-feeding exist with black women being less likely to 
breastfeed compared to white women (59, 60).  Some studies have reported that breast-
feeding is associated with a small decrease in weight retention post-partum (61, 62) which in 
combination with a lower prevalence of breastfeeding among blacks could contribute to the 
disparity in the prevalence of obesity.   
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Smoking 
A strong negative correlation has been consistently observed between cigarette smoking rates 
and obesity (63).  This association is explained by the appetite suppressing effect of nicotine, 
one of many components in tobacco.  By suppressing appetite, smokers are believed to 
decrease food intake and thus have lower overall body size compared to non-smokers (63). 
Alcohol consumption 
Mechanistically, alcohol consumption is thought to lead to an increase in food intake because 
of its relatively high contribution of kilocalories (7 kcal/g), its relaxing effect on the nervous 
system, and its minimal effect on satiety (64).  While most epidemiologic studies have shown 
that energy from alcohol is added to energy from food intake without any compensation for 
the extra calories provided by alcohol, associations between alcohol intake and obesity have 
been observed less consistently (65).  Among British men, increasing alcohol intake was 
associated with general obesity (as measured by BMI) and even more strongly with central 
obesity (as measured by waist-to-hip ratio and waist circumference) (66).  These results, in 
light of conflicting reports in the literature regarding associations between obesity and 
alcohol indicate a need for future research based on fat distribution and alcohol consumption.  
Socioeconomic status 
Underlying many of the observed associations between environmental and behavioral 
characteristics and obesity is the issue of socioeconomic status (SES).  In a descriptive 
review of the literature regarding obesity and SES, McLaren reported that in resource-rich 
countries, such as the US, lower SES was associated with larger body size among women in 
nearly two-thirds of the reviewed studies (67).  Racial differences in BMI have been found to 
be only partially explained by measures of SES such as education and income (68-71).  
Wang and Beydoun (69) hypothesize that a major reason for this finding is that factors such 
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as body image, lifestyle, social structure, and physical environment are responsible for much 
of the racial difference in body size and that these constructs are not adequately accounted 
for by adjustment for standard SES measures such as education and income.  Clearly, careful 
attention to measurement and adjustment for SES is imperative in untangling associations 
between race, obesity, and environmental and behavioral characteristics.   
Summary 
Links between Individual-level behavioral and environmental determinants of obesity are 
depicted in Figure 1.1.  As described above, many factors affect obesity in adults and these 
factors are often associated with one another. 
Genetic determinants of obesity 
 Given that the prevalence of obesity has risen quickly in only a few decades, it is 
likely that environmental factors are largely responsible.  However, well before the 
occurrence of the recent rapid increase in the prevalence of obesity, a small but stable 
proportion of the population was obese.  In the NHANES from 1960-1962, the prevalence of 
obesity among women age 20-74 was 15.8%.  A decade later, in NHANES 1, the prevalence 
was only slightly higher at 16.6% (22).  The presence of a small but consistent group of 
individuals with increased body size that existed before the pro-obesigenic environmental 
changes in recent decades indicates that genetics plays an important role in the development 
of obesity in at least some individuals. 
Further strengthening the hypothesis that obesity has strong genetic determinants is 
that obesity has been found to be highly heritable.  A recent review of the literature regarding 
the genetic epidemiology of obesity reports heritability estimates from twin, adoption, and 
family studies ranging from 16 to 85% for BMI (72). Thus, the genetic underpinnings of 
obesity are an important component of a complete understanding of obesity.  Genetic variants 
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may also play an important role in determining which individuals are susceptible to obesity 
in an environment of abundant, energy-dense food and low physical activity levels (23, 72, 
73). 
Common obesity (as opposed to obesity related to a rare Mendelian disorder) is an 
example of a complex disease that may follow either the ‘common disease/common variant’ 
(CD/CV) paradigm or the ‘common disease/rare variant’ (CD/RV) paradigm, and the 
scientific community remains divided as to which scenario best describes the genetic 
underpinnings of obesity (74).  The CD/CV paradigm says that common, complex diseases 
are likely due to disease loci which have one or only a few variants that occur with a high 
frequency in the population (75-78).   The CD/RV paradigm is similar to the CD/CV 
paradigm in that both are attempts to explain the genetic basis of complex diseases and both 
recognize that multiple disease loci are likely to be involved.  However, the CD/RV 
paradigm says that instead of disease risk being due to disease loci with a few common 
variants occurring at high frequency in the population, disease risk is due instead to many 
loci each with multiple variants with low population frequency (74, 77).  The CD/CV 
paradigm suggests that common mutations are generally found in multiple human 
populations while the CD/RV paradigm suggests that mutations may be population-specific 
(76).  Depending on the true underlying genetic structure of obesity, different types of studies 
(linkage versus association) will have varying degrees of success.  For example, association 
studies are likely to be successful only if the CD/CV paradigm is correct because effect 
estimates for disease risk are modest in magnitude and require ample sample size for the 
statistical signal to be detected (76, 77). 
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Loci linked to BMI have been found on all chromosomes except Y via linkage studies 
(including genome-wide linkage studies); however, very few regions have been replicated 
(72, 79).  Linkage analysis has proven very useful for identifying genes for monogenetic 
diseases but limited power and the challenges of obtaining family-based data have 
contributed to less success for linkage studies of common complex diseases (72); thus few 
validated genes for obesity-related phenotypes have been identified via linkage studies.   
In contrast, the vast majority of studies showing associations between obesity and specific 
genes have been association studies (72).  In a 2007 review of the genetic epidemiology of 
obesity, Yang et al. report that 426 findings of positive associations in 127 candidate genes 
have been identified to date, and that 22 of these genes have been supported by at least five 
positive studies (72).  The advent of genome-wide association studies (in which several 
hundred thousand SNPs are genotyped for each study subject and examined for association 
with the outcome of interest) has increased the identification of potentially important genes 
in relation to obesity that were not previously identified by the candidate gene approach.  For 
example, in 2007, FTO, a gene not previously identified as being associated with obesity, 
was identified via a genome-wide association study (80) and replicated by other groups (81, 
82). 
Lack of replication in both linkage and association studies is a serious concern and 
may be due to issues such as high rates of false positives, lack of amply powered study 
samples, and insufficient attention to the potential for population stratification (72).  
Relatively small sample sizes have precluded previous studies from being able to examine 
gene-gene and gene-environment interactions (such as with physical activity and dietary 
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patterns), limiting our ability to understand fully the role that genetics plays in the 
development of obesity (72).   
Associations between obesity and chronic disease 
Cancer risk   
This project sought to further our understanding of associations between environmental and 
genetic factors and obesity.  Long range, an important goal of the SCCS is to gain a better 
understanding of cancer risk as it relates to obesity in different racial groups because obesity 
is one of the few modifiable risk factors for many cancer sites.  This work is particularly 
important because of the higher prevalence of overweight and obesity among black women 
and observed disparities in cancer mortality for several common sites.  For example, the 
mortality rate for breast cancer in the US in 2005 was 23.3 per 100,000 women among whites 
and 32.8 per 100,000 women among blacks (83).   Similarly for colorectal cancer, the 
mortality rate among whites in 2005 was 14.1 per 100,000 compared to 21.2 per 100,000 
among blacks (83).  This project was unique because with obesity as a focus, the results of 
this study will assist in the generation of research hypotheses to be tested in the future in the 
SCCS and other studies in relation to multiple cancer sites.  Thus a brief description of 
obesity and a select group of cancers based on either population burden or strength of 
evidence are provided here.    
Obesity is associated with incidence and mortality for several of the most common 
cancer sites (1, 84-86).  In the Cancer Prevention Study II (CPS II), including 495,477 
women followed for 16 years, the relative risk for all cancer mortality was 1.62 (1.40-1.87) 
comparing women with a BMI of > 40 kg/m2 to women with a BMI between 18.5 and 24.9 
kg/m2 (86).  Among the women in the CPS II, obesity was found to be associated with 
cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, kidney, breast, 
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uterus, cervix, and ovaries with RRs ranging from 1.46 (0.94-2.24) for colorectal cancer to 
6.25 (3.75-10.42) for the uterus (86).  The 2002 report on Cancer Prevention, Weight 
Control, and Physical Activity from the International Agency for Research on Cancer 
(IARC) concludes that, based on a comprehensive evaluation of the literature, there is 
sufficient evidence for a cancer-preventive effect of avoidance of weight gain for colon, post-
menopausal breast cancer, endometrial cancer, kidney, and esophageal cancers (87).   
Obesity is an established risk factor for breast cancer (88) and the association has 
been found to differ by menopausal status (89). Among premenopausal women, obesity has 
generally been found to be inversely associated with breast cancer risk (89, 90).  In a meta-
analysis, Ursin and colleagues found reductions in the relative risk (RR) for breast cancer 
among four cohort studies (RR for 8 kg/m2 reduction in BMI=0.70, 95% CI=0.54-0.91) and 
19 case-control studies (RR for 8 kg/m2 reduction in BMI=0.88, 95% CI=0.76-1.02) 
although the individual study estimates were quite heterogeneous (91).  More recently, in the 
Pooling Project of Diet and Cancer, a pooled analysis of seven large prospective studies, the 
RR for breast cancer among women with a BMI > 33 kg/m2 was 0.58 (95% CI=0.34-1.00) 
compared to women with a BMI < 21 kg/m2.  A similar reduction in the RR was seen for 
women with a BMI between 31 and 33 but not for women with a BMI below 31 (92).  
Additional studies have found similar results although variation is evident when different 
measures of obesity, such as waist-to-hip ratio versus BMI, are considered (89).  Notably, 
these studies have almost entirely been conducted in white women (93).   
In contrast, among postmenopausal women, increased body size is positively 
associated with breast cancer risk (89, 90).  In the same pooling project analysis described 
above, the RR for breast cancer among postmenopausal women with a BMI greater than 28 
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kg/m2 was 1.26 (95% CI=1.09-1.46) compared to women with a BMI < 21 kg/m2.  A 
stronger positive association with obesity was seen among women who had never used 
hormone replacement therapy (HRT) (92).  In the Women’s Health Initiative cohort, 
evidence of effect measure modification by HRT was also seen with obesity found to be a 
risk factor for breast cancer among non-users of HRT but not among women who had ever 
used HRT (94).  Positive associations between adult weight gain and breast cancer risk as 
well as central adiposity and breast cancer risk have been consistently reported as well (89, 
90). 
Consistent evidence also exists to link colorectal cancer and obesity (1). In the 2002 
IARC report, relative risks for colorectal cancer in obese women were reported to be 
approximately 1.2-1.5 (87). The observed relative risks are generally lower in women than in 
men (1, 95) but the coupling of colorectal cancer as the third most common incident cancer 
among women (4) and the high prevalence of obesity in the United States makes even 
modest relative risks such as these an important public health concern.  Some authors have 
suggested that the weak associations seen for women are due to effect measure modification 
by menopausal status or estrogenic effects (96, 97).  In a cohort of nearly 90,000 women in 
Canada, the RR for colorectal cancer in the entire cohort was 1.08 (95% CI 0.82-1.41) but 
differed significantly for premenopausal women (RR=1.88, 95% CI=1.24-2.86) and post-
menopausal women (RR=0.73, 95% CI=0.48-1.10) (96).  Similar results were seen in a 
population-based case-control study of colon cancer in California, Utah, and Minnesota with 
an RR of 2.19 (95% CI=0.94-5.07) for premenopausal women (comparing women with a 
BMI >30 to women with a BMI <23) and an RR of 1.29 (95% CI=0.93-1.73) for 
postmenopausal women.  These authors also stratified women based on estrogen status (with 
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positive status describing women who were either premenopausal or were postmenopausal 
and taking HRT, and negative status including postmenopausal women not taking HRT).   
Estrogen-positive women had an RR of 2.50 (95% CI=1.51-4.13) for colorectal cancer while 
estrogen-negative women had an adjusted RR of 0.96 (95% CI=0.65-1.41) (97).  The 
possibility of effect measure modification by menopausal status or estrogen level has been 
inconsistent, though. In the Women’s Health Study which examined nearly 40,000 women, 
BMI was found to be positively associated with increased colorectal risk overall.  However, 
in analyses of postmenopausal women, the relationship was not modified by estrogen 
exposure (98).   
In a 2005 review of all English-language literature published between 1969 and 2004, 
Modessitt and colleagues found that the most consistent finding linking obesity and cancer is 
for endometrial cancer (99).  These authors report a three- to tenfold increase in endometrial 
cancer risk associated with obesity.  In a larger review of obesity and cancer, Calle and Thun 
reported that evidence from both case-control and cohort studies showed an increase in risk 
of endometrial cancer for overweight or obesity to be in the range of two- to fourfold (1).  
Two major types of endometrial cancer are distinguishable with the more common (80%) 
endometrioid carcinomas being more strongly associated with obesity than the rarer serous 
papillary, clear cell, or squamous carcinomas (100).  However, many studies have not been 
able to examine associations with obesity by subtype (99, 100). 
Cardiovascular disease risk  
Obesity is a major risk factor for both cardiovascular disease (CVD) morbidity and mortality.  
Despite some controversy regarding the exact shape of the overall BMI-mortality curve, the 
preponderance of evidence points to an elevated risk of death from CVD among obese 
individuals.  Using NHANES I,II, and III data, Flegal et al. reported relative risks that were 
  18
consistently above 1.0 for all cardiovascular disease mortality among obese (BMI > 30 
kg/m2) individuals (101).  These authors attributed between 9 and 13% of total CVD 
mortality to obesity although they noted that the association between CVD mortality and 
obesity may have been decreasing over time (101).  In the Framingham Heart Study, 
similarly elevated relative risks for cardiovascular death were found among obese women 
(RR=1.56, 95% CI=1.00-2.43) although not among obese men (RR=0.98, 95% CI=0.59-
1.63) (102).  McGee and colleagues in the Diverse Populations Collaboration examined 
associations between obesity and mortality from coronary heart disease (CHD) and all 
cardiovascular disease (CVD) using meta-analytic techniques and person-level data from 26 
observational studies (103).  Relative risks comparing obese to healthy weight women were 
1.62 (95% CI 1.46-1.81) for CHD mortality and 1.53 (95% CI 1.38-1.69) for CVD mortality.  
Similar elevations were observed among males (103). 
Obesity is also associated with incident CVD including heart disease, the leading 
cause of death in the United States, and stroke, the third-leading cause of death (57). Among 
women in the NHANES III sample, obesity classes 1 (BMI 30-34.9 kg/m2), 2 (BMI 35-39.9 
kg/m2) and 3 (BMI 40+ kg/m2) were associated with increased prevalence ratios for 
coronary heart disease ranging from 1.6 (for obesity class 1) to nearly 3.0 (for obesity class 
3) (104).  Using incident CVD, obese women in the Framingham Heart Study cohort were 
found to have elevated risk of total cardiovascular disease (RR=1.39, 95% CI=1.14-1.68) as 
well as increased risk of angina pectoris (RR=1.63, 95% CI=1.18-2.25) and myocardial 
infarction (RR=1.46, 95% CI=0.94-2.28); however, no association was seen with 
cerebrovascular disease (102).  Congestive heart failure and atrial fibrillation have also been 
found to be associated with obesity (105). 
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The association between obesity and cardiovascular disease is mediated in part via 
CVD risk factors that are highly associated with obesity including hypertension, insulin 
resistance, and dyslipidemia (23).  Many studies have found associations between obesity 
and type 2 diabetes.  For example, among women in the Nurses Health Study, the relative 
risk of type 2 diabetes over 14 years of follow-up among women with a baseline BMI greater 
than 31 kg/m2 was in excess of 40 times higher than for women with a baseline BMI less 
than 22 kg/m2 (106).  In the Framingham cohort, obesity was associated with both 
hypertension (RR=2.63, 95% CI 2.20-3.15) and diabetes (RR=1.36, 95% CI=1.03-1.78) 
among women (102).  Additional studies have found strong positive associations between 
increasing blood pressure and BMI (105).  For example, in NHANES III, strong associations 
between high blood pressure and obesity were found among women less than 55 years of age 
with prevalence ratios ranging from 1.65 (for overweight) to 5.45 (for obesity class III).  
Among women over 55, hypertension was still associated with increasing BMI category 
although the prevalence ratios were smaller in magnitude (1.41 for obesity class III, for 
example) (104).  High cholesterol level was also found to be associated with increasing 
category of BMI among women less than age 55 in the NHANES III sample with prevalence 
ratios around 1.7 for obesity classes 1, 2, and 3 (104). 
Biologic mechanism linking obesity to cancer and cardiovascular disease 
 While not exhaustive, several of the important obesity-mediated biologic pathways to 
cancer and cardiovascular disease (CVD) are depicted in Figure 1.2.  Obesity is linked to 
cancer through several pathways, including the insulin resistance pathway (1, 87).  With an 
increase in adipose tissue, other body tissues become insensitive to insulin which triggers the 
production of larger amounts of insulin, ultimately resulting in a state of hyperinsulinemia.  
Chronic hyperinsulinemia causes a decrease in insulin-like growth factor binding proteins 
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(IGFBP-1 and IGFBP-2) which in turn results in higher levels of free IGF-1 in the blood.  
This is important because IGF both stimulates cell proliferation and inhibits apoptosis, two 
processes that are involved in carcinogenesis.  Sex hormone-binding globulin (SHBG) 
synthesis is reduced by elevated levels of free IGF-1 as well as by chronic hyperinsulinemia 
directly.  SHBG is a binding site for estrogen and thus lowered levels of SHBG increase the 
amount of unbound estrogen in the blood.  Estrogen is a known promoter of carcinogenesis 
due to its pro-cell proliferation and anti-apoptotic qualities.   
In addition to the insulin-IGF-SHBG pathway, obesity directly affects estrogen levels 
and thus increases the risk of hormone-sensitive cancer sites such as breast and endometrium 
(107).  In particular, in post-menopausal women, the principal source of estrogen is the 
conversion of androstenedione to estrone in the adipose tissue.  The insulin resistance 
pathway also links obesity to CVD due to the strong association between chronic 
hyperinsulinemia and type 2 diabetes, which is both a CVD endpoint as well as a risk factor 
for other CVD events such as coronary heart disease (108).   
In addition to the insulin resistance pathway, obesity is linked to carcinogenesis as 
well as CVD via the inflammation pathway.  As will be described further in the next section 
of this work, adiponectin is inversely associated with obesity.  Decreased adiponectin levels 
result in the activation and proliferation of immune cells and inflammatory cytokines such as 
TNF-α (109).  These cells contribute to a state of chronic inflammation.  Carcinogenesis is 
thought to result from the chronic inflammatory state as a result of the effects of sustained 
tissue damage and damage-induced cell proliferation (110).  Decreased adiponectin levels 
also may act directly on cancer cells by decreasing cell arrest and apoptosis while increasing 
cell proliferation (111). 
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Obesity is also hypothesized to be linked to cancer via inflammation with 
cyclooxygenase-2 (COX-2) being one of the likely mediators.  COX-2 is up-regulated at sites 
of inflammation, likely by the inflammatory cytokines, growth factors, and tumor promoters 
(112).  The increased levels of COX-2 inhibit apoptosis as well as promote angiogenesis 
leading to carcinogenesis (112, 113). 
Decreased levels of adiponectin are also directly related to the formation of 
atherosclerotic plaques by down-regulating vascular adhesion molecules and inhibiting the 
transformation of macrophages to foam cells (6).  The formation of atherosclerosis is a major 
risk factor for coronary artery disease and other CVD events.  Other cytokines such as 
interleukin-6 (IL-6) and CRP are also believed to be intermediates in the pathway between 
obesity, CVD risk factors (such as hypertension) and CVD outcomes (105). 
While the pathways discussed above are hypothesized to be important links between 
obesity and cancer and CVD, their relative importance is yet to be determined in relation to 
one another as well as to other pathways not yet explored.  Importantly, it appears that the 
cytokines, including adiponectin, may play an important role in several pathways linking 
obesity and chronic disease.  
Biology of adiponectin 
Adiponectin protein  
Adipose tissue was traditionally considered to be an energy storage organ, but beginning in 
the early 1990s, it was discovered that adipose tissue also functions as an endocrine organ, 
secreting proteins that affect multiple metabolic pathways (114).  These proteins are 
alternatively called cytokines, adipokines, and adipocytokines.  One such protein, 
adiponectin, was independently characterized by four different laboratories in the mid-1990s 
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(115-118) but did not receive the type of scientific attention that was given to leptin until the 
late 1990s to early 2000s (6). 
Adiponectin is produced exclusively in adipose tissue and is found in a high 
concentration in the blood, accounting for approximately 0.01-0.05% of total serum protein 
(6, 114).  Four domains including a total of 247 amino acids make up adiponectin including 
an amino-terminal signal sequence, a variable region, a collagenous domain, and a carboxy-
terminal globular domain (called “globular adiponectin”) (119).   In circulation, adiponectin 
is found to be almost entirely full-length although a small amount of globular adiponectin is 
also present (120).  Adiponectin is synthesized as single units which subsequently bond with 
other units to form higher order multimers (or isoforms) that are secreted into the 
bloodstream (121).  Adiponectin is present in serum and plasma in several of these higher-
order forms including as a trimer (formed by three single units which bond in a ball and 
stick-like structure), a hexamer (which consists of two trimers bonded in a head-to-head 
manner via disulphide bond) and as higher-order structures called high molecular weight 
(HMW) adiponectin (9, 121).  The HMW forms appear to consist mainly of 18 subunits (six 
trimers) which form either a flat fan-shape or a bouquet-like structure (121).  The specific 
isoform is thought to influence the biological activity of adiponectin through differential 
activation of downstream pathways although more research is needed to understand the 
specific actions of the different isoforms (122).  Recent data indicates that the HMW isoform 
binds most avidly to its receptors (123) and may be more strongly associated with insulin 
resistance and the metabolic syndrome (123-125).   
Adiponectin levels appear to be relatively stable within individuals who do not 
undergo drastic changes in body weight.  Circadian variation has been shown to be low 
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overall with adiponectin levels varying less than 20% throughout the day, and slightly more 
variation seen in females than in males (126).  Most evidence seems to indicate that 
adiponectin levels remain unchanged in relation to meal ingestion (126).  Among 48 Chinese 
males, adiponectin levels measured during four seasons over one year apart were highly 
correlated (intra-class correlation coefficient [ICC]=0.81) (127).  In another study of 300 
white men, in blood samples collected one year apart, adiponectin levels had a similarly high 
ICC of 0.85 (128). 
In a 2005 review of recent progress made in adiponectin research, Kadowaki and 
Yamauchi put forth an “adiponectin hypothesis” in which they postulate that reduced 
adiponectin levels result from interactions between SNPs in the adiponectin-encoding gene, 
environmental factors such as diet, and down-regulation of adiponectin receptors linked to 
obesity.  The resulting reduction in adiponectin levels then plays a causal role in the 
development of insulin resistance, type 2 diabetes, metabolic syndrome, and atherosclerosis 
(120).  Because increased levels of adiponectin are inversely associated with obesity 
phenotypes as well as several obesity-related disease outcomes, adiponectin may be a useful 
therapeutic tool in the treatment of insulin resistance, type 2 diabetes, obesity, cardiovascular 
disease, and cancer; however, to date, most studies that have demonstrated a reduction in 
these morbidities after administration of adiponectin have been in rodents (6, 119, 120).   
Adiponectin receptors  
Two adiponectin receptors have been identified to date, AdipoR1 and AdipoR2 (6, 120). 
These receptors are found in the cell membrane and are located throughout the body in liver, 
muscle, and adipose tissue although AdipoR1 is found predominantly in muscle cells while 
AdipoR2 is primarily found in the liver (129).  AdipoR1 has the highest affinity for globular 
adiponectin (which accounts for only a small proportion of circulating adiponectin) while 
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AdipoR2 binds both globular and full-length adiponectin (130). The binding of adiponectin 
to these receptors mediates the activation of AMP kinase which leads to expression of 
peroxisome proliferators-activated receptor-alpha (PPAR-α) (120).  This activity is believed 
to increase gene expression of enzymes related to fatty acid oxidation and glucose uptake (6, 
120).  This process is thought to be one of the main mechanisms linking adiponectin and 
insulin sensitivity.  Additionally, increased obesity is thought to either directly decrease 
expression levels of adiponectin receptors or reduce the post-receptor signaling which may 
also contribute to insulin resistance (6).  T-cadherin, a calcium-dependent transmembrane 
adhesion protein, has also been found to be a third receptor for full-length adiponectin in 
vascular endothelial cells and smooth muscle (6, 129).  
Genes encoding adiponectin and adiponectin receptors 
The human adiponectin gene, known as ADIPOQ, has been identified and is located on 
chromosome 3q27 (8).  ADIPOQ is approximately 17,000 base pairs (bp) in length and 
consists of three exons and two introns (131).  The genes coding for the adiponectin receptors 
(ADIPOR1 and ADIPOR2) have also been identified.  The adiponectin receptor 1 gene 
(ADIPOR1) is located on chromosome 1q32 and is approximately 17,000 bp in length.  The 
gene encoding adiponectin receptor 2 (ADIPOR2) is located on chromosome 12q13 and is 
approximately 97,000 bp (132). 
Race and gender differences in adiponectin levels  
Gender differences in adiponectin levels have been observed in many studies.  Most studies 
have found that women have higher adiponectin levels than men even after adjustment for 
body size and fat distribution (133-138).  One small study of prepubescent children found no 
evidence for gender differences in adiponectin levels (134) but little evidence indicates this 
pattern is true in adults.  Gender differences are hypothesized to exist due to multiple factors.   
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Increased levels of HMW adiponectin among women are thought to contribute to gender 
differences in measures of total adiponectin (139).  In addition, inhibition of adiponectin 
production from circulating androgens is also thought to keep adiponectin levels lower in 
males (126).    
Racial differences in adiponectin levels have been examined in a relatively small 
number of studies most of which had low sample sizes; however, reports have been generally 
consistent that adiponectin levels are lower in blacks compared to whites and the differences 
emerge relatively early in life (134, 140).  Two small studies of children and early 
adolescents both reported that adiponectin levels were lower in blacks compared to whites in 
both genders (134) and among boys after matching on BMI percentile (140).  Two additional 
studies of middle-age adults reported lower adiponectin levels in American blacks (N=212) 
(141) and in African blacks (N=27) (136) compared to whites.  Two larger cohorts of young 
(age 23-45) and middle-aged (age 48-58) adults also reported lower adiponectin levels in 
black participants compared to white participants (137, 142). In a large study of older adults 
(age 70-79), adiponectin levels were found to be lower in blacks (N=1044) compared to 
whites (N=1429) (143).  Hulver and colleagues (144) reported mean adiponectin levels in 
strata of race and obesity status.  They found that mean adiponectin levels were similar in 
obese white women, obese black women, and non-obese black women but higher in non-
obese white women (144).  In a study of white and black South Africans, adiponectin levels 
were lower in normal weight blacks compared to whites but no differences were seen for 
overweight and obese women (145).  Both of these studies to examine adiponectin levels 
over categories of body size were limited by their small overall sample size (N=85 and 
N=217, respectively).  Wassel Fyr and colleagues measured the percentage of European 
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ancestry using 35 ancestry informative markers in a sample of 1241 older adults (age 70-79) 
who self-reported as black.  In models adjusted for adiposity, fasting glucose levels, insulin 
levels, blood pressure, and lipids, increasing adiponectin levels were found to increase as the 
percentage of European ancestry increased (146).  This pattern is consistent with the previous 
reports described above that found lower adiponectin levels among blacks compared to 
whites using self-report. 
Environmental and behavioral factors correlates of adiponectin levels 
Dietary factors and weight loss. The effect of specific dietary factors on adiponectin levels 
has not been carefully examined to date; however, there are several studies of weight loss in 
relation to adiponectin levels.  Among individuals who have lost significant amounts of body 
mass either through long-term restricted diets or surgical intervention, adiponectin levels 
have been shown to increase (147).  However, in studies of moderate weight loss through 
traditional diet or exercise interventions, changes in adiponectin levels have been smaller or 
non-existent (147).  Adiponectin levels also do not appear to respond acutely to meal size or 
composition (147).  The earliest study to examine total calorie as well as macronutrient 
intake yielded no associations with adiponectin (148).  Fiber has reported to be positively 
associated with adiponectin among diabetics (149, 150), a finding which is consistent with 
known inverse associations between both fiber intake and glucose levels and adiponectin 
levels and glucose levels due to reduced glucose output in the liver related to adiponectin 
action (147).   
Alcohol. Alcohol is known to be associated, through moderate consumption, with improved 
insulin sensitivity and cardiovascular outcomes (151).  Adiponectin is hypothesized to be an 
intermediary in the chain of effects linking alcohol to these outcomes via several pathways 
including the reduction of TNF-α, reduction in liver glucose production, and increased 
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muscle fat oxidation (152).  Several small studies have demonstrated increased adiponectin 
levels in relation to increased alcohol consumption (152-154) and it has also been suggested 
that different types of alcohol (i.e. beer, wine, or liquor) have differing effects on adiponectin 
levels (153). 
Physical activity. Physical activity has been examined in relation to adiponectin levels in 
several cross-sectional studies as well as intervention trials but results have been conflicting 
(155, 156).  A recent review of 33 of these studies found generally that exercise increases 
adiponectin levels, perhaps in a dose-response relationship with moderate to high intensity 
exercise showing stronger effects than low intensity activity (155).   
Cigarette smoking. Cigarette smoking has been associated with reduced adiponectin levels 
in previous studies but the mechanism is unclear (74, 157).  Direct action of nicotine on 
adipocytes is one hypothesis to explain this inverse relationship as are less direct results of 
cigarette smoking including inflammation, tissue hypoxia, and sympathetic nervous system 
action related to nicotine receptors (135, 157).   
Associations between adiponectin levels and chronic disease 
Adiponectin levels and obesity 
Serum adiponectin levels are negatively correlated with body mass index and waist-to-hip 
ratio (WHR) (6, 114) which reflect overall adiposity and fat distribution, respectively.  This 
is somewhat paradoxical given that most cytokines (such as leptin) increase directly in 
relation to body fat.  It has been hypothesized that feedback loops exist between obesity, 
adiponectin expression, and regulation of the adiponectin receptors, resulting in the observed 
inverse association between obesity phenotypes and adiponectin levels in the blood (119, 
120).   
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Most evidence to date regarding the obesity-adiponectin relationship has been 
observed in white or Japanese populations (133, 135, 138, 158).  Despite the known 
differences in the prevalence of obesity and risk for obesity-related disease, a relatively low 
number of studies have examined the relationship between adiponectin and obesity in blacks 
and many have had very small sample sizes.  In a study of adolescents including 40 white 
and 46 black participants, Degawa-Yamauchi et al. observed that adiponectin was negatively 
correlated with both BMI and percentiles of BMI (140).  In another small study, Hulver et al. 
found that adiponectin was negatively correlated with BMI only among whites (N=48) but 
not blacks (N=37) (144) while, in contrast, Araneta et al. found that adiponectin was 
negatively associated with increasing tertiles of BMI, waist girth, and WHR in both blacks 
(N=212) and whites (N=143) (141).  Comparing black and white South Africans, adiponectin 
levels were found to be negatively correlated with BMI in each race group in univariate 
analysis although not in the final multivariate model (145). In a genetically homogeneous 
sample of 431 individuals from 7 families living on the Caribbean island of Tobago, 
adiponectin was also found to be negatively correlated with BMI (159).   
Only a few large studies to date have examined associations with body size in 
populations with a sizeable number of black participants.  Among 522 black participants in 
the Insulin Resistance Atherosclerosis (IRAS) Family Study, visceral adipose tissue 
measured by CT was strongly negatively correlated with adiponectin levels (160).  In the 
Atherosclerosis Risk in Communities Study (ARIC), mean adiponectin levels were found to 
decrease over categories of BMI (<25, 25-<30, and 30+ kg/m2) in 630 black and 523 white 
participants age 48-58 (132). Further, the adjusted mean adiponectin values were lower for 
black women than for white women in each BMI category (142).  Waist circumference was 
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found to be negatively associated with adiponectin levels in the CARDIA study which 
included 1615 white and 1360 black young adults (age 23-45) (137). 
Adiponectin levels and cancer 
The process of understanding the complex relationships linking obesity, the 
adipokines, and cancer is an evolving and very active field of research (8).  Here I review the 
studies conducted to date regarding adiponectin levels in major cancer sites that affect 
women.  In the cancer literature, only in the most recent years have research teams begun to 
examine associations between adiponectin and breast cancer both in vitro and in vivo.   In 
vitro studies have examined the effects of adiponectin on epithelial breast tissue and on 
breast cancer cell lines.  MCF-7 breast cancer cells were found to express functional 
adiponectin receptors in several in vitro studies (161-164).  Conflicting evidence exists as to 
whether breast cancer cell proliferation is inhibited by adiponectin with some groups finding 
evidence for this activity in vitro (161, 164, 165) while others have been unable to replicate 
this finding (162, 163).  Additionally, several tumor cell lines have been shown to express the 
adiponectin receptors AdipoR1 and AdipoR2 indicating that adiponectin could act directly on 
cancer cells through signaling of its receptors (166). 
To date, at least seven studies in human populations have examined associations 
between adiponectin and breast cancer risk.  Five relatively small case-control studies 
conducted in women residing in Japan, Greece, and Taiwan found a reduced risk of breast 
cancer at the highest levels of adiponectin compared to the lowest levels (167-171).  In two 
studies (167, 170), the results were consistent between pre- and post-menopausal women 
while two others found an association only among post-menopausal women (169, 171).   The 
Japanese study also found that lower adiponectin levels were associated with larger tumors 
and higher grade tumors but these results have yet to be replicated (170).  A fifth case-control 
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study, conducted in Korea, found no association between tertiles of adiponectin and breast 
cancer risk (OR=0.92, 95% CI=0.46-1.81) (172). The Nurses Health Study used pre-
diagnosis blood samples for a prospective case-control study including 1,477 cases and 2,196 
controls (173).  These authors found that breast cancer risk was reduced when comparing the 
highest quartile of adiponectin to the lowest among post-menopausal women (OR=0.73, 95% 
CI=0.55-0.98) but not among pre-menopausal women (173).  With the exception of the 
Nurses Health Study, the remaining case-control studies to have examined adiponectin levels 
in relation to breast cancer used blood samples collected post-diagnosis.  Without a clear 
understanding of the determinants of adiponectin levels, the measurement of adiponectin in 
blood samples in women after a cancer diagnosis has been made has serious implications for 
potential bias and is an important limitation.  Notably, none of these studies included any 
appreciable numbers of women of African descent.   
Scant literature is available examining potential associations between adiponectin and 
colorectal cancer.  In one laboratory study, adiponectin was found to increase proliferation 
and increase inflammatory actions in human colon cells (174), and in another, adiponectin 
was found to inhibit colorectal cancer cell growth (175).  Observational study results are few 
and thus far inconsistent.  Among men in the Health Professionals Follow-up study, 
colorectal cancer risk was reduced when comparing the highest to the lowest quartile of 
serum adiponectin (RR=0.50, 95% CI=0.26-0.97) (176) but in a case-control study (also 
among males) in Norway and Sweden the RR for highest to lowest quartile of serum 
adiponectin was 0.9 (95% CI=0.6-1.4) (177).  Two additional small case-control studies 
found lower adiponectin levels in colorectal cancer patients compared to controls (178, 179).  
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Notably, there have been no adequately powered studies to examine adiponectin levels in 
relation to colorectal cancer among women or among blacks.   
In one small study in Japan, adiponectin receptors were found to be expressed in 
healthy endometrial tissue (180).  Adiponectin suppressed cell proliferation in two 
endometrial carcinoma cell lines via induction of cell cycle arrest and apoptosis in another 
(181), but, generally, few in vitro studies have been conducted examining the effects of 
adiponectin on either healthy or cancerous endometrial tissue.  Several case-control studies 
have examined the association between adiponectin in serum or plasma and endometrial 
cancer in women.  While each study categorized adiponectin differently (including by 
tertiles, quartiles, and standard deviations), the collective results point to an inverse 
association between increasing adiponectin level and risk of endometrial cancer (182-186).  
Only one study included any black women but the proportion was small (15% of 117 cases) 
and no race-specific analyses were conducted (185).   
Adiponectin levels and diabetes 
Adiponectin has been examined in relation to several measures related to glucose sensitivity 
and insulin action including the homeostasis model assessment of insulin resistance 
(HOMA), insulin sensitivity, and fasting glucose levels.  Both black and white participants 
were included in at least six studies, several relatively small, examining adiponectin levels in 
relation to HOMA.  Four reports found that adiponectin was negatively associated with 
HOMA in all study participants (137, 140, 141, 145) while two others found evidence for a 
negative association with HOMA only in white participants (136, 144).  Another study 
comprised only of black participants found HOMA to be negatively associated with 
adiponectin levels in univariate analysis but not in the final multivariate model (187).  
Several authors have found evidence for a positive association between insulin sensitivity 
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and adiponectin levels including among a small group of black and white children (134), in a 
small convenience sample of unknown racial background (135), and in a large family-based 
study of Hispanics and blacks (160).  The association between adiponectin levels and fasting 
glucose has been found to be negative in at least one large study (160) but not in two other 
smaller studies (140, 144).  
Incident type 2 diabetes in relation to adiponectin levels was examined in a 2009 
meta-analysis that included thirteen prospective studies (188).  Nearly 15,000 participants 
were included in the meta-analysis and the RR for type 2 diabetes overall was found to 0.72 
(95% CI=0.67-0.78) for each 1-log ug/ml increase in adiponectin level.  Of the studies 
included in this meta-analysis, two included black participants (142, 189).  Using ARIC data, 
Duncan et al. reported an odds ratio of 0.58 (0.34-0.99) for incident type 2 diabetes 
comparing the highest quartile of adiponectin to the lowest quartile in a combined group of 
blacks (N=523) and whites (N=630).  This association was similar by race although there 
was some suggestion that the magnitude of effect may be larger in blacks than in whites 
(142).  In contrast, among a combined group of blacks (N=905) and whites (N=1451) age 70-
79, adiponectin levels were not found to be associated with incident type 2 diabetes 
(RR=1.04 (95% CI=0.69-1.56)) but no race-stratified estimates were provided (189). 
Adiponectin levels and cardiovascular disease 
Adiponectin levels have been examined in relation to cardiovascular disease (CVD) as well 
as in relation to several risk factors for CVD including HDL cholesterol levels and 
hypertension.  Adiponectin was positively correlated with HDL cholesterol in studies of 
whites (135, 158) and blacks (160).  The HMW form of adiponectin may be more strongly 
associated with HDL-cholesterol (190).  Previous work including both cross-sectional and 
prospective studies have linked low adiponectin levels to hypertension (191-193).  There 
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remains some uncertainty about the role played by insulin resistance in the adiponectin-
hypertension relationship as some studies report an association only among participants with 
insulin resistance, but at least some evidence indicates that low adiponectin levels may affect 
the development of hypertension at an early stage, without involvement of insulin resistance 
(192). 
Despite adiponectin’s anti-inflammatory and anti-atherogenic properties, evidence of 
a reduction in risk of CVD in relation to increased adiponectin levels has been conflicting 
(194).  Using a case-control design nested within the largely white Health Professionals 
Follow-up Study, Pischon and colleagues examined adiponectin levels in 266 males with 
non-fatal myocardial infarction and fatal coronary heart disease and 532 controls. After 
multivariate adjustment, the relative risk for CHD (including both fatal and non-fatal events) 
was 0.56 (95% CI=0.32-0.99) comparing the highest quintile of adiponectin to the lowest 
quintile (195).  A case-control study of coronary artery disease in Japanese men had similar 
results with an OR of 0.5 for the highest versus lowest quartile of adiponectin (196).  A meta-
analysis of seven prospective studies conducted through 2005 with nonfatal MI or CHD 
death as the outcome found an odds ratio of 0.84 (95% CI=0.70-1.01) comparing the top 
third of adiponectin levels to the bottom third (197).  A large population-based longitudinal 
study in Germany (published after the meta-analysis) found that the hazard ratio for incident 
coronary heart disease (CHD) was 0.62 (95% CI=0.39-0.98) comparing the highest to the 
lowest tertile of adiponectin but this association was attenuated after adjustment for HDL-
cholesterol level (198).  Other recent studies have found no significant association between 
adiponectin levels and CVD events after adjustment for other risk factors (199, 200).  Lara-
Castro et al. have speculated that the studies to date indicate that the independent association 
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between adiponectin and CVD risk is not strong but rather adiponectin may affect CVD risk 
indirectly via its effects on intermediaries such as HDL cholesterol (190). 
The first study to examine whether adiponectin is associated with coronary heart 
disease among both blacks and whites included 1,044 blacks and 1,429 whites ages 70 to 79 
from the Health, Aging, and Body Composition Study (143).  This study found that 
adiponectin was negatively associated with a higher prevalence and incidence of CHD in 
black subjects but not in white subjects (143).  Kanaya et al. have suggested that biological 
differences that affect the action of adiponectin, such as differences in levels of lipoprotein 
lipase or the proportion of visceral fat, may be responsible for these racial variations (143).  
Overall, however, there is a dearth of reports examining cohorts with large numbers of blacks 
and females in the CVD-adiponectin literature.     
Genetic variants in ADIPOQ, ADIPOR1, and ADIPOR2 in relation to obesity 
Polymorphisms in ADIPOQ have been examined in relation to a variety of obesity 
phenotypes in many studies.  Nomenclature of the SNPs has evolved over time; in ADIPOQ, 
two SNPs, rs2241766 (commonly called 45TG or SNP45) and rs1501299 (commonly 
called 276GT or SNP276) were among the earliest to be discovered and most frequently 
studied in this gene.   
SNP rs2241766 is a silent polymorphism in exon 2 of ADIPOQ that results in a T to 
G substitution and it has been examined in relation to BMI in several studies.  Carriers of the 
G allele in rs2241766 have been observed to have higher BMI values than TT homozygotes 
in populations from Taiwan (201) and France (202) as well as in a subgroup of Germans with 
a family history of diabetes (203).  However, carriers of the G allele in rs2241766 have also 
been reported to have lower BMI values than TT homozygotes (204-206) or to be unrelated 
to BMI (207-209).  Waist circumference was also found to be associated with the T to G 
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substitution in rs2241766 in one study (210).  Another SNP that has been frequently 
examined in relation to obesity is rs1501299 located in intron 2 of ADIPOQ.  This SNP was 
not associated with BMI in several studies (205-209)   
Early studies examined SNPs rs2241766 and rs1501299 individually while more 
recent studies have looked at haplotypes comprised of these two SNPs in relation to body 
size.  In the Nurses Health Study, women with the haplotype defined as T at rs2241766and G 
at rs1501299 were found to have a higher prevalence of obesity than women with other 
haplotype structures (204).  Similarly, participants in an Italian study with haplotypes 
including T at rs2241766and G at rs1501299 were found to have higher body weight and 
higher waist circumference than those with other haplotype structures (211). 
Other variants in ADIPOQ have been reported to be associated with obesity although few 
have been replicated.  At least one group examined a SNP in the intronic region between 
exons 2 and 3 (called IVS2+G62T) in which those with the GT genotype had higher BMI 
those with the GG genotype (210).  A SNP in the proximal promoter region of ADIPOQ 
(formerly called SNP -11377, now rs266729) has been examined in at least six studies and no 
association between this SNP alone and BMI was observed in most of the reports (206, 208, 
209, 212, 213).  In a group of diabetics, those with the CC or CG genotype of rs266729 were 
found to have higher BMI than those with the GG genotype (214).  Another SNP in ADIPOQ 
(formerly called -11391, now rs17300539) has also been examined in several studies with 
obesity phenotypes as the outcome.  Associations have been inconsistent with some reports 
having null findings (208, 209), another reporting that the A allele in rs17300539 is 
associated with lower BMI and waist and hip circumferences (213), and another reporting no 
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association with BMI or waist circumference but an association with visceral adipose tissue 
(VAT) as measured by computed tomography (CT) (206).  
Only one study has examined polymorphisms in the adiponectin receptors, ADIPOR1 
and ADIPOR2, in relation to body size, and there was no association found between any 
SNPs and obesity-phenotypes including BMI, percentage body fat, or waist circumference 
(205).   
While the evidence is not yet conclusive, genetic polymorphisms in the genes 
encoding adiponectin and adiponectin receptors do appear to be linked to adiponectin and 
obesity-related phenotypes.  However, despite the known differences in obesity between 
whites and blacks, single nucleotide polymorphisms (SNPs) in ADIPOQ, ADIPOR1, and 
ADIPOR2 have been examined almost exclusively in populations that did not include 
individuals of African descent.   
Genetic variants in ADIPOQ, ADIPOR1, and ADIPOR2 in relation to adiponectin 
levels 
Several studies have examined polymorphisms in the gene encoding adiponectin in relation 
to measured concentrations of adiponectin in blood although most of the early studies were 
small and few included sizeable numbers of women or blacks.  A 2007 meta-analysis was 
conducted of the studies up to this date examining variants in ADIPOQ in relation to 
adiponectin levels.  Three SNPs met the criteria for meta-analysis (at least 2,000 individuals 
had been genotyped in all studies combined): rs17300539, rs1501299, and rs2241766.  Two 
of these SNPs (rs17300539, genotyped in five studies, and rs1501299, genotyped in twelve 
studies) were significantly associated with adiponectin levels in the meta-analysis while 
rs2241766 (genotyped in ten studies) was not (215).  Notably, all of the studies included in 
this meta-analysis included study populations that were exclusively white or Asian.  Not 
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included in the Menzaghi meta-analysis was a study of 747 Spanish individuals which found 
that the G/G genotype of rs1501299 was associated with lower adiponectin levels compared 
to carriers of the G/T or T/T genotype (216) as well as a study of 867 Korean women which 
found similar results to the Spanish study (217). 
As genotyping costs have been reduced and genotyping platforms have been 
developed to accommodate large numbers of SNPs, research teams have begun genotyping 
larger numbers of SNPs, often with a tag-SNP approach, and examining them in relation to 
adiponectin levels.  Heid et al. genotyped 15 tag SNPs in 1,770 healthy Austrian adults 
(N=663 female) and found significant associations with adiponectin levels for 11 of these 
SNPs individually and with several haplotypes, many more than had previously been 
detected in other studies (218).  In two samples of white women from the United Kingdom 
(UK), Kyriakou et al. found and replicated positive associations for four SNPs in ADIPOQ 
(rs17300539, rs182052, rs16861209, and rs1501299) (219).  Among 2,543 white adults in 
the Framingham Offspring Study (half female), 22 tag SNPs in ADIPOQ were genotyped 
and two were found to be strongly associated with adiponectin levels: rs17300539 (which 
was also significant in the 2007 meta-analysis, the Austrian study, and the UK studies) and 
rs822387.   
Two recent genome-wide association studies (GWAS) reported a strong association 
with adiponectin levels and SNP rs17366568 on ADIPOQ in European whites (220, 221).  
Ling et al. also found two additional SNPs in ADIPOQ to be strongly associated with 
adiponectin levels (rs3774261 and rs6773957) in European whites (220).  Heid et al. found 
low regulatory potential for rs17366568 indicating that it is likely located near to a functional 
variant but is not functional itself (221).   
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To date, only one study (the GWAS of white Europeans by Ling et al.) has examined 
adiponectin levels in relation to SNPs in ADIPOR1 and ADIPOR2 and no significant 
associations were found (220). 
Summary 
 Taken collectively, the research conducted to date linking adiponectin and obesity 
provide compelling evidence that careful examination of this association will help us to 
better understand the development and prognosis of several high burden diseases including 
several cancers, type 2 diabetes, and cardiovascular disease.  In addition, the lack of studies 
focused on adiponectin among blacks highlights a clear and immediate need for studies in 
populations with a sizable proportion of black participants.  In particular, few studies have 
quantified the blood levels of adiponectin in relation to body size in a large population of 
blacks and whites over a wide range of age and body size in order to evaluate potential 
differences in the magnitude and form of the association across racial groups.  Additionally, 
while associations with body size, adiponectin levels, and genetic polymorphisms in the 
ADIPOQ genes have been observed in several populations, few studies have included 
sufficient numbers of black subjects to assess whether the observed associations are the same 
across racial groups.  Finally, very few studies have examined ADIPOR1 and ADIPOR2 
polymorphisms in relation to adiponectin levels and body size and none have been conducted 
in black participants.  Overall there is only limited information in the literature regarding the 
relationship between adiponectin and environmental and genetic correlates among blacks.  
The work presented here takes an important step in filling this void in our understanding of 
these relationships and indicates areas for future research.
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Figure 1.1  Individual-level behavioral and environmental determinants of obesity 
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Figure 1.2  Selected obesity-mediated pathways linking cancer and CVD 
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CHAPTER 2: RESEARCH METHODS 
 
Overview 
I conducted a cross-sectional analysis of a sample of women enrolled in the Southern 
Community Cohort Study (SCCS) in order to examine associations between adiponectin 
levels, obesity (as measured by body mass index [BMI]), environmental and behavioral 
factors, and genetic variants in the ADIPOQ, ADIPOR1, and ADIPOR2 genes.  These 
women were previously selected for a separate study funded by Susan G. Komen for the 
Cure to examine behavioral and genetic determinants of obesity in women enrolled in the 
SCCS (grant number OP05-0927-DR1), hereafter called “The Komen Obesity Project”.  A 
sample of 1,000 white women and 1,000 black women was utilized for these analyses.  
Institutional Review Board (IRB) approval was granted for this study by the IRBs at 
Vanderbilt University, Meharry Medical College, and the University of North Carolina at 
Chapel Hill.  Three specific aims were examined in this work: 
Specific Aim 1: Determine whether adiponectin levels among black women as compared to 
white women are associated with BMI and environmental and behavioral factors including 
physical activity, energy and nutrient intake, alcohol consumption, smoking, reproductive 
factors, and co-morbid conditions. 
Specific Aim 2: Determine whether adiponectin levels among black women as compared to 
white women are associated with genetic polymorphisms in tag-SNPs in the ADIPOQ, 
ADIPOR1 and ADIPOR2 genes and, in exploratory analyses, interactions between 
environmental factors and genetic polymorphisms in the ADIPOQ, ADIPOR1 and ADIPOR2 
genes. 
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Specific Aim 3: Determine whether BMI among black women as compared to white women 
are associated with genetic polymorphisms in tag-SNPs in the ADIPOQ, ADIPOR1 and 
ADIPOR2 genes; and in exploratory analyses, interactions between environmental factors 
and genetic polymorphisms in the ADIPOQ, ADIPOR1 and ADIPOR2 genes. 
Below, details of the Southern Community Cohort Study (the parent study for the proposed 
research), the study sample utilized for the research, assessment of the outcomes and 
exposures outlined in Specific Aims 1, 2, and 3, and the statistical methods used in the 
analyses are described. 
Parent Study: The Southern Community Cohort Study 
This research project was based on a sample of women selected from the Southern 
Community Cohort Study (SCCS) in February 2006.  The SCCS is a prospective cohort 
study being conducted by Vanderbilt University in collaboration with Meharry Medical 
College and the International Epidemiology Institute. The SCCS began participant 
enrollment in 2002.  The objective of the SCCS is to examine a large population of both 
black and white individuals to seek answers to unresolved and understudied questions 
regarding the underlying causes of certain cancers, especially causes of the important 
disparities in cancer incidence and mortality across racial groups (1).  Several large cohort 
studies have been conducted in various geographic areas of the United States, but none 
include large numbers of both black and white participants or a majority of participants from 
rural, low-income, or disadvantaged populations.  The SCCS is thus unique in its position to 
investigate factors that underlie disparities in health risks related to race and socioeconomic 
status. 
  62
SCCS participant recruitment  
At the time of the selection of the current study sample (February 2006), over 47,000 adults 
age 40-79 from the southeast region of the United States had been enrolled into the SCCS 
through community health centers (CHCs) located in both rural and urban locales throughout 
twelve southeastern states.  These CHCs are government-funded health care facilities that 
provide basic health services primarily to low-income individuals (2).  Enrollment of cohort 
members through CHCs began in April 2002 and more than two-thirds of the SCCS 
participants who were enrolled through the CHCs were black.  The location of the 60 CHCs 
that enrolled SCCS participants through February 2006 are shown in Figure 2.1.   
 Potential study participants were CHC patients, friends or family members who were 
accompanying patients, and users of CHC pharmacies.  Participants were recruited to join the 
study in-person at the CHC by a trained study interviewer.  In order to be eligible to join the 
SCCS, participants must have been between the ages of 40-79, not under treatment for cancer 
in the past year (with the exception of non-melanoma skin cancer), able to provide an address 
and telephone number, and English-speaking. 
Baseline interview 
 After obtaining informed consent, a trained study interviewer conducted an in-person 
baseline interview for each participant which lasted approximately 50 minutes.  The 
interview was conducted using a laptop computer and a specially-designed computer-assisted 
personal interview (CAPI) with substantial logic-checking and skip pattern features built into 
the instrument.   The interview gathered information including demographics, anthropometric 
measurements, physical activity, smoking, reproductive history, personal  
medical history, family medical history, medication use, emotional well-being and social 
support, religion/spirituality, health insurance, use of medical and cancer screening services, 
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and occupational history.  The longest section of the interview was an 89-item food 
frequency questionnaire designed specifically for this population.  It was empirically derived 
from the third National Health and Nutrition Examination Survey (NHANES-III) to include 
foods commonly eaten by Southerners and foods that are likely to differ between blacks and 
whites (3, 4). Alcohol consumption and use of vitamin supplements were also assessed in the 
baseline interview.  
SCCS Participants 
The SCCS was very successful at enrolling the target populations of blacks and people of 
low socioeconomic status.  As of February 2006 (the time at which the sample of women for 
this research was selected), 61% of the over 56,000 enrolled participants were female and 
75% were black.  Of the women enrolled through February 2006, 61% reported a yearly 
household income less than $15,0000 (Table 2.1).  Nearly 40% of these women reported not 
having health insurance. The prevalence of co-morbidities and obesity at baseline was high 
among the women in the SCCS with 23% reporting a diagnosis of diabetes and 60% 
reporting a diagnosis of hypertension.   A wide range of body sizes was evident in the women 
enrolled in the SCCS with very stable proportions in each category from healthy weight 
(BMI between 18.5 and 24.9 kg/m2) to overweight (BMI between 25.0 and 29.9 kg/m2) to 
obesity classes I, II, and III (BMI 30.0-34.5, 35.0-39.9, and > 40.0 kg/m2, respectively)  (4).  
The distribution of body size is consistent with NHANES data that show that black women 
tend to be heavier than white women (5) and also with numerous reports that show women of 
low SES (such as are found in the SCCS) generally have a distribution of BMI that is higher 
than that of women of high SES (6). 
Data quality considerations 
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The baseline interview of the SCCS was conducted by study interviewers at each of the 
participating CHCs.  Study interviewers from each CHC were trained together by the SCCS 
study team during intensive one-week training periods.  Standardized interviewing 
techniques such as remaining neutral and using a common set of probes to elicit appropriate 
information from participants were stressed.  Quality control measures were in place to 
assess the quality of the interviews during the time that the interviewers were working in 
each CHC.  These measures included telephone calls to a random subset of enrolled 
participants to confirm answers to a selected set of approximately ten interview questions and 
evaluations of tape recorded interviews by study staff.   
Error detection in baseline interview data 
Study interviewers conducted the baseline interview using a laptop computer and a 
computer-assisted personal interview (CAPI).  The CAPI included built-in ranges for each 
variable as well as extensive logic checking and skip patterns.   Interview data were 
transmitted to a central server each evening from the CHCs and a daily quality control report 
was run to check for any abnormalities.  The use of the CAPI helped to ensure high quality, 
relatively clean data that was consistent within each participant.   
 For some measures, the large range of acceptable values allowed for some error to be 
introduced.  This is relevant for the self-reported weight and height data which were used to 
calculate BMI, one of the measures used in this project.  For example, women were asked to 
report their current weight with values between 50 and 500 pounds accepted by the CAPI.  
Data entry errors within this range could generally not be detected by the CAPI.  However, 
the self-reported data are believed to be generally of high quality for several reasons.  First, it 
is believed that the in-person nature of the interview was a deterrent for gross under- or over-
reporting of weight by the participants.  Also, for approximately 25% of the SCCS 
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population, weight and height were measured in the CHC as part of the medical visit on the 
day of the baseline interview, and this information was abstracted from the medical record by 
the study interviewer.  The correlation is extremely high overall for the BMI values 
calculated from self-reported height and weight data compared to BMI calculated from the 
medical record data (Pearson correlation coefficient > 0.95).  For the sub-sample of 
participants with both medical record and self-reported values available, the self-reported 
height and weight were compared to the medical record-abstracted height and weight and 
inconsistencies were resolved by consensus of the SCCS study team as to the most plausible 
correct value.  In the rare event that a plausible value could not be determined, the value was 
set to missing.  For the purposes of this project, only women with non-missing self-reported 
height and weight values were eligible to be sampled.  
Blood samples 
Participants were also asked to donate a blood sample at the time of the baseline interview in 
the CHC.  If blood was refused, participants were asked to donate a buccal cell sample.  Only 
the 7% of participants reporting prior hepatitis infection (of any type) and the 1% reporting 
HIV/AIDS were not asked for a blood or buccal cell sample (because of shipping 
regulations). Nearly all participants (98%) who were asked to donate a biologic specimen 
(blood or buccal cells) did so.  Overall, about half of the cohort members provided a blood 
sample with the other half choosing to provide a buccal cell sample instead of blood.  
Characteristics of women enrolled through February 2006 who did and did not 
provide blood samples are described in Table 2.2 (women with HIV or hepatitis who were 
prevented from being eligible to provide a sample are not included); because almost the 
entire cohort who are eligible to provide a biologic sample did so (98%), the column of 
women who did not provide a blood sample largely reflects the women who chose to donate 
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a buccal cell sample rather than blood.  Slightly more white women provided a blood sample 
compared to black women (26% versus 21%).  Missing values were also slightly more 
common for all of the characteristics for women who did not provide a blood sample 
compared to women who did.  Generally, though, the women were similar across groups of 
blood provision.   
The blood sample was drawn in the CHC laboratory by a staff phlebotomist and 
generally shipped on ice on the same day of collection for next-morning delivery to 
Vanderbilt University.   Once received at Vanderbilt, blood samples were spun at 1,500g for 
10 minutes, using a refrigerated centrifuge (at 4°C). The plasma was then removed and 
transferred to four sterile 2mL cryovials. White blood cells were aliquoted into two 2mL 
vials and red blood cells were stored in two 2mL vials.  For each sample, serum was 
transferred into four 2mL vials and blood clot into two 3.5mL vial. All samples are stored in 
freezer boxes and kept at -80°C. A computerized inventory tracking system has been 
developed, which can quickly track and locate the storage position of all samples for each 
cohort participant by study ID. 
Several safeguards were in place to ensure that errors in the blood collection were 
kept to a minimum.  First, when blood was collected from each participant at the CHC, a pre-
printed bar code label was attached to the blood tubes to correspond to the ID number 
assigned to each participant by the CAPI.  Daily tracking of blood samples and ID numbers 
was conducted to ensure that the labeling was done properly.  The time and date of the 
sample collection was recorded on the tube of blood and was entered into an Access database 
at the Vanderbilt laboratory.  Quality control reports were run each day to check for data 
entry errors in the time and date fields. 
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SCCS Biospecimen Pilot Study 
In 2005, after three years of enrollment into the cohort, 792 participants were selected for the 
SCCS Biospecimen Pilot Study.  The goal of the SCCS Biospecimen Pilot Study was to 
establish the feasibility and improve the efficiency of utilization of the SCCS biospecimen 
repository (including blood, buccal, and urine samples) for future examinations of genomic, 
proteomic, hormonal and other potential markers of cancer and other disease risk.   
The sample of 792 was drawn using a 2 x 2 x 3 x 3 factorial design based on four 
factors which included sex (male/female), race (black/ white), smoking status 
(current/former/ never), and BMI (<25, 25-29, >30 kg/m2).  Eight separate projects were 
undertaken involving blood samples from these 792 participants with including an 
investigation of blood biomarkers for obesity which measured serum adiponectin and leptin 
levels.  The Hormone Assay Core Laboratory in the Diabetes Research and Training Center 
at Vanderbilt University, funded by the National Institute of Diabetes, Digestive and Kidney 
Diseases successfully measured adiponectin levels from thawed serum in the pilot study 
participants.   
Race-specific measures of adiponectin for the women in this pilot study are presented 
in Table 2.3.   Adiponectin levels were successfully measured in 196 of 198 white women 
and 195 of 198 black women (total N=391).  Adiponectin levels were significantly higher 
among white women than among black women (two-sided t-test p-value <0.0001).  This 
difference across races is consistent with observations from other studies comparing 
adiponectin levels between whites and blacks (7-14).  The adiponectin measure was highly 
variable in this pilot study with standard deviations of 12.4 and 19.1 for black and white 
women, respectively.  Among the women in the biosample project, the coefficient of 
variation (CV) for within-subject measures was 7.8% for the adiponectin assay. 
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Sample selection 
This project utilized the sample of women already selected for The Komen Obesity Project 
which included several separate studies under a large grant from Susan G. Komen for the 
Cure to examine behavioral and genetic determinants of obesity in women enrolled in the 
SCCS.  The sample was selected first by including the 395 women who were previously 
included in the SCCS Pilot Biomarker Project (after excluding one women who withdrew 
from the SCCS), and second, by selecting a random sample of 1,605 women from the SCCS 
population.  The sample of 1,605 women was chosen from an initial pool of 28,158 women 
enrolled in the SCCS as of February 26, 2006.  Because the Komen Obesity Project included 
the measurement of blood biomarkers as well as genetic markers, only women who provided 
a blood sample (not a buccal cell sample) were eligible for selection.  Thus, of the 28,158 
women initially identified, 14,093 were eligible to be sampled based on the availability of a 
blood sample.  The 14,093 women were flagged as ineligible for selection for several reasons 
(and more than one may have applied to any woman).  Women were excluded if they 
donated the blood sample on a different day from their baseline interview (N=288); donated a 
sample that was damaged during shipping or processing (N=76); reported a racial/ethnic 
background other than white or black (N=772); had a BMI outside the range of 18.5-45 
kg/m2 (N=2,459); were missing data on questions relevant to menopausal status, blood 
collection, or dietary intake (N=1,195); reported a prior diagnosis with breast cancer 
(N=166); or were included in the SCCS pilot biomarker project (N=395), leaving a 
population of 10,585 women from which to select the 1,605 women. 
Sampling was based on three stratification factors including two strata of race (white 
or black), two strata of menopausal status (pre- or post-), and four strata of BMI (18.5-24.9, 
25-29.9, 30-34.9, and 35-45 kg/m2).  The long-term goal of the Komen Obesity Project was 
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to further our understanding of obesity as a risk factor for breast cancer and thus the sample 
was stratified on menopausal status because the obesity-breast cancer relationship may differ 
before and after menopause (15).  BMI stratification was utilized in order to ensure adequate 
numbers of women across all levels of body size. 
These sixteen strata (2x2x4) of race-menopausal status-BMI were first populated by 
the 395 women from the pilot biomarker project and then by random selection of the 10,585 
eligible women.  A total of 127 women were selected for each stratum.  This included 125 
women as the initial sample and two additional women who served as alternates in the event 
that unforeseen problems arose in the lab with the blood sample for the women selected 
initially.   
Thus, the final sample used in these analyses included 2,000 women, stratified by 
race (white/black), menopausal status (pre-/post-), and BMI (18.5-24.9, 25-29.9, 30-34.9, and 
35-45 kg/m2). 
Table 2.4 shows descriptive characteristics of the women who provided a blood 
sample (N=14,093), were eligible for selection into the proposed research after exclusionary 
criteria were applied (N=10,585), and were selected for the final sample (N=2,000).  These 
tabulations show that the women who were eligible after all exclusionary criteria were 
applied (N=10,858) as well as the final sample (N=2,000) were very similar to the entire 
cohort of women with available blood samples in their household income and educational 
attainment.  The age distribution of the final sample of 2,000 women was lower than that of 
the overall cohort of SCCS women due largely to the stratification of the selected women by 
menopausal status.  By selecting the sample of 2,000 to include 50% premenopausal women, 
the average age of the sample is lower than that in the overall cohort of women. 
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Outcome assessment 
Adiponectin levels 
A single one milliliter aliquot of serum was thawed for each participant and further aliquoted 
into 50 uL tubes which were used for multiple assays as part of the Komen Obesity Project.  
Blood levels of adiponectin were measured in serum blood samples and used as an outcome 
measure for Specific Aims 1 and 2 in this study.   
Serum adiponectin levels was determined by immunoassay using the LINCOplex kit 
(Luminex® xMAPTM Technology, St. Louis, MO) at the Vanderbilt Hormone Assay & 
Analytical Services Core Laboratory.  Samples were assayed in batches of 16 as follows: A 
total of 125 batches were created with 16 women per batch.  Each batch contained one 
woman from each stratum of BMI-race-menopausal status.  Duplicate samples for five 
randomly selected participants were selected to be included in random batches.  In addition, 
five repeat samples from a pooled serum sample were included randomly in order to assess 
the reliability and validity of the assay.   Each sample was run in duplicate by the laboratory 
resulting in two measures of adiponectin for each selected sample (and up to four measures 
for the five women randomly selected as duplicates).  The coefficient of variation (CV) was 
calculated for each sample as the standard deviation of the two measures divided by the mean 
of the two measures.  Adiponectin levels were successfully measured in 1,992 of the 2,000 
samples (eight samples failed due to a filter plate error or low sample volume).  The intra-
assay coefficient of variation was 9.4% overall and was similar to other studies that have 
used this assay and reported CVs (CV range 1.8% to 13.3%) (7, 8, 13). 
Body mass index 
Body mass index (BMI) was the primary outcome for Specific Aim 3.  BMI was also used as 
an exposure measure in Specific Aim 1.  During the baseline SCCS interview, participants 
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were asked for their current weight (or weight before pregnancy if they were pregnant at the 
time of the interview) in pounds as well as their current height in feet and inches.  Weight 
was converted to kilograms, height was converted to meters, and then BMI was calculated 
from these self-reported values as [weight (kg)] / [height (m)]2. 
The range of BMI values used in these analyses was 18.5 to 45.0 kg/m2 by design.  
Women were only eligible to be selected for the study sample if they had a non-missing BMI 
value that was between 18.5 and 45 kg/m2.  The proportion of women with missing BMI 
values was very small (N=393 or 1.4% of the study population).  A larger proportion of 
women (N=2,066 or 7.3%) were excluded based on very low (<18.5 kg/m2) or high (>45 
kg/m2) BMI values.  These exclusions were put in place in order to have adequate numbers 
of women across the range of BMI values to reduce model fit problems in the analysis related 
to sparse data.  This range reflects the WHO categories from healthy weight all the way 
through obesity class III.  BMI is one of many measures of body size that can be used to 
determine whether an individual is overweight or obese.  BMI was selected over other body 
size variables such as waist-to-hip ratio, skinfold measures, or body scans (such as DEXA or 
CT) due to time and cost constraints associated with the large sample size of the SCCS and 
the many locations in which participants were enrolled. 
The biggest source of error for the BMI measurement came from the use of self-
reported weight and height values.  Reports in the literature indicate that heavier women are 
more likely to under-report their weight and over-report their height leading to 
underestimates of their true BMI (16).  We were able to assess the extent of the 
misclassification via measured height and weight data that were abstracted from CHC 
medical records for approximately one-quarter of the SCCS participants.  BMI values 
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calculated from self-reported height and weight in the SCCS were very highly correlated 
with BMI values calculated from medical record data overall (Pearson correlation coefficient 
> 0.95) as well as within strata of race, education, income, and BMI.  It is also expected that 
the nature of the in-person interview reduced gross under- or over-reporting by participants 
that may occur more often in mailed or telephone questionnaires. 
Exposure assessment: Environmental and behavioral factors 
Potential environmental and behavioral determinants of adiponectin levels were obtained 
from the baseline SCCS interview.  They included demographic factors as well as lifestyle 
factors such as physical activity, reproductive factors, total energy intake and specific 
nutrient intakes, alcohol consumption, smoking, and co-morbid conditions.   
Age.  Age at the time of the baseline interview was calculated as the difference in the date of 
baseline interview and the reported date of birth.  Age was generally treated as a continuous 
measure.  
Income. Annual household income was reported in the baseline interview (for the year prior 
to the interview) in broad categories including <$15,000, $15-24,999, $25-49,999, and 
>$50,000-$99,999, and $100,000+.  Because of the small number of participants who 
reported income in the highest category, the top two categories were collapsed into $50,000+.   
Education level.  Educational attainment was also reported by the participants in the baseline 
interview.  For stability of estimates, education was grouped into categories for analysis 
including <9 years, 9-11 years, 12 years or completion of high school, and some college or 
more. 
Physical Activity.  Summary physical activity measures were calculated from questions 
asked in the SCCS baseline physical activity questionnaire.  This instrument was developed 
for the SCCS and was designed to comprehensively assess both active and sedentary 
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behaviors done at home, work, and during leisure-time.  Five questions about sedentary 
behaviors asked for the amount of time per day spent sitting in a car or bus, at work, 
watching TV or seeing movies, using a computer at home, and for other reasons (examples 
provided were sitting at meals, talking on the phone, reading, playing games, or sewing).  
Time spent in light, moderate, and strenuous activity at home and work were assessed 
separately for weekdays and weekends and then combined using weighted averages.  During 
the interview, handcards were given to the participants with examples of light work 
(examples were standing at work, light office work, shopping, cooking, child care), moderate 
work (examples were manufacturing work cleaning house, gardening, mowing lawn, home 
repair), and strenuous work (examples were loading trucks, construction work, farming).  
Two questions eliciting time spent in moderate sports (examples were bowling, dancing, 
golf, or softball) and vigorous sports (examples were jogging, aerobics, bicycling, tennis, 
swimming, weight lifting, or basketball) were also asked.  Two walking questions asked 
about time spent walking slowly (examples were moving around the house, walking at work, 
walking the dog) and walking fast (examples were climbing stairs, walking for 
transportation, or for exercise).   All of the physical activity behaviors described above were 
assessed at the time of the baseline SCCS Interview.  The same examples were provided to 
all participants, regardless of gender or race.  The SCCS study team has developed 
algorithms for transforming self-reported hours and minutes of physical activity into 
summary quantitative measures of hours per day or metabolic equivalent (MET)-hours per 
day based on the MET values suggested in the Compendium of Physical Activities by 
Ainsworth and colleagues (17).  Total activity MET-hours per day includes light, moderate, 
and strenuous household and occupational work as well as moderate and vigorous sports.  
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Total physical activity (MET-hours/day) was evaluated in quartiles based on the distribution 
of the entire sample of 2,000 women. 
Dietary Intake.  Total energy intake as well as specific macronutrient intakes (including fat, 
carbohydrate, and protein) was calculated from the 89-item food frequency questionnaire 
(FFQ) included in the baseline interview.  The SCCS investigators have developed a 
computer program to score the FFQ based on sex-, age-, and region-specific food intakes 
from 24-hour dietary recalls conducted by NHANES and CSFII (4).  The program outputs 
raw energy intake, raw nutrient intakes for individual macro- and micro-nutrients, energy-
adjusted nutrient intakes, and dietary intake using food group servings.  For the current study, 
total energy intake as well as macronutrient intake (fats, carbohydrates, and proteins) and 
fiber intake were examined in relation to adiponectin levels and obesity.  Total energy as well 
as the three macronutrients and fiber were selected because of their known or suspected 
associations with obesity and because of the dearth of information available on their 
association with adiponectin levels.  Women were ranked based on quartiles of nutrient 
intakes based on the distribution of the entire sample of 2,000 women.  While the absolute 
energy intakes estimated from an FFQ are not adequately measured, the ranking of women 
based on quartiles was appropriate for FFQ-derived intakes and has been shown to be a valid 
measure of dietary intake in epidemiologic studies with a variety of disease outcomes (18). 
Alcohol consumption.  Participants were asked about the frequency and amount of alcohol 
consumption in the past year during the SCCS baseline interview.  Light beer, regular beer, 
red wine, white wine, and liquor were assessed separately from each other.  All alcohol 
questions (light beer, regular beer, white wine, red wine, and liquor) related to frequency 
were asked “Over the past year, how often did you drink [Beer/Wine/Liquor]?” and 
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respondents were given the answer choices of Never, Rarely, Once per month, 2-3 times per 
month, once per week, 2-3 times per week, 4-6 times per week, once per day, or more than 
once per day.  Participants were also asked how many beers, glasses of wine, or number of 
liquor drinks they had on a typical occasion. Servings per day were calculated from the 
frequency measures (for example, once per week will be weighted as 1/7 drinks per day), 
then multiplied by the quantity reported and finally combined into a single summary measure 
of number of alcoholic drinks per day.   Alcohol consumption was categorized into 0, 1- < 2, 
and 2+ drinks per day for analysis.  
Smoking.  In the SCCS CAPI, participants were first asked whether they had smoked more 
than 100 cigarettes in their lifetime.  If they answered ‘yes’, they were asked if they smoked 
cigarettes currently, at what age they started smoking, and the average number of cigarettes 
they smoked per day (at the time of the baseline interview).  If they were not current 
smokers, participants were asked for the age at which they quit smoking cigarettes.  From 
these CAPI questions, women were categorized as never smokers (answered ‘No’ to smoking 
more than 100 cigarettes in their lifetime), former smokers (answered ‘Yes’ to smoking more 
than 100 cigarettes in their lifetime but ‘No’ to smoking cigarettes now), or current smokers 
(answered ‘Yes’ to smoking more than 100 cigarettes in their lifetime and ‘Yes’ to smoking 
cigarettes now).  These categories were treated as a single categorical variable with three 
levels.  Alternatively, duration of smoking was also calculated as none for never smokers and 
in number of years (by subtracting age at starting from age at quitting).  Smoking intensity 
was calculated by multiplying the amount by the duration of smoking (assuming that the 
current number of cigarettes smoked per day reflected past smoking history).  These three 
alternative measures of smoking were examined and as expected, were found to be highly 
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correlated with one another.  Thus, the measure of smoking with the highest univariate 
association with adiponectin was selected for examination in the multivariate models.  This 
measure was smoking duration which was categorized as never smoker, <20, 20-29, and 30+ 
years. 
Menopausal status.  Menopausal status was assessed in the SCCS baseline interview by 
asking women “Have you ever been through menopause, or have your menstrual periods 
stopped for at least six months?”  Women who answered ‘Yes’ to this question were 
classified as post-menopausal while women who answered ‘No’ were classified as pre-
menopausal. 
Reproductive factors.  Factors related to pregnancy and breastfeeding were obtained from 
the SCCS baseline interview.  Participants were asked “How many of your pregnancies have 
resulted in a live birth?”  From this question, the number of live births will be categorized 
into none, 1-2, 3-4, and 5+.   Age at menarche (in years) was examined in categories of ages 
<12, 12, 13, 14, and 15+.   Number of months of breastfeeding was highly correlated with the 
number of live births but was correlated less strongly with adiponectin in univariate analysis 
compared to number of live births so breastfeeding was dropped from the multivariate 
analyses. 
Co-morbid conditions.  SCCS participants were asked if they had ever been told by a 
physician that they had a variety of co-morbid conditions including diabetes, heart attack or 
coronary artery bypass surgery, hypertension, high cholesterol, and depression.  Each of 
these conditions was examined as a dichotomous variable (Yes/No). 
HDL cholesterol.  Using blood samples collected at baseline enrollment into the SCCS, 
high-density lipoprotein (HDL) cholesterol was measured in serum by the Vanderbilt Lipid 
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Laboratory using the ACE Clinical Chemistry System and the ACE HDLC Reagent 
(#SA1038) following the manufacturer’s protocols (Alfa Wassermann, Inc, West Caldwell, 
NJ).  The intra-assay coefficient of variation was 1.6%.  While the samples in which 
cholesterol was measured were convenience and not fasting samples, HDL-cholesterol was 
not associated with fasting status (p=0.5 for blacks, p=0.4 for whites comparing fasting 
versus non-fasting levels) (Table 2.5). 
Exposure Assessment:  Genetic markers 
Selection of SNPs.  
 For specific Aims 2 and 3, genetic variation in the ADIPOQ, ADIPOR1 and 
ADIPOR2 genes were considered to be the primary exposure measures.  SNP selection 
included the selection of variants that represent common variation in the genes of interest via 
tag SNPs.  The International HapMap project was the primary data source for the selection of 
the SNPs (19).  The HapMap Project was begun in 2002 to provide a public resource to 
support medical genetic research (19).  Phase I of the project sought to genotype at least one 
common SNP every 5 kilobases across the human genome using four geographically diverse 
populations (20).  269 samples were genotyped including 30 parent-offspring trios from 
Yorubans in Ibadan, Nigeria (abbreviated as the YRI population); 30 parent-offspring trios 
from Utah in the United States (abbreviated as the CEU population); 45 Han Chinese in 
Bejing, China; and 44 Japanese in Tokyo, Japan (20). In 2005, Phase I was complete and the 
International HapMap Consortium reported that over 1,000,000 SNPs had been identified, 
examined for quality control purposes, and found to be polymorphic in the 269 samples (20).  
Phase II of the HapMap Project was completed and reported upon in 2007; it included the 
genotyping of an additional 2.1 million SNPs in the same 269 samples to obtain a SNP 
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density of approximately 1 per kilobase (21).  The HapMap Project has been widely used as a 
resource for the selection of tag SNPs across the genome (21). 
The pattern of linkage disequilibrium (LD), a measure of dependence between two 
genetic loci, varies a great deal from population to population.  This variation is due to 
factors such as genetic drift, migration, admixture, and rapid population expansion (22).  For 
example, in a population with fewer generations (i.e. archeologically young), there is likely 
to be higher LD because there have been fewer recombination events compared to a more 
ancient population (with many more generations since its founding) in which it may be more 
difficult to detect LD.  This variation in LD between populations has important implications 
for the search for disease predisposing genes.  Important for this project which included both 
white and black women is the implication that different numbers of SNPs for the same gene 
may be required for each population in order to capture the variation within a given region.  
It has been shown that there is less LD in African populations than in Western European 
populations which indicates more variation in allele frequency and thus that more SNPs may 
need to be genotyped in an African population that in a Western European population to 
detect associations between markers and diseases (20).   Reich et al. have suggested that the 
presence of large blocks of LD in northern European populations compared to smaller blacks 
of LD among Africans suggests that the resolution of gene maps may be much finer in the 
populations with smaller blocks of LD, thus resulting in a better ability to pinpoint specific 
SNPs responsible for disease in these populations (23). 
Using the Tagger pairwise method implemented in Haploview, tag SNPs were 
selected based on a minor allele frequency greater than 5% in either the CEU or YRI 
populations and an r2 value >0.8 (where r2 is a measure of the correlation between alleles at 
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two markers) as determined from the HapMap Project (19).  Because the Illumina 
GoldenGateTM assay was selected to be the genotyping platform for this project, the selected 
tag SNPs were evaluated by Illumina, and tag SNPs were reselected when Illumina indicated 
that a particular SNP was not likely to succeed using GoldenGateTM. 
The SNPs that were genotyped in ADIPOQ are listed in Table 2.6 and are diagramed 
in Figure 2.2. A total of 25 SNPs were selected to provide adequate gene coverage for both 
the white and black women included in this study.  The SNPs that were genotyped in 
ADIPOR1 are found in Table 2.7.  Nineteen SNPs were selected for this gene.  A list of 
SNPs genotyped in ADIPOR2 is found in Table 2.8. A total of 28 SNPs were selected to 
provide coverage of this gene.  Figures 2.3 and 2.4 show the gene structure and SNP 
coverage for ADIPOR1 and ADIPOR2, respectively. 
Population stratification 
In recent years, an extensive body of literature has been published documenting potential 
biases in observations from genetic association studies (such as this project) that result from 
population stratification.  Population stratification refers to a particular type of confounding 
in which substructures that exist within human populations due to non-random mating 
confound the association between a genetic variant and disease outcome (24, 25).  In order 
for population stratification to create bias in observed measures of association, the gene 
under study must show variation in allele frequency across subpopulations, and these 
subpopulations must also have differing baseline risk of the disease outcome (26). 
There is clear debate in the literature about the extent of the problem of population 
stratification (25, 27).  Thomas and Witte argue that allele frequencies of many genes vary 
greatly across populations and that the degree of variation is directly related to the genetic 
distance between the populations (27).  These authors also point to marked differences in 
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disease rates across populations, and conclude that these two factors are sufficiently 
important to warrant attention to population stratification in association studies of unrelated 
individuals (27).  Thomas and Witte emphasize the use of related controls for genetic 
association studies to account for population stratification, which is, unfortunately, a difficult 
and impractical standard to meet for most studies in terms of recruitment, sample size, and 
other issues of practicality and efficiency.  In a counterpoint piece to the opinions voiced by 
Thomas and Witte, Wacholder and colleagues state that they believe population stratification 
is not a serious threat to the validity of well-designed and well-analyzed association studies, 
at least for cancer outcomes and in non-Hispanics of European descent (25).  Wacholder et 
al. argue that meaningful population stratification is unlikely when multiple ethnic groups are 
studied unless both the range of disease rates and the frequency of the disease-causing 
genotype vary greatly (25).  Whether their arguments hold in studies of blacks and for such 
complex disease outcomes as obesity, such as in this project, is unclear.  Rebbeck and Sankar 
(26) strike a balance in their 2005 commentary by claiming that while the evidence is limited 
to show that population stratification cause biases in most common epidemiologic studies, 
the potential for confounding is real and researchers should use appropriate study designs or 
analytic methods to evaluate and account for any bias. 
There are several ways to account for population stratification.  Beyond using family-
based designs (which are costly and often impractical) or simple adjustment for self-reported 
ethnicity (which may not fully capture the scope of the problem), several different methods 
have been proposed to address population stratification.  Pritchard and Rosenberg suggested 
an approach known as structured association (SA) (28-30).  SA assumes that a heterogeneous 
study population is composed of several homogeneous subpopulations.  Individuals are 
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assigned to subpopulation clusters based on derived vectors of information regarding 
ancestral origin using a Bayesian clustering approach.  These clusters representing ancestry 
can be used as covariates in statistical models.  Using readily available software packages 
makes the implementation of SA relatively easy and straightforward. However, the number 
of subpopulation clusters is user-defined and results may vary based on the number of 
clusters used.  Devlin et al. proposed an alternative approach that they call genomic control 
(GC) (31).  Because population stratification results in over-dispersion of test statistics used 
to assess association, GC is used to estimate the degree of over-dispersion by testing multiple 
polymorphisms throughout the genome and then determining the appropriate empirical 
distribution for a test statistic (24, 31).  Price et al. note that GC adjusts test statistics by a 
uniform factor which may be insufficient for markers that differ strongly across ancestral 
populations or may result in a loss of power for markers that do not exhibit strong 
differentiation (32).  Price et al. proposed a third method for accounting for population 
stratification via the use of principal components.  The principal components method infers 
continuous axes of genetic variation from a set of genetic markers, and these components are 
then used as covariates in the analysis of the genotype-disease association of interest in order 
to account for population stratification (32). 
Selection of Ancestry Information Markers (AIM) SNPs 
Freedman et al. demonstrated that genotyping only a few dozen markers cannot rule out 
modest levels of population stratification and that larger numbers of markers need to be 
evaluated in order to bring the 95% upper bound on stratification within 10% of the true 
value (33).  Because this project was conducted as part of the larger Komen Obesity Project 
which utilized a multiplex assay, several hundred AIMs were selected for genotyping and the 
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resulting genotypes were utilized in these analyses to assess and control for population 
stratification.   
292 Ancestry Informative Markers (AIMs) SNPs were ultimately selected for this 
project.  A list of potential AIM SNPs was generated from two sources.  A group at 
Vanderbilt University led by Dr. Scott Williams generated a list of 360 SNPs that was 
derived from analyses comparing frequencies between individuals of European (CEU) and 
African (YRI) descent in HapMap using chi-square values to rank the markers.  Additionally, 
a list of AIM SNPs from an Illumina-designed panel for ancestry estimation was obtained 
(N=1,508).  Allele frequencies for these 1,868 SNPS were updated using HapMap release 22 
data.  Potential AIM SNPs on the Y chromosome were excluded (because the genotyped 
sample included only females) as were SNPs without detailed information about 
chromosome position (N=1826 remaining).  The position of each candidate gene in the 
Komen Obesity Project was identified with 5 Mb flanking on either side.  All potential AIM 
SNPs within any of the candidate genes or the 5 Mb flanking regions were excluded (N=635 
remaining).  After exclusion of potential AIM SNPs by chromosomal location, additional 
potential AIM SNPs were deleted that had a minor allele frequency of < 0.05 in both the 
CEU and YRI populations in HapMap (N=367).  Finally, 300 of the remaining 367 potential 
AIM SNPs were selected based on the highest allele frequency differences between the CEU 
and YRI populations in HapMap.  Of these 300 AIM SNPs, 292 passed the Illumina Scoring 
algorithm and were sent for genotyping. 
DNA Extraction 
Genomic DNA was obtained from buffy coat using Qiagen’s DNA Purification kits (Qiagen 
Inc., Valencia CA) following the manufacturer’s protocol.  The average DNA yield for each 
sample was about 20 g, which allowed for numerous PCR amplifications. 
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Genotyping 
The genotyping for this project was conducted in conjunction with the Komen Obesity 
Project which in total examined 40 candidate genes related to obesity.  Genotyping took 
place at Vanderbilt University in the laboratory of Dr. Jeffrey R. Smith.  The genotyping was 
conducted using the Illumina GoldenGateTM assay (Illumina, Inc. San Diego, CA) (34, 35).  
A total of 1,536 SNPs (including those located on the three genes of interest for this research) 
were assayed together using GoldenGateTM.  The Illumina assays have very high genotype 
call rates (99.97% for the 1,536 loci multiplex) and high reproducibility (>99. 9%).  
Statistical tools within BeadStudio software from Illumina were utilized by Dr. Smith’s lab to 
evaluate genotyping success and confidence.  SNPs were excluded with call rates < 85% and 
samples that were found to be duplicates were removed.  Call rates were re-estimated and 
1,420 SNPs with call rates > 95% were included in the final analytic dataset for the overall 
Komen Obesity Project. Blinded QC samples (N=29) and another 171 pairs of duplicated 
samples were included and the consistency rate was 99.9%.  All samples showed a call rate > 
90% and thus no samples were excluded based on low call rate. 
For this study, all SNPs that were selected in the three genes of interest (ADIPOQ, 
ADIPOR1, and ADIPOR2) were successfully genotyped and had call rates greater than 95% 
except for one, rs11612383 located on ADIPOR2 which had a very low call rate and was 
excluded from further analyses.  Of the 292 AIM SNPs that were sent for genotyping, 276 
(95%) were successfully genotyped with call rates greater than 95%. 
Of the 2,000 women selected for analysis, genotyping was successful for 1,990 (N=996 black 
and N=994 white women).  Twenty-three women were excluded from the analyses because 
of discrepancies between self-reported race and ancestry estimates derived from 
STRUCTURE (Figure 2.5).  Among women who self-reported their race as ‘Black/African 
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American’, six were excluded who had an estimated percentage of African ancestry less than 
20%.  Similarly, for women who self-reported their race as ‘White’, 17 were excluded who 
had an estimated percentage of African ancestry greater than 30%.  Overall,1,967 women 
remained for analyses (N=990 black and N=977 white). 
Quality control of genotyping data 
Every effort was made to minimize potential errors during genotyping.  The laboratory staff 
remained blinded as to any characteristics of the women selected for the study.  Suitable 
negative and positive controls were run including water samples in random wells and a 
standard set of control DNA samples.  In addition, ten blinded duplicate samples for women 
in this study sample were genotyped for comparison purposes. 
Once genotyping was complete, each allele was assessed for Hardy-Weinberg 
equilibrium (HWE).  The proportion of observed alleles was compared to the expected 
proportion of alleles using the relationship p2 + 2pq + q2 = 1 (where p and q represent the 
frequencies of each of the two alleles for a given SNP) (36).  A chi-square test with one 
degree of freedom was used to compare the observed and expected proportions and HWE 
was determined to be violated if the p-value is less than 0.05. 
HWE was examined separately for blacks and whites.  A total of 12 SNPs had HWE 
p-values <0.05 and these SNPs were carefully examined for genotyping errors by Dr. Smith’s 
laboratory staff.  Because HWE holds only under strict conditions (including random mating, 
no selection or migration into or out of the population, no mutation, no population 
stratification, and an infinite sample size) (36) and it is plausible that these conditions were 
not fully met in this study population, SNPs that were found to be not in HWE but did not 
appear to have been genotyped incorrectly were decided a priori not to be removed from the 
analysis.  Based on this guideline, only one SNP (rs1648707 located on ADIPOQ) which 
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deviated extremely from HWE (p=8.6x10-16 in whites and p=1.3x10-16 in blacks) was 
excluded from further analysis. 
Statistical Methods 
The statistical methods for this research included univariate data analysis, bivariate data 
analysis including each exposure and outcome pair, and regression modeling for each 
exposure and outcome pair with careful consideration paid to confounding, multiple testing, 
and diagnostics.  In addition, the AIM SNPs were used to derive both allelic ancestry clusters 
and principal components to be used for adjustment for population stratification.  Because 
one of the main interests of this project was to examine differences between white and black 
women, analyses were stratified by race unless otherwise specified.  
Derive ancestry allelic clusters and principal components from Ancestry Informative 
Markers 
The 292 genotyped ancestry informative markers (AIMs) were used to derive two 
independent sets of variables to be considered for inclusion in the final statistical models to 
account for population stratification.  The first method to be considered was principal 
components that empirically estimate ancestry based on the method of Price et al. (32).  The 
EIGENSTRAT stratification correction method as implemented in EIGENSOFT version 2.0 
software, available from David Reich’s laboratory at The Harvard Genetics Department and 
the Broad Institute, was utilized to derive the first five principal components for each race 
group (37).  The second method under consideration included the derivation of ancestry 
allelic clusters from STRUCTURE Version 2.2.3 software 
(http://pritch.bsd.uchicago.edu/structure.html) (29).  STRUCTURE infers individual 
proportions of ancestry from K clusters, where K is specified in advance and corresponds to 
the number of posited ancestral populations.  Individuals are assigned admixture estimates 
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(i.e., ancestry allelic clusters, or AAC) from multiple ancestral populations, with the 
admixture estimates summing to 1 across these population clusters.  Given that the 
participants in this project were selected for inclusion based on self-reported race being only 
white or black, and the number of Asian and Hispanic participants in the SCCS is very low, 
K was specified to be 2 and thus two AACs were generated for each individual: one for 
African ancestry and one for European ancestry.  AAC proportions (ranging from 0.00 to 
1.00) for each individual were estimated from the AIM SNPs. 
Both the ancestry allelic clusters derived from STRUCTURE and the principal 
components partitioning ancestry that were created as output from EIGENSOFT were 
examined as potential confounders in the regression modeling.  Both methods of adjustment 
for population stratification resulted in nearly identical effect estimates between the SNPs 
and the outcomes of interest, adiponectin level (Tables A.1a, A.1b, and A.1c) and BMI 
(Tables A.1a, A.1b, and A.1c).  Thus, the STRUCTURE approach (using ancestry allelic 
clusters) was selected for the final analyses because fewer degrees of freedom were required 
for the single term for African ancestry compared to the principal components approach. 
Univariate data analysis 
Frequencies for all categorical exposure, outcome, and potentially confounding variables 
were computed among the white and black women and examined for outliers.  These 
measures included age, education, and income, physical activity, reproductive factors, total 
energy intake and specific nutrient intakes, alcohol consumption, smoking, and co-morbid 
conditions as well as the individual genotypes.  Descriptive statistics including means, 
standard deviations, medians, and ranges were calculated for the continuous measures of 
adiponectin level and BMI.   
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Bivariate data analysis 
Further exploratory data analysis was conducted via bivariate data analysis of each exposure 
and outcome pair.  The purpose of the bivariate analyses was to better understand the crude 
associations observed in these data as well as to examine the potential for confounding. 
For Specific Aim 1, correlation coefficients were examined between adiponectin level 
(outcome) and BMI (exposure).  Descriptive statistics for adiponectin levels and BMI by 
categories of environmental and behavioral factors were also examined. 
For Specific Aim 2, descriptive statistics for adiponectin levels were tabulated by 
genotype for each SNP in ADIPOQ, ADIPOR1 and ADIPOR2 (Tables A.3, A.4, and A.5). 
For Specific Aim 3, descriptive statistics for BMI were tabulated by genotype for 
each SNP in ADIPOQ, ADIPOR1 and ADIPOR2 (Tables A.6, A.7, and A.8). 
Regression modeling 
SAS/STAT software, Version 9.2 of the SAS System for Windows (SAS Institute Inc., Cary, 
NC, USA) was used for all analyses. 
There were two main objectives in Specific Aim 1:  the first was to characterize the 
relationship between adiponectin and BMI within each race group and the second was to 
determine predictors of adiponectin after adjustment for BMI.   Linear regression models 
were developed to address each of these objectives.  Adiponectin was the outcome variable 
for these regression models and was treated as a continuous measure.  The distribution of 
adiponectin was skewed and thus, a log-transformation was applied to better meet modeling 
assumptions (38). 
To address the first objective of Specific Aim 1, continuous BMI was treated as the 
main exposure variable and was regressed on adiponectin.  Potential confounders were 
determined from the literature (as described in Chapter 1) and included age at baseline SCCS 
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interview, household income, educational attainment, physical activity, HDL-cholesterol, 
dietary intake (total energy, fat, carbohydrate, protein, and fiber), cigarette smoking, 
menopausal status, number of live births, age at menarche, and co-morbidities (diabetes, 
heart attack or coronary artery bypass surgery, hypertension, high cholesterol, and 
depression).  Potential confounders were added to the regression model using backwards 
model selection with a change-in-estimate criterion of > 5% used to determine confounding 
(Tables A.9 and A.10).  Potential modifiers of the BMI-adiponectin relationship were 
assessed using the likelihood ratio test (LRT) to compare models with and without 
interaction terms for BMI and potential modifiers.  Using the LSMEANS option in 
SAS/STAT PROC GLM, adjusted geometric means for adiponectin were calculated from 
linear regression models that included standard categories of BMI (<18.5, 18.5-24.9, 25-29.9, 
30-34.9, 35-39.9, and 40-45 kg/m2) and the final set of confounders. 
To address the second objective of Specific Aim 1, a prediction model for adiponectin 
was developed with log-adiponectin as the outcome.  BMI was forced into the model and 
then environmental and behavioral factors were added sequentially.  BMI was forced into the 
model in order to determine the relative predictive ability of the environmental and 
behavioral factors after adjustment for obesity which is known to be strongly associated with 
adiponectin level.  With an emphasis on prediction of adiponectin levels, all covariates that 
appreciably improved prediction of adiponectin were retained in the final model.  
Improvement in model prediction was assessed using Akaike's information criterion (AIC) 
which takes into account improvements in the model goodness-of-fit while imposing a 
penalty for an increasing number of parameters being estimated.  Potential predictors were 
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included in the final model as long as their addition resulted in an AIC value at least one unit 
lower than the AIC for the smaller-order model (Tables A.11 and A.12). 
Standard regression diagnostics were applied to the final linear regression models to 
ensure that the assumptions of the linear regression model are not violated.  These included 
transformation of adiponectin using a log-transformation; examining the mean, variance, and 
independence of the residuals from the regression models; examining whether particular 
observations controlled the fit of the model; and examining whether there was collinearity 
between any of the covariates in the model (38).  
Additional modeling was performed by re-running the final prediction model 
developed for black and white women separately after stratifying women according to their 
decade of birth in order to assess potential cohort effects.  The strata included 1924-1939, 
1940-1949, 1950-1959, and 1960-1969.  The results of these models are shown in Table 
A.13. 
For Specific Aims 2 and 3, the general approach to estimating the associations 
between adiponectin levels (Specific Aim 2) and BMI (Specific Aim 3) and genetic 
polymorphisms in ADIPOQ, ADIPOR1 and ADIPOR2  was to use linear regression models 
to examine single SNP-outcome associations (See Tables A.14, A.15, and A.16 for 
adiponectin as the outcome and Tables A.17, A.18, and A.19 for BMI as the outcome).  The 
genotype frequencies of each SNP were examined separately for black and white women and 
SNPs with a MAF < 0.01 for a particular race group were not examined further within that 
race group. 
Each of the genotyped SNPs from the three genes of interest was examined 
individually in relation to adiponectin or BMI using the general (co-dominant) genetic model 
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of inheritance.  The referent genotype was selected to be the most common race-specific 
homozygous genotype within each race group.  For SNPs in which less than 10 women had 
the rare homozygous genotype, a dominant model was used that combined women with the 
rare homozygous genotype with those with the heterozygous genotype.  The co-dominant 
genetic model does not impose restrictions on the relationship between the estimates for each 
genotype. Because there was no a priori hypothesis about the model form for the SNP-
adiponectin associations or the SNP-BMI associations, the use of the two degree of freedom 
test for the co-dominant model was used because it has been shown have good overall 
performance for any of the possible underlying modes of inheritance (additive, dominant, or 
recessive) (39).  Potential confounders were determined a priori and included only age at 
baseline interview and a measure to account population stratification.  Nothing else was 
considered to be a possible confounder because there were no other factors believed to affect 
both the SNPs (the exposure of interest) and adiponectin and BMI (the outcomes of interest).  
Ancestry allelic clusters from STRUCTURE as well as principal components from 
EIGENSTRAT (both derived from the set of 292 AIM SNPs) were individually examined as 
covariates to account for population stratification.  Estimates from models using each of 
these approaches were found to be essentially the same and thus the STRUCTURE estimates 
were selected for all subsequent analyses because of the smaller degrees of freedom required.  
Examination of the parameter estimates from the general models was used to determine 
whether a different model form (additive, dominant, or recessive) was potentially more 
appropriate for the data.  In the case that a different model form was suggested, additional 
models were examined using the alternate model form. 
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To examine interactions between the environmental factors and individual SNPs in 
exploratory analyses, regression models were developed that included cross-product terms 
for each SNP-environmental factor.  These terms were assessed through likelihood ratio tests 
of models with and without the cross-product terms.  Only the SNPs that were found to be 
significantly associated with adiponectin based on the single SNP-outcome analyses 
described above were considered for the exploratory SNP-environmental factor interaction 
analyses.  While this study had low power to detect interactions, observed interaction will be 
used to generate future research projects within the SCCS and beyond. 
Multiple comparisons 
Multiple comparisons were an extremely important consideration in this project which 
included three genes each with multiple SNPs being examined in individual statistical 
models.  In order to address the multiple testing that was conducted, a Bonferroni correction 
was applied.  The Bonferroni correction was implemented by dividing the alpha level (set at 
0.05 for these analyses) by the total number of tests that were conducted.  Alpha values of 
0.00096 and 0.00075 were used for white and black women, respectively, based on the final 
analysis of 52 and 67 SNPs.   
Statistical considerations related to enrollment at Community Health Centers  
Women were enrolled into the SCCS at Community Health Centers (CHCs) and thus the data 
can be viewed as clustered within CHCs.  If there is clustering by CHC, the parameter 
estimates from the linear regression model may be misspecified and the variance measures 
may be biased downwards.  Direct adjustment for CHC was deemed unfeasible due to the 
large number of indicator variables that would be required.  An alternate method of 
accounting for variation resulting from the location of the CHC was devised.  The location of 
each CHC was geocoded and then merged to the United States Census data to determine the 
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county location.  Each county was assigned a Rural-Urban Continuum code as defined by the 
United States Department of Agriculture Economic Research Service (40).  There are 9 
Rural-Urban Continuum codes that classify metro (or urban) counties by the size of their 
metro area and non-metro (or rural) counties by degree of urbanization and proximity to a 
metro area.  This 9-level variable was collapsed into a dichotomous rural/urban variable and 
was included in the statistical models used to examine the associations between BMI and 
adiponectin.  There were no differences in the BMI-adiponectin effect estimates with and 
without adjustment for the CHC location and thus this variable was not included in the final 
models.    
Missing data 
Overall, in the SCCS there is a very small amount of missing data from baseline interview.  
The baseline interview data were collected using a CAPI that required each question to be 
answered by the study participant before the next question was asked by the study 
interviewer.  In addition, nearly all participants (99%) completed the baseline interview.  
Adiponectin levels were successfully measured in 1992 out of 2,000 women included in this 
study (99.6%).  Among the 1,992 women with measured adiponectin levels in this study, 
there were no missing values for BMI, age at interview, educational attainment, menopausal 
status, diabetes, heart attack/coronary artery disease, or hypertension.   Missing values were 
small for household income (N=13), total physical activity (N=9), HDL-cholesterol (N=16), 
alcohol consumption (N=5), cigarette smoking (N=10), number of live births (N=1), age of 
menarche (N=12), high cholesterol (N=2), and depression (N=2).  The largest source of 
missing data was from variables derived from the scored FFQ including total energy intake, 
macronutrient intake and fiber intake (N=68 missing for all).  The Illumina GoldenGateTM 
assay was carefully selected because it has a record of a high probability of genotyping 
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success.  Indeed, for most SNPs, all women were successfully genotyped.  Only 11 SNPs 
were not able to be genotyped for the entire sample of women and the most common number 
of samples that failed genotyping was one (for 5 SNPs).  Because of the small amount of 
missing data overall and the reasonable assumption that these data are missing completely at 
random, complete case analyses were conducted. 
Power calculations 
Statistical power was calculated for the sample of 2,000 women prior to the collection of the 
study data.  A sample size of 1000 was assumed for all calculations because the models were 
stratified by race.  An alpha-level of 0.05 was assumed throughout.  The power calculations 
were generated using Proc Power in SAS/STAT software, Version 9.1 of the SAS System for 
Windows and the QUANTO program (41).  
For specific aim 1, adiponectin as a continuous measure was the outcome.  
Adiponectin measures from the SCCS biomarker pilot study of 391 women were used for the 
power calculations.  The mean adiponectin value for black women was 25.9 ug/mL (std 
dev=19.1) while the mean adiponectin value for white women was 16.6 ug/mL (std 
dev=12.4).  The exposures of interest were BMI as well as environmental factors including 
physical activity, reproductive factors, energy and nutrient intake, alcohol consumption, 
smoking, and co-morbid conditions.  These exposures were entered into a single multiple 
linear regression model with adiponectin as the outcome. 
Because of interest not just in a single exposure-outcome association but also in 
determining which factors were predictive of adiponectin levels, the increase in the R2 value 
between an intercept-only model and a model with all parameters was examined.  Table 2.9 
shows the predicted power for various R2 values.  While these R2 values are overall low, 
they are not inconsistent with many epidemiologic models in which predictive power is 
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relatively low.  However, Table 2.9 shows that except for extremely small differences in R2, 
the study was amply powered to develop a prediction model for adiponectin. 
For specific aim 2, a series of linear regression models with adiponectin as the 
outcome were developed.  To calculate the power to detect a difference in the β coefficients 
for each genotype in relation to adiponectin level, a single linear regression model with 
adiponectin as a continuous outcome with mean 17 and standard deviation of 12.4 (based on 
the results from the black women in the SCCS Biospecimen Study) and a single SNP with 3 
genotype categories was assumed.  A Bonferroni correction was applied to the α-level of 
0.05 by assuming models were be constructed for 72 typed SNPs (over the 3 genes) resulting 
in a final α-level of 0.05/72 = 6.9x10-4 (42).  Table 2.10 shows the power calculated over a 
range of minor allele frequencies (MAF) (0.05 to 0.40) and β coefficients.  The β coefficients 
represent change in adiponectin level between genotype categories; little is known about 
what change in adiponectin has clinical meaning making the selection of β coefficients 
somewhat arbitrary but for the purposes of these power calculations, values for change in 
adiponectin were selected that have been observed in weight loss studies and between gender 
and race groups (43).  The MAF values were selected to represent the range of MAF values 
found in the selected SNPs (see tables 2.4-2.6).  For changes greater than 5.0 ug/mL of 
adiponectin, even the lowest MAF values were well-powered.  For smaller changes in 
adiponectin levels, only the analyses of the more common SNPs were well-powered.  
For specific aim 3, a similar series of linear regression models with BMI as the outcome were 
developed.  To calculate the power to detect a difference in the β coefficients for each 
genotype in relation to BMI, a single model with BMI as a continuous outcome with mean 30 
and standard deviation of 6.5 (calculated from the sample of 2,000 women already selected 
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for the proposed research) and a single SNP with 3 genotype categories was assumed.  A 
Bonferroni correction was applied using the final α-level of 0.05/72 = 6.9x10-4.  Table 2.11 
shows the power calculated over a range of minor allele frequencies (MAF) (0.05 to 0.40) 
and β coefficients.  For a change in BMI of 2.5 or greater, there is ample power at all but the 
smallest MAF values.  A change in BMI of 2.5 kg/m2 is equivalent to half the distance 
between each of the categories of BMI that have been set forth by the WHO as being 
correlated with negative health consequences (44).  As expected, power was lowest for 
models in which smaller changes in β coefficients and low MAF values were assumed but 
the study was overall well-powered for differences in BMI that are expected to be clinically 
relevant (i.e. BMI changes greater than 2.5 kg/m2) for all but the rarest SNPs selected for 
genotyping.   
Strengths and limitations 
This project was uniquely poised to take advantage of the SCCS population, the only large 
cohort study to date that has enrolled black and white participants of a similarly low 
socioeconomic level.  Because of the rapidly increasing obesity prevalence in the US and the 
large differential in the proportion of overweight and obese women by race, this work was 
urgently needed to further our understanding of obesity in both black and white women.   
Previous studies have been able to examine adiponectin in relation to obesity in white women 
but this was one of the first studies to examine adiponectin in relation to obesity in a large 
group of black and white women over a wide range of age and body size as well as to 
characterize associations between adiponectin and environmental/behavioral characteristics 
independent of obesity.     
An important limitation of this study is that it was cross-sectional and thus 
temporality could not be assessed for the relationships examined between adiponectin, 
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obesity, and environmental factors.  Additionally, factors measured at the time of the baseline 
interview (such as alcohol intake, diet, and physical activity) were assumed to reflect past 
exposures and to be reflective of the levels that may have influenced current body size but 
this cannot be determined using the cross-sectional study design. 
An additional limitation of this study was that weight (and thus BMI) was not 
assessed over the life course for each woman.  A further limitation of the BMI measurement 
was the use of self-reported height and weight values rather than measured values.   While 
older literature has indicated a high concordance for measured and self-reported values of 
height and weight (45), a more recent review indicates that height tends to be overreported 
while weight tends to be underreported (46).  This phenomenon may even be exaggerated in 
overweight women (16) leading to underestimates in BMI.  However, the nature of the in-
person interview and the high concordance observed between self-reported values and 
measured height and weight on a subset of participants in the SCCS indicates any effects of 
error resulting from self-reported body size were likely small.  A final limitation regarding 
BMI is that the sampling for the proposed research excluded women with a BMI > 45 kg/m2.  
If the relationship between adiponectin and BMI is non-linear (i.e. the slopes are different for 
women in the included BM range of 18.5 – 45 kg/m2 compared to the excluded women with 
BMI greater than 45 kg/m2), the estimates from the models created in these analyses may not 
be correct for women with an extremely large body size.  Thus, the results of this study are 
not informative as to associations with BMI at extreme levels but are useful in gaining a 
better understanding of these associations in the range of body size most often observed in 
the population.  
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The measurement of adiponectin was based on a single blood sample which is 
another limitation of the proposed design.  Because of the complexity of the SCCS design, it 
was not feasible to obtain multiple blood samples from participants.  Previous studies of 
adiponectin levels have frequently relied on single measurements as well.   A pilot study 
from the Health Professionals Follow-up study found that adiponectin levels measured one 
year apart in a sample of 20 men were highly correlated (intraclass correlation 
coefficient=0.85), indicating that a single measurement of adiponectin may be sufficient for 
risk assessment in large epidemiologic studies (47).  A study of 48 Chinese men also 
demonstrated that adiponectin values measured across four seasons were high correlated 
(intraclass correlation coefficient=0.81) (48). 
Additionally, the blood samples in which adiponectin was measured were not fasting 
samples.  Unfortunately, little research is available to determine the effects of fasting versus 
non-fasting blood samples on adiponectin concentration.  While many small studies that have 
examined adiponectin in relation to insulin or glucose levels have used fasting samples (7, 
10, 12), adiponectin levels have not been measured exclusively in fasting samples in large 
cohort studies (for example, a combination of fasting and non-fasting samples were used to 
measure adiponectin in the Nurses Health Study and Health Professionals Follow-up Study 
(49, 50)).  In the current study, women were stratified by fasting status in order to address 
whether fasting affected the measurement of adiponectin levels.  Approximately 44% of the 
2,000 women in this study reported their last meal more than 8 hours before their blood draw 
and were considered fasting.  There were no differences in the measured adiponectin levels 
by fasting blood status (black women fasting v. non-fasting mean adiponectin=14.9 v. 15.9, 
p=0.25; white fasting v. non-fasting mean=20.2 v. 19.6, p=0.6).  Additionally, models were 
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restricted to the 421 black and 450 white women with fasting blood samples and the 
association between BMI and adiponectin was compared to the results for the entire sample 
(Table A.20  Fasting status was not a consideration for the associations examined between 
BMI and genetic polymorphisms in ADIPOQ, ADIPOR1, and ADIPOR2.  
A further limitation of this study is related to the measurement of the covariates.   
Diet, alcohol, and physical activity measures were derived from instruments developed 
specifically for the SCCS baseline interview.  Validation studies for the FFQ and the physical 
activity questions are currently in progress within the SCCS.  Preliminary results indicate that 
the SCCS FFQ is able to generate useful rankings among cohort members for dietary intakes 
(51) and that the physical activity measures when compared to objective measures (such as 
accelerometer-measured activity) have reasonable validity and reliability and are comparable 
to other validated physical activity questionnaires (personal communication, Dr. Maciej 
Buchowski, 2009).  Current smoking status has been validated in the SCCS Biospecimen 
Pilot Study using cotinine measurements in blood samples and smoking status was found to 
be generally well-correlated with cotinine levels (52).  
Finally, the study sample used for these analyses was drawn from the larger SCCS 
population which enrolled participants through Community Health Centers (CHCs).  Because 
of this method of recruitment, external validity was a potential limitation.  The CHCs used 
for enrollment were located in the southeastern United States, and the patient population 
from these CHCs may differ for many characteristics from the general US population.  In 
addition, the population that utilizes health services at CHCs is generally of lower SES and a 
higher proportion of patients lack health insurance than in the general population.  Finally, 
the SCCS cohort has a higher prevalence of co-morbidities (such as diabetes and 
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hypertension) than the general population, limiting generalizability.  Because of the inherent 
differences in the CHC population from the general US population, in interpreting the results 
of this study, care was taken so as to not to make inferences about the black or white 
population of the US in general.  However, it should be emphasized that the use of the SCCS 
participants for this research was also a major strength first, because of the large number of 
blacks participants and second, because few previous studies have included large numbers of 
both black and white women of similarly low socioeconomic status and geographic location. 
Summary 
Adiponectin may be an important link between obesity and disease risk and may be a useful 
therapeutic for cardiovascular disease, cancer, and type 2 diabetes.  However, limited data 
are available regarding adiponectin levels or its correlates in black women.  Additionally, 
adiponectin levels are highly heritable and a number of single nucleotide polymorphisms 
(SNPs) in the genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1 and 
ADIPOR2) have been examined in relation to circulating adiponectin levels and obesity 
phenotypes although again, few of these studies have included black participants.  Cross-
sectional interview data and blood samples collected from 2,000 women (1,000 black and 
1,000 white) who enrolled in the Southern Community Cohort Study at Community Health 
Centers in twelve southeastern states from 2002 to 2006 were used in this project to assess 
adiponectin levels in relation to BMI, environmental and behavioral factors, and genetic 
variants in ADIPOQ, ADIPOR1, and ADIPOR2.  Adiponectin levels in relation to BMI and 
environmental and behavioral characteristics were evaluated using race-specific linear 
regression models with adjustment for potential confounders.  In addition 25 tag-SNPs in 
ADIPOQ, 19 in ADIPOR1, and 27 in ADIPOR2 were examined in relation to adiponectin 
levels and BMI.  SNP-adiponectin and SNP-BMI associations were evaluated using race-
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stratified linear regression models with adjustment for age and percentage of African 
ancestry to account for possible population stratification. A   race-specific Bonferroni p-value 
threshold was employed for significance testing.  This study was able to assess associations 
between obesity, adiponectin, and environmental and genetic correlates in the largest-to-date 
sample of black and white women over a range of age and body sizes from similar 
socioeconomic and geographic backgrounds.
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Figure 2.1 Location of Community Health Centers for enrollment of participants into the 
Southern Community Cohort Study, 2002-2006 
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Map of ADIPOQ, Located on Chromosome 3q27
SourceL NCBI build 35 and HapMap data release 21a (January 2007)
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Figure 2.2 Map of SNPs selected for genotyping in ADIPOQ 
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Map of ADIPOR1, Located on Chromosome 1q32
Source: NCBI build 35 and HapMap data release 21a (January 2007)
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Figure 2.3  Map of SNPs selected for genotyping in ADIPOR1 
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Map of ADIPOR2, Located on Chromosome 12q13
Source: NCBI build 35 and HapMap data release 21a (January 2007)
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Figure 2.4  Map of SNPs selected for genotyping in ADIPOR2 
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Figure 2.5  Percentage of African ancestry as estimated by STRUCTURE from 292 Ancestry 
Informative Markers for black women (N=996) and white women (N=994) successfully 
genotyped for ADIPOQ, ADIPOR1, and ADIPOR2 by self-reported race categories (black 
and white). 
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Table 2.1 Selected characteristics for female participants enrolled in the Southern 
Community Cohort Study through February 2006 
 
 Black women 
N=20,635 
White women 
N=6,574 
 N % N % 
Age at interview     
       40 – 49 10,271 49.8 2,743 41.7 
       50 – 59 6,612 32.0 2,214 33.7 
       60 – 69 2,777 13.5 1,232 18.7 
       70 – 79 975 4.7 385 5.9 
Household income      
   < $15K 12,627 62.0 3,853 59.3 
       $15 - $25K 4,863 23.9 1,294 19.9 
       $25 - $50K 2,223 10.9 816 12.6 
    > $50K 658 3.2 531 8.2 
Education (yrs)     
    < 9  1,628 7.9 612 9.3 
       9-11 5,001 24.2 1,368 20.8 
      12 8,143 39.5 2,643 40.2 
   > 12 5,855 28.4 1,948 29.7 
Health Insurance     
     None 2,744 42.1 7,935 38.7 
     Private 1,540 23.6 4,726 23.1 
     Medicare/Medicaid 1,519 23.3 5,698 27.8 
    Other1 714 11.0 2,124 10.4 
Diabetes2     
    Yes 5,044 24.5 1,342 20.5 
    No 15,556 75.5 5,214 79.5 
Hypertension3     
    Yes 12,989 63.0 3,365 51.3 
    No 7,613 37.0 3,189 48.6 
BMI (kg/m2)     
   < 18.5 217 1.1 131 2.0 
       18.5 – 24.9 3,299 16.2 1,535 23.5 
       25.0 – 29.9 5,202 25.5 1,714 26.3 
       30.0 – 34.9 5,101 25.0 1,424 21.8 
       35.0 – 39.9 3,367 16.5 861 13.2 
     > 40.0  3,215 15.8 860 13.2 
 
1 Reported as Military/VA or ‘other’ insurance 
 
2 Has a doctor ever told you that you have had diabetes or high blood sugar? (not during 
pregnancy) 
 
3 Has a doctor ever told you that you have had high blood pressure?
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Table 2.2 Characteristics of 28,158 female Southern Community Cohort Study (SCCS) 
participants enrolled through February 2006 who did and did not provide blood samples at 
the baseline SCCS interview  
 
 Provided 
blood sample 
N=14,093 
No blood sample 
provided 
N=14,065 
 N % N % 
Race  
    Black 9,961 70.7 10,674 75.9
    White 3,655 25.9 2,919 20.8
    Other 459 3.3 378 2.7
    Missing 18 0.1 94 0.7
Age at interview  
       40 – 49 6,827 48.4 6,606 47.0
       50 – 59 4,556 32.3 4,606 32.8
       60 – 69 2,110 15.0 2,046 14.6
       70 – 79 600 4.3 807 5.7
    Missing 0 0.0 0 0.0
Household income   
   < $15K 8,623 61.2 8,341 59.3
       $15 - $25K 3,219 22.8 3,105 22.1
       $25 - $50K 1,582 11.2 1,579 11.2
    > $50K 501 3.6 748 5.3
    Missing 168 1.2 292 2.1
Education (yrs)  
    < 9  1,178 8.4 1,145 8.1
       9-11 3,314 23.5 3,182 22.6
      12 5,635 40.0 5,428 38.6
   > 12 3,945 28.0 4,216 30.0
    Missing 21 0.2 94 0.7
BMI (kg/m2)  
   < 18.5 135 1.0 227 1.6
       18.5 – 24.9 2,390 17.0 2,618 18.6
       25.0 – 29.9 3,515 24.9 3,625 25.8
       30.0 – 34.9 3,436 24.4 3,289 23.4
       35.0 – 39.9 2,262 16.1 2,073 14.7
     > 40.0  2,210 15.7 1,985 14.1
    Missing 145 1.0 248 1.8
 
Note: Women who reported hepatitis or HIV infection are not included in this table because 
they were not eligible to provide a blood sample due to shipping restrictions.
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Table 2.3  Descriptive statistics for adiponectin levels (ug/ml) measured in the Southern 
Community Cohort Study biospecimen pilot study among females 
 
 Black women White women 
Mean 16.6 25.9 
Median 13.0 19.3 
Std. deviation 12.4 19.1 
Range 1.9 – 86.7 0.0 – 98.0 
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Table 2.4 Characteristics of female Southern Community Cohort Study (SCCS) participants 
enrolled in the SCCS through February 2006 who provided a blood sample (N=14,093), were 
eligible for selection into the proposed research after exclusionary criteria were applied 
(N=10,585), and were selected for the final sample (N=2,000) 
 
 All women with 
blood 
N=14,093 
Eligible for sample 
selection 
N=10,585 
Selected for 
proposed research 
N=2,000 
 N % N % N % 
Race  
    Black 9,961 70.7 7,805 73.7 1,000 50.0
    White 3,655 25.9 2,780 26.3 1,000 50.0
    Other 459 3.3 0 0.0 0 0.0
    Missing 18 0.1 0 0.0 0 0.0
Age at interview  
       40 – 49 6,827 48.4 5,078 48.0 1,183 59.2
       50 – 59 4,556 32.3 3,410 32.2 511 25.6
       60 – 69 2,110 15.0 1,650 15.6 266 11.3
       70 – 79 600 4.3 447 42 80 4.0
Household income   
   < $15K 8,623 61.2 6,454 61.0 1,219 61.0
       $15 - $25K 3,219 22.8 2,477 23.4 441 22.1
       $25 - $50K 1,582 11.2 1,186 11.2 246 12.3
    > $50K 501 3.6 360 3.4 81 4.0
    Missing 168 1.2 108 1.0 13 0.7
Education (yrs)  
    < 9  1,178 8.4 873 8.3 164 8.2
       9-11 3,314 23.5 2,507 23.7 467 23.4
      12 5,635 40.0 4,284 40.5 827 41.4
   > 12 3,945 28.0 2,918 27.6 542 27.1
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Table 2.5.  Descriptive statistics for HDL-cholesterol values by study sample and race 
 
 HDL 
 White Black 
Total   
   N 988 988
   Mean (Std dev) 49.5 (13.1) 55.9 (15.4)
   Median (Q1-Q3) 48 (41-55) 53 (45-64)
Pilot Sample 
   N 195 195
   Mean (Std dev) 52.0 (13.6) 57.9 (4835)
   Median (Q1-Q3) 50 (42-59) 55 (47-67)
Komen Sample 
   N 793 793
   Mean (Std dev) 48.9 (12.9) 55.4 (15.4)
   Median (Q1-Q3) 47 (40-55) 53 (45-63)
Fasting 
   N 445 417
   Mean (Std dev) 49.1 (13.9) 55.5 (14.8)
   Median (Q1-Q3) 48 (40-55) 53 (46-62)
Non-Fasting 
   N 543 570
   Mean (Std dev) 49.8 (12.4) 56.2 (15.9)
   Median (Q1-Q3) 48 (41-57) 54 (45-64)
p-value1 0.42 0.51
 
1 p-value from t-test comparing fasting mean to non-fasting mean within each stratum of race
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Table 2.6 Single nucleotide polymorphisms (SNPs) in the ADIPOQ gene selected for 
genotyping 
 
SNP 
Caucasian 
MAF1,4 
African 
MAF2,4 
African-American 
MAF3,4 
rs1648707 0.37 0.36  
rs864265 0.13 0.15  
rs822387 0.10 0.35  
rs16861194 0.07 0.31  
rs182052 0.35 0.40 0.45 
rs16861205 0.04 0.22  
rs822391 0.17 0.00  
rs16861210 0.10 0.16  
rs822396 0.15 0.00  
rs12495941 0.31 0.39  
rs7649121 0.25 0.00  
rs9877202 0.01 0.20  
rs17366568 0.15 0.05  
rs3821799 0.46 0.39  
rs3774261 0.38 0.43  
rs17366743 0.08 0.00  
rs6444174 0.00 0.24  
rs1063539 0.13 0.01  
rs9842733 0.00 0.14  
rs1403697 0.00 0.20  
rs7641507 0.00 0.06  
rs6444175 0.29 0.28  
rs1403696 0.00 0.30  
rs7628649 0.10 0.38  
rs17373414 0.11 0.00  
 
1 From HapMap CEU population 
 
2 From HapMap YRI population 
 
3 From TSC 42 African-American population 
 
4 MAF = Minor allele frequency
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Table 2.7 Single nucleotide polymorphisms (SNPs) in the ADIPOR1 gene selected for 
genotyping 
 
SNP 
Caucasian 
MAF1,3 
African 
MAF2,3 
rs6672643 0.12 0.33 
rs2185781 0.21 0.31 
rs4336908 0.19 0.10 
rs10920531 0.33 0.29 
rs7539542 0.29 0.00 
rs1342387 0.45 0.49 
rs7518457 0.00 0.09 
rs12045862 0.23 0.08 
rs2275737 0.44 0.48 
rs12733285 0.26 0.00 
rs10753929 0.20 0.23 
rs1539355 0.33 0.42 
rs10800888 0.00 0.17 
rs6666089 0.33 0.00 
rs7523903 0.00 0.30 
rs2232849 0.00 0.13 
rs2232847 0.33 0.13 
rs2232844 0.00 0.06 
rs2232842 0.01 0.15 
 
1 From HapMap CEU population 
 
2 From HapMap YRI population 
 
3 MAF = Minor allele frequency
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Table 2.8 Single nucleotide polymorphisms (SNPs) in the ADIPOR2 gene selected for 
genotyping 
 
SNP 
Caucasian 
MAF1,3 
African 
MAF2,3 
rs758027 0.00 0.13 
rs1029629 0.32 0.23 
rs7304096 0.00 0.06 
rs2058033 0.15 0.00 
rs7975600 0.13 0.14 
rs11832817 0.29 0.15 
rs12826079 0.09 0.00 
rs10773982 0.33 0.37 
rs11061946 0.07 0.00 
rs10773983 0.35 0.13 
rs11612383 0.32 0.27 
rs12316367 0.49 0.10 
rs10773989 0.47 0.30 
rs2058112 0.13 0.13 
rs12298275 0.00 0.08 
rs7134070 0.01 0.14 
rs7967137 0.13 0.24 
rs7138701 0.01 0.21 
rs11614639 0.46 0.31 
rs10773991 0.48 0.23 
rs4140993 0.01 0.20 
rs16928751 0.13 0.13 
rs2286384 0.48 0.39 
rs12342 0.33 0.14 
rs1044471 0.47 0.22 
rs7294540 0.46 0.08 
rs13219 0.44 0.18 
rs2058111 0.42 0.24 
 
1 From HapMap CEU population 
 
2 From HapMap YRI population 
 
3 MAF = Minor allele frequency
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Table 2.9 Power for Specific aim 1 
 
R2 value between full model and intercept-only model Predicted Power 
0.20 >0.99 
0.10 >0.99 
0.05   0.99 
0.04   0.98 
 
 
 
 
 
Table 2.10 Power for Specific Aim 2 (adiponectin as continuous outcome) 
 
 Minor Allele Frequency 
β coefficient 0.05 0.10 0.20 0.30 0.40 
2.5 0.05 0.19 0.52 0.72 0.81 
5.0 0.64 0.97 >0.99 >0.99 >0.99 
7.5 0.99 >0.99 >0.99 >0.99 >0.99 
 
 
 
 
 
Table 2.11 Power for Specific Aim 3 (BMI as continuous outcome) 
 
 Minor Allele Frequency 
β coefficient 0.05 0.10 0.20 0.30 0.40 
1.50 0.09 0.32 0.72 0.88 0.93 
2.50 0.57 0.95 >0.99 >0.99 >0.99 
5.00 >0.99 >0.99 >0.99 >0.99 >0.99 
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CHAPTER 3: SERUM ADIPONECTIN IN RELATION TO BODY MASS INDEX 
AND OTHER PREDICTORS IN BLACK AND WHITE WOMEN 
 
Abstract 
Adiponectin is a promising biomarker linking obesity and disease risk and may be a useful 
therapeutic for cardiovascular disease, cancer, and type 2 diabetes.  However, limited data 
are available regarding adiponectin in black women among whom obesity is highly 
prevalent.  We conducted a cross-sectional analysis in Southern Community Cohort Study 
participants to assess racial differences and correlates of serum adiponectin.  Adiponectin 
was measured in 996 black and 996 white women age 40-79 years recruited at community 
health centers across the southeastern US from 2002 to 2006.  Blacks had significantly lower 
adiponectin levels than whites (geometric means 11.7 versus 15.1 ug/ml, p<0.0001). Among 
blacks, adiponectin levels were lower among overweight and obese women compared to 
healthy weight women but showed no clear decreasing trend with increasing severity of 
obesity; adjusted geometric means (95% confidence interval) were 15.0 (13.8-16.4), 11.5 
(10.6-12.5), 9.7 (9.0-10.6), 11.4 (10.3-12.6), and 10.9 (9.5-12.6) ug/ml for body mass index 
[BMI] categories of 18.5-24.9, 25-29.9, 30-34.9, 35-39.9, and 40-45.  In contrast, among 
whites there was a monotonic reduction in adiponectin across all BMI categories (adjusted 
geometric means = 19.9 (18.3-21.7), 15.1 (13.9-16.4), 14.3 (13.2-15.5), 12.5 (11.2-13.9), and 
11.0 (9.7-12.5) ug/ml). In multiple linear regression models, BMI, age, HDL-cholesterol, and 
hypertension were important predictors of adiponectin in both groups whereas 
socioeconomic status (education and income), cigarette smoking, physical activity, and 
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dietary, reproductive, and co-morbidity indices were not significant predictors in either black 
or white women.  Our results indicate that racial differences exist in both the magnitude and 
form of the adiponectin-BMI association. 
Introduction 
Adiponectin is a protein produced exclusively in adipose tissue that appears to play a critical 
role in mediating physiological effects such as insulin sensitivity, inflammatory response, 
and cell proliferation.  Adiponectin levels are inversely associated with obesity and are 
thought to decrease in individuals with increased adiposity through down-regulation of 
adiponectin receptors (1).  Adiponectin may also be affected by diet, physical activity, 
comorbidities, and other environmental factors as well as variation in genes encoding 
adiponectin or its receptors (1).  Because adiponectin is inversely associated with obesity 
phenotypes as well as several obesity-related diseases (2), there is speculation that 
adiponectin activity may be a useful target in the prevention of cardiovascular disease, 
cancer, and type 2 diabetes (1, 2).  With the highest prevalence of obesity found among non-
Hispanic black women (39%) and the lowest among non-Hispanic white women (22%) (3), 
differences in adiponectin levels across race groups may contribute to disparities in obesity-
related diseases between black and white women.  
Identifying correlates of adiponectin and ascertaining whether they vary by race is 
likely to enhance the development of effective adiponectin-related chemopreventive 
strategies.  Thus, the goal of this analysis was to examine associations between adiponectin 
levels, body mass index (BMI), and other potential correlates and to assess whether 
associations varied by race. 
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Methods and Procedures 
Institutional Review Boards at Vanderbilt University, Meharry Medical College, and the 
University of North Carolina at Chapel Hill approved this study.  
Study population 
The Southern Community Cohort Study (SCCS) is a prospective epidemiologic cohort study 
designed to examine racial disparities in cancer incidence and mortality (4).  Study 
enrollment began in 2002 in 12 southeastern states at Community Health Centers (CHC) 
which are government-funded facilities providing health services primarily to low-income 
individuals in medically underserved areas (5).  As described previously (4), participants 
were required to be age 40-79 years, English-speaking, and not have undergone treatment for 
cancer within the past year.  From over 47,000 participants enrolled through early 2006, a 
sub-sample of 2,000 women who provided a blood sample at study enrollment and self-
reported their race as either ‘Black/African American’ or ‘White’ was selected for further 
biomarker analyses.  This included a random sample of 395 women selected in 2005 within 
three strata (race, BMI, and smoking status) and a second random sample of 1,605 women 
selected in 2006 in equal numbers across race, BMI, and menopausal status categories.    
Data collection 
Trained study interviewers led all participants through a structured questionnaire 
using a computer-assisted interview with extensive skip patterns and range and logic checks.  
The interview elicited information including demographics, anthropometrics, and several 
aspects of health and behavior.  Physical activity was measured using a questionnaire 
developed for the SCCS to comprehensively assess active and sedentary behaviors at the 
time of the interview.  Dietary intake in the year prior to the baseline interview was measured 
using an 89-item food frequency questionnaire (FFQ) designed specifically for the SCCS to 
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elicit information about foods most commonly eaten in the southeastern United States (6, 7).  
For the 20% of women who were patients in the CHC on the day of the baseline interview, 
measured height and weight were abstracted from medical records for validation purposes. 
A convenience blood sample was collected at the time of recruitment using one 
EDTA-containing plasma tube and one serum BD Vacutainer® tube.  For this study, the 
median time between the last reported meal and blood collection was 6.0 for blacks and 6.3 
for whites (p=0.07).  Fasting blood, defined as at least 8 hours since last meal, was collected 
for 44% of the participants.  Blood samples were shipped cold to Vanderbilt University in 
Nashville, TN, where they were processed for storage at -80° C.  84% of the blood samples 
were received the day after the blood draw and 98% were received within two days.  The 
samples were frozen for an average of 2.6 years (range 3 months to 5 years) prior to analysis. 
Laboratory assays 
Adiponectin levels were measured in serum by immunoassay using the LINCOplex 
kit (Luminex® xMAPTM Technology, St. Louis, MO) in the Vanderbilt Hormone Assay and 
Analytical Services Core Laboratory in duplicate for each woman.  The average of the two 
measurements was used in all analyses.  Duplicate sets of samples for five randomly selected 
women as well as five repeat samples from each of two pooled samples were measured to 
assess the reliability and validity of the assay.  Adiponectin levels were successfully 
measured in 1,992 of the 2,000 samples (eight samples failed due to a filter plate error or low 
sample volume).  The intra-assay coefficient of variation was 9.4%.  High-density lipoprotein 
(HDL) cholesterol was measured in serum by the Vanderbilt Lipid Laboratory using the ACE 
Clinical Chemistry System and the ACE HDLC Reagent (#SA1038) following the 
manufacturer’s protocols (Alfa Wassermann, Inc, West Caldwell, NJ).  The intra-assay 
coefficient of variation was 1.6%.  Neither adiponectin nor HDL-cholesterol was associated 
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with fasting status (for adiponectin, p=0.3 for blacks, p=0.6 for whites; for HDL, p=0.5 for 
blacks, p=0.4 for whites).   
Statistical Methods 
For this cross-sectional analysis, data from 1,992 women with measured adiponectin 
were analyzed.  BMI was calculated from self-reported values as [weight (kg)] / [height 
(m)2].  Dietary intakes, total physical activity, and HDL-cholesterol were categorized into 
quartiles based on the distribution of the entire sample.  Other characteristics were 
categorized as shown in Table 3.1.  The Wilcoxon signed rank test was used to compare 
adiponectin levels between groups.      
Adiponectin had a skewed distribution (Figure 3.1), and therefore was log-
transformed to better meet modeling assumptions (8).  To ease presentation, back-
transformed values are shown.  Linear regression models were constructed for blacks and 
whites separately.  All models were adjusted for sample selection (395 selected in 2005 
versus 1605 selected later) and age at baseline interview.  Further adjustment for factors used 
in the sample selection (cigarette smoking status and menopausal status) did not alter the 
results and were not included in the models presented here.  Categorized covariates with 
inherent order were modeled using indicator variables rather than as ordinal variables 
because the assumption of linearity was not generally met.   
The first analytic objective was to characterize the relationship between adiponectin 
and BMI within each race group.  Continuous BMI was regressed on adiponectin, and 
potential confounders (determined from the literature and categorized as shown in Table 3.1) 
were added to the model using backwards model selection with a change-in-estimate 
criterion of > 5%.  Potential modifiers of the BMI-adiponectin relationship were assessed 
using the likelihood ratio test (LRT) to compare models with and without interaction terms 
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for BMI and potential modifiers.  Adjusted geometric means for adiponectin were calculated 
from linear regression models that included standard categories of BMI (<18.5, 18.5-24.9, 
25-29.9, 30-34.9, 35-39.9, and 40-45 kg/m2) and the final set of confounders.   
The second analytic goal was to determine predictors of adiponectin after adjustment 
for BMI.  BMI was forced into the linear regression model and potential predictors were then 
added sequentially.  Prediction models were compared using Akaike’s Information Criterion 
(AIC) which balances model fit with model complexity (9), and potential predictors were 
included in the final model as long as their addition resulted in an AIC value at least one unit 
lower than the AIC for the smaller-order model.   
SAS/STAT software, Version 9.1 of the SAS System for Windows (SAS Institute 
Inc., Cary, NC, USA) was used for all analyses. 
Results 
Adiponectin levels were nearly 25% lower among black women compared to white 
women (geometric means: 11.7 versus 15.1 ug/ml, respectively, p<0.0001).  After adjustment 
for BMI and age, adiponectin was still significantly lower in blacks (p<0.0001).  Unadjusted 
adiponectin levels decreased with increasing BMI categories in both groups although not as 
consistently among blacks (Table 3.1).  There was a strong positive association between 
adiponectin and both age and HDL-cholesterol while adiponectin was slightly lower among 
women reporting diabetes or hypertension.  Unadjusted adiponectin levels increased with 
increasing alcohol consumption in whites but not in blacks.  Adiponectin was not 
consistently associated with education, income, physical activity, cigarette smoking, or any 
of the dietary or reproductive indices.   
Figure 3.2 illustrates race-specific associations between BMI and adiponectin 
adjusted for HDL-cholesterol, the only variable found to be a confounder of the BMI-
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adiponectin relationship.  Adjusted mean adiponectin levels for blacks were lower than those 
for whites within each category of BMI although the differences for women in the highest 
categories of BMI (35-39.9 and 40+) were small.  Among blacks, adiponectin decreased over 
BMI values up to 30-34.9 before leveling off at the highest levels of BMI.  In contrast, 
among whites, adiponectin declined steadily over increasing categories of BMI.  Menopausal 
status did not modify the BMI-adiponectin relationship (LRT p=0.9 for blacks, p=0.6 for 
whites) (data not shown).  In models restricted to 420 black and 450 white women with 
fasting blood samples, the association between BMI and adiponectin was unchanged for both 
groups.   
 Table 3.2 shows race-specific prediction models for adiponectin.  Based on the AIC 
values, BMI was an important predictor of adiponectin in both race groups although the 
regression coefficient was larger in magnitude among whites.  Age, HDL-cholesterol, and 
hypertension were also predictive of adiponectin in both groups.  None of the other factors 
examined added additional predictive value.   
Discussion 
In this largest to-date, cross-sectional study of black and white women from similar 
geographic and socioeconomic situations, we observed that blacks had lower adiponectin 
levels than whites even after adjustment for BMI.  Our results expand upon previous studies 
that have also found lower levels of adiponectin in blacks but were limited either by small 
numbers of black participants (10-13) or limited age ranges (14-16), indicating that racial 
differences in adiponectin exist across the adult age spectrum.   
Adiponectin has consistently been found to be negatively correlated with obesity in 
white and Asian populations (17-19).  Despite racial differences in the prevalence of obesity 
and risk for obesity-related disease, few large studies have examined adiponectin in relation 
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to obesity in blacks.  As did our study, several small studies (11, 13, 20) as well as the 
Atherosclerosis Risk in Communities Study (14) found that adiponectin decreased over 
categories of BMI in blacks and that adjusted adiponectin values were lower for black 
women compared to white women in each BMI category.  Our analysis included larger 
numbers of women with higher values of BMI than in previous studies, and we showed for 
the first time that the form of the BMI-adiponectin association may differ by race with white 
women showing a consistent decline in adiponectin over all levels of BMI while among 
blacks, adiponectin was lower among overweight and obese women compared to healthy 
weight women but there was little trend with increasing severity of obesity.   
Our first-ever extensive examination of potential predictors of adiponectin found few 
factors that were strongly predictive of adiponectin.  Adiponectin levels rose with advancing 
age, consistent with earlier studies (17, 21).  The direction of this association has previously 
been noted to be paradoxical; abdominal fat, which is inversely associated with adiponectin, 
increases with age indicating that adiponectin levels should decrease with age.  One potential 
explanation for this seeming contradiction is that estrogen, thought to inhibit adiponectin, 
decreases with age allowing adiponectin to rise (17).  We also observed a strong positive 
association between HDL-cholesterol and adiponectin, as have others (17, 21).  
Mechanistically, it is hypothesized that decreased adiponectin levels may affect hepatic 
insulin resistance leading to increased hepatic lipase activity and decreased HDL levels (17, 
21).  While the cross-sectional nature of our data did not allow us to examine the temporality 
of the HDL-adiponectin relationship, our data demonstrate that this strong association holds 
across race and age groups.   
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Low adiponectin levels have been inversely linked to hypertension (22-24) including 
in one study of blacks (24), a finding we also observed in both race groups.  A few prior 
studies have found this association only among participants with insulin resistance, but at 
least some evidence indicates that low adiponectin levels may affect the development of 
hypertension at an early stage, without involvement of insulin resistance (23).  We found that 
adiponectin levels were only slightly lower among diabetics, and after adjustment for BMI 
and age, diabetes and adiponectin were not significant associated.  This was somewhat 
unexpected since adiponectin and diabetes incidence have previously been shown to be 
inversely linked (25).  One explanation may be that many SCCS women with prevalent 
diabetes were receiving treatment for their diabetes, thus reducing effects of 
hyperinsulinemia on adiponectin levels.   
Neither physical activity nor dietary factors were predictive of adiponectin levels 
despite their known roles as major components of energy balance.  In contrast, a prior study 
found that physical activity was associated with increased adiponectin levels, with 
moderate/high intensity activity showing stronger effects than low intensity activity (26).  It 
is possible that the activity levels in our population were too low overall to detect effects on 
adiponectin levels; in fact, less than 20% of the women in either race group in this study met 
the recommended guidelines for physical activity (27).  Little research has been conducted 
regarding associations between dietary factors and adiponectin.  One study found no 
association between total calories or macronutrient intake and adiponectin (28) while fiber 
was found to be positively associated with adiponectin among diabetics (29, 30).  It seems 
likely that there are many intermediaries in the pathways linking diet and physical activity to 
adiponectin, making the detection of associations difficult in our cross-sectional dataset.  
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Additionally, it is possible that once age, BMI, and HDL-cholesterol were included in models 
for adiponectin, minimal additional predictive value was added by factors such as diabetes, 
diet, and physical activity which are reasonably expected to be predictive of adiponectin but 
are also strongly associated with age, BMI, and HDL-cholesterol.  While standard in large 
epidemiologic studies, the physical activity and dietary intakes obtained via questionnaire are 
known to contain substantial measurement error which may have resulted in the attenuation 
of observed associations with adiponectin.   
Inferences from this study should also be considered in light of potential limitations 
related to our measurement of adiponectin.  The high-molecular weight (HMW) form of 
adiponectin has been suggested to be the more biologically active (31) and thus, we may 
have been unable to detect certain associations because we (like most other large, population-
based studies) did not specifically measure HMW adiponectin.  Additionally, adiponectin 
was measured only at a single point in time.  Studies in white and Chinese individuals found 
that adiponectin levels measured one year apart were highly correlated, indicating that a 
single measurement of adiponectin is likely sufficient for large epidemiologic studies (32, 
33).  Another possible limitation of our adiponectin measurement is that it was not conducted 
exclusively in fasting samples; however, analyses limited to samples provided more than 8 
hours since the last meal did not show any appreciable differences from those using the entire 
population. 
The use of self-reported height and weight measures is also a potential limitation.  A 
recent review indicates that among women, height tends to be over-reported and weight 
under-reported (34).  However, data from the 1999-2004 National Health and Examination 
Survey show that despite errors in self-report, BMI categories based on self-reported values 
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demonstrate good agreement with BMI categories from measured values (35).  These data 
also showed that under-reporting was more common in whites and among well-educated 
women (35) which suggests that the BMI values calculated from self-report in the SCCS may 
be less vulnerable to bias than in other studies of more educated, white participants.  
Furthermore, in the SCCS, BMI values calculated from self-reported height and weight were 
very highly correlated with BMI values calculated from medical record data overall (Pearson 
correlation coefficient > 0.95) as well as across strata of race and BMI, indicating that our 
self-reported values provide a useful measure of BMI in the context of an epidemiologic 
study.  
A major strength of this study is the utilization of the SCCS resource.  By design, the 
black and white participants arose from similar geographic and SES backgrounds facilitating 
the examination of racial differences by minimizing the potential role of SES-driven 
confounding, a limitation that clouds the interpretation of results from many previous studies.  
Our study also overcomes limitations from previous studies which were hampered by small 
numbers of black participants, narrow age ranges, and few participants with BMI greater than 
35. 
Analysis of this large population of highly comparable black and white women shows 
that adiponectin levels are lower in blacks than in whites and that adiponectin is inversely 
associated with obesity but the shape of the BMI-adiponectin association differs by race.  
Additionally, we demonstrated that age, HDL-cholesterol, and hypertension are strong 
correlates of adiponectin in both race groups.  Future work within the SCCS and other studies 
with diverse populations will be guided by these findings as the mechanistic role played by 
adiponectin in the development of disease is examined.  Further, efforts to develop 
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interventions that can alter adiponectin levels for the prevention of diseases such as 
cardiovascular disease, cancer, and diabetes may be guided by the racial differences in 
adiponectin levels and its correlates observed in this study.
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Table 3.1.  Descriptive statistics for unadjusted serum adiponectin levels (ug/ml) characteristics among 1,992 women in the Southern 
Community Cohort Study, 2002-2006 
 
 Black women White women 
 N Geometric 
Mean 
25th-75th 
percentile 
   N Geometric  
Mean 
25th-75th  
percentile 
All participants 996 11.7 7.0 19.1 996 15.1 9.0 24.7
Body mass index (kg/m2) 
 < 18.5  8 19.2 8.8 36.2 10 27.1 13.5 48.3
    18.5 – 24.9 240 16.1 9.6 25.7 239 22.2 13.6 36.6
    25.0 – 29.9 249 11.9 7.4 18.7 248 15.6 9.8 25.0
    30.0 – 34.9 250 9.5 5.9 14.4 249 13.5 8.7 20.9
    35.0 – 39.9 165 10.7 6.0 17.9 146 11.9 7.7 18.5
    40.0 +  85 9.8 6.0 16.6 104 9.9 5.9 15.4
Age at interview         
       40 – 44 330 10.8 6.5 18.0 341 13.3 8.5 20.8
       45 – 49 265 11.4 6.7 18.7 243 14.0 8.2 21.6
       50 – 54 148 12.1 7.2 19.7 136 16.1 8.6 28.0
       55 – 59 105 12.4 7.3 21.5 120 16.7 10.1 30.1
       60 – 64 53 13.3 8.6 19.1 93 17.6 10.6 28.2
       65 – 69 50 13.9 7.4 25.0 29 19.4 11.8 32.9
       70 – 74 25 13.9 8.4 25.3 24 23.8 13.7 43.3
       75 – 79  20 16.1 10.4 21.4 10 32.2 24.8 51.4
Household income         
   < $15K 620 11.8 7.0 19.0 594 14.9 9.4 24.1
       $15 - $25K 236 11.5 6.9 18.3 205 14.7 8.6 25.3
       $25 - $50K 115 12.8 6.8 20.6 129 16.4 8.6 29.9
    > $50K 16 10.5 6.1 18.8 64 15.8 11.0 22.9
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Table 3.1 (continued).  Descriptive statistics for unadjusted serum adiponectin levels (ug/ml) characteristics among 1,992 women in 
the Southern Community Cohort Study, 2002-2006 
 
 Black women White women 
 N Geometric 
Mean 
25th-75th 
percentile 
N Geometric 
Mean 
25th-75th 
percentile 
Education (years) 
    < 9  78 13.2 7.7 22.4 85 14.5 8.3 22.0
       9-11 241 11.8 7.1 18.9 224 14.5 8.9 25.2
      12 415 12.0 7.2 19.8 411 15.4 9.0 25.5
   > 12 262 10.8 6.1 18.2 276 15.3 9.4 22.7
Physical activity (Met-hrs/day) 
    Q1 (<10.2) 248 12.5 7.5 20.3 247 14.3 8.7 21.9
    Q2 (10.2-18.3) 256 11.8 6.9 19.5 240 16.3 9.8 27.2
    Q3 (18.4-29.2) 255 11.4 6.9 18.5 242 14.9 8.8 24.9
    Q4 (>29.2) 233 11.4 6.8 18.5 262 15.2 8.8 25.7
HDL cholesterol (mg/dl) 
    Q1 (<43) 170 7.6 5.0 10.8 314 10.4 6.6 16.8
    Q2  (43-50) 231 9.4 5.8 14.9 272 14.6 9.6 21.9
    Q3  (51-60) 245 13.7 8.5 21.4 220 17.6 10.8 29.4
    Q4  (>60) 342 15.1 9.3 24.4 182 24.8 16.2 40.9
Total energy intake (kcal/day) 
    Q1 (<1352) 213 10.9 6.2 18.0 268 16.0 9.2 27.2
    Q2  (1352-1875) 226 12.4 7.6 18.9 254 15.4 8.8 26.5
    Q3  (1876-2644) 217 12.5 7.2 22.7 264 14.4 8.9 21.9
    Q4  (>2644) 294 11.5 7.2 18.0 187 14.1 8.7 22.8
Total fat intake (g/day)      
    Q1 (<49) 215 10.6 6.1 18.0 266 16.5 9.6 29.8
    Q2  (49-71) 234 12.4 7.5 18.7 247 14.7 8.7 22.6
    Q3  (72-103) 223 12.3 7.0 22.4 258 14.5 8.9 23.2
    Q4  (>103) 278 11.8 7.3 18.4 203 14.4 8.8 23.2
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Table 3.1 (continued).  Descriptive statistics for unadjusted serum adiponectin levels (ug/ml) characteristics among 1,992 women in 
the Southern Community Cohort Study, 2002-2006 
 
 Black women White women 
 N Geometric 
Mean 
25th-75th 
percentile 
N Geometric 
Mean 
25th-75th 
percentile 
Carbohydrate intake (g/day) 
    Q1 (<173) 208 11.3 6.4 18.8 273 16.0 9.4 27.5
    Q2  (173-240) 226 12.6 7.7 21.6 255 15.7 9.1 27.5
    Q3  (241-335) 227 11.5 6.5 18.7 254 14.1 8.5 22.1
    Q4  (>335) 289 11.7 7.5 18.5 192 14.1 8.8 22.8
Protein intake (g/day) 
    Q1 (<49) 221 11.0 6.1 18.2 260 15.8 8.7 27.6
    Q2  (49-70) 227 11.4 6.8 17.9 254 14.7 8.8 23.2
    Q3  (71-100) 234 12.9 7.3 23.1 247 15.7 9.7 26.0
    Q4  (>100) 268 11.9 7.4 18.6 213 13.8 8.7 22.0
Fiber intake (g/day)  
    Q1 (<11) 220 11.2 6.8 17.6 261 14.9 8.3 24.1
    Q2  (11-16) 227 11.6 6.9 19.9 254 14.7 9.2 24.3
    Q3  (17-24) 229 12.6 7.0 20.5 252 16.1 9.5 28.8
    Q4  (>24) 274 11.8 7.3 18.7 207 14.4 8.9 22.2
Alcohol consumption (drinks per day)      
    0 496 11.8 7.1 19.7 591 14.5 8.6 23.5
    1 - < 2 386 11.9 7.0 19.1 366 15.6 9.4 25.3
    2+ 111 11.1 6.4 18.7 37 20.9 13.2 36.5
Duration of cigarette smoking (years)      
      Never smoker 414 11.2 6.8 18.0 328 15.3 8.8 25.6
    <20 133 11.9 6.6 19.3 121 15.4 9.8 25.1
      20-29 236 11.8 7.1 18.3 248 14.6 9.3 22.6
      30+ 209 12.8 7.2 22.5 293 15.2 8.9 26.2
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Table 3.1 (continued).  Descriptive statistics for unadjusted serum adiponectin levels (ug/ml) characteristics among 1,992 women in 
the Southern Community Cohort Study, 2002-2006 
 
 Black women White women 
 N Geometric 
Mean 
25th-75th 
percentile 
N Geometric 
Mean 
25th-75th 
percentile 
Menopausal status  
    Pre- 499 11.0 6.5 17.6 497 13.5 8.4 21.6
    Post- 497 12.5 7.5 20.4 499 16.8 10.3 28.6
Number of live births         
    None 101 13.1 7.2 22.8 96 14.5 9.1 28.6
    1-2 332 12.5 7.2 20.6 477 15.0 8.7 23.2
    3-4 358 11.0 6.5 18.4 323 15.4 9.6 25.2
    5+ 205 11.3 7.1 16.7 99 15.1 8.9 25.1
Age at menarche (years) 
   <12 186 11.0 6.6 18.2 217 13.5 8.3 22.1
     12 258 11.8 7.0 19.6 277 14.1 8.6 22.5
     13 219 11.6 6.6 19.2 255 16.5 10.3 27.2
     14 131 13.4 8.8 20.0 93 17.4 8.9 33.0
     15+ 197 11.5 7.0 19.3 147 15.9 9.6 24.3
Diabetes1         
    Yes 220 11.5 6.2 19.8 164 13.4 7.5 22.1
    No 776 11.8 7.1 19.0 832 15.4 9.3 25.1
Heart attack or coronary bypass surgery1      
    Yes 41 13.9 8.6 23.8 51 15.0 9.8 21.5
    No 955 11.6 6.9 18.9 945 15.1 9.0 25.0
Hypertension1         
    Yes 600 11.3 6.5 18.7 462 13.8 7.9 22.5
    No 396 12.4 7.7 19.7 534 16.3 9.9 25.5
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Table 3.1 (continued).  Descriptive statistics for unadjusted serum adiponectin levels (ug/ml) characteristics among 1,992 women in 
the Southern Community Cohort Study, 2002-2006 
 
 Black women White women 
 N Geometric 
Mean 
25th-75th 
percentile 
N Geometric 
Mean 
25th-75th 
percentile 
High cholesterol1         
    Yes 280 11.5 6.8 18.8 371 14.1 8.6 22.1
    No 715 11.8 7.0 19.1 624 15.7 9.3 25.6
Depression1         
    Yes 214 11.4 6.5 18.0 479 14.7 9.0 23.1
    No 782 11.8 7.1 19.4 515 15.5 9.1 25.4
 
1 Has a doctor ever told you that you have….? 
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Table 3.2.  Linear regression results from prediction models for log-adiponectin (ug/ml) in black and white women 
 
 Black women White women 
Predictor Βeta Std err p-value Partial R2 Βeta Std err p-value Partial R2
Body Mass Index (kg/m2) -0.017   0.0036 <0.0001    0.05 -0.029   0.003 <0.0001    0.11
HDL-cholesterol (mg/dl) 0.10 0.10
    Q1 (<43) Referent Referent
    Q2  (43-50)  0.17   0.067  0.01 0.29  0.053  <0.0001
    Q3  (51-60)  0.53   0.067 <0.0001 0.41  0.057  <0.0001
    Q4  (>60)  0.59   0.064 <0.0001 0.67  0.063  <0.0001
Age at interview (years)  0.010   0.003 <0.0001  0.01    0.015  0.003 <0.0001  0.02
Hypertension -0.085   0.046  0.07  0.003   -0.072  0.044  0.10  0.002
 
Adjusted model R2 0.17 0.27
 
Note: . Model estimates for the intercept and sample selection term are not shown. 
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Figure 3.1.  Distribution of crude adiponectin levels (ug/ml) in 996 black and 996 white 
women 
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Figure 3.2.  Adjusted geometric means  and 95% confidence intervals for adiponectin by 
body mass index categories in 1,992 black and white women (adjustment factors include age, 
sample selection, and HDL-cholesterol). 
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CHAPTER 4: ADIPOQ, ADIPOR1, AND ADIPOR2 POLYMORPHISMS IN 
RELATION TO SERUM ADIPONECTIN LEVELS AND BODY MASS INDEX IN 
BLACK AND WHITE WOMEN 
 
Abstract 
Adiponectin is an adipose-secreted protein with suspected influence on insulin 
sensitivity, inflammation, and atherogenesis.  Adiponectin levels are highly heritable and a 
number of single nucleotide polymorphisms (SNPs) in the genes encoding adiponectin 
(ADIPOQ) and its receptors (ADIPOR1 and ADIPOR2) have been examined in relation to 
circulating adiponectin levels and obesity phenotypes.  Despite differences in adiponectin 
levels and obesity prevalence by race, few studies of these adiponectin-related genes have 
included black individuals.  Using cross-sectional interview data and blood samples collected 
from 1,967 women (977 black and 990 white) enrolled in the Southern Community Cohort 
Study from 2002 to 2006, we examined 25 tag-SNPs in ADIPOQ, 19 in ADIPOR1, and 27 in 
ADIPOR2 in relation to serum adiponectin levels and body mass index (BMI).  Associations 
were evaluated using race-stratified linear regression models with adjustment for age and 
percentage of African ancestry to account for possible population stratification.  Using race-
specific Bonferroni p-value thresholds for significance testing, one SNP in ADIPOQ was 
found to be significantly associated with serum adiponectin levels in white, but not black, 
women.  Adiponectin levels (ug/ml) among white women for SNP rs17366568 were 9.3 for 
the A/A genotype, 13.7 for A/G, and 15.9 for G/G, p=0.00036.   No other SNPs were 
associated with adiponectin or BMI among blacks or whites.  We confirmed a recent 
association from two genome-wide association analyses between rs17366568 and 
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adiponectin in whites, and further, we are the first to report a lack of association for this SNP 
in a large population of black women.  Because adiponectin is highly heritable and varies by 
race, but significant associations with polymorphisms in ADIPOQ, ADIPOR1, and ADIPOR2 
have been few in this and other studies, future work including large numbers of individuals 
of several clearly-defined race groups is needed to detect additional genetic variants that 
affect adiponectin and BMI levels.  
Introduction 
Adiponectin is a collagen-like protein produced exclusively in adipose tissue and found in 
relatively high concentration in serum (1).  Adiponectin plays an important role in several 
physiological pathways including those related to insulin action, inflammation, and 
atherogenesis (1, 2).  Adiponectin levels are inversely associated with adiposity (1, 3) and 
show variation by gender and race with lower levels in women compared to men (4) and in 
blacks compared to whites (5).   
Adiponectin is encoded by the gene ADIPOQ, located on chromosome 3q27.    Two 
adiponectin receptors have been identified and are encoded by the genes ADIPOR1 (located 
on chromosome 1q32) and ADIPOR2 (located on chromosome 12q13).  Heritability 
estimates for adiponectin are high (ranging from 30% to 70%) (6, 7) and thus the genes 
encoding adiponectin and its receptors are plausible candidates for association with serum 
levels of the protein.  Additionally, because adiponectin is strongly associated with body size, 
the adiponectin-related genes are also reasonable candidate genes for obesity.  Single 
nucleotide polymorphisms (SNPs) in ADIPOQ, ADIPOR1 and ADIPOR2 have been 
examined in association with adiponectin levels and obesity phenotypes in several studies but 
results have been quite inconsistent (6).  Further, virtually no studies of these genes have 
included black participants despite known racial differences in the prevalence of obesity (8) 
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and evidence showing differences in adiponectin levels by race.  Thus, the goal of this study 
was to examine polymorphisms in ADIPOQ, ADIPOR1 and ADIPOR2 in relation to 
adiponectin levels and body mass index (BMI) in a large sample of both black and white 
women. 
Methods 
Institutional Review Boards at Vanderbilt University, Meharry Medical College, and the 
University of North Carolina at Chapel Hill approved this study. 
Study population 
The Southern Community Cohort Study (SCCS) is a prospective epidemiologic cohort study 
designed to examine racial disparities in cancer incidence and mortality (9).  Study 
enrollment began in 2002 in twelve southeastern states at Community Health Centers (CHC) 
which are government-funded facilities providing health services primarily to low-income 
individuals in medically underserved areas.  As described previously (9), participants were 
required to be age 40-79 years of age, English-speaking, and not have undergone treatment 
for cancer within the past year.  From over 47,000 participants enrolled through early 2006, a 
sub-sample of 2,000 women who provided a blood sample at study enrollment and self-
reported their race as either ‘Black/African American’ or ‘White’ was selected for further 
biomarker analyses.  This included a random sample of 395 women selected in 2005 within 
strata of race, BMI, and smoking cigarette status, and a second random sample of 1,605 
women selected in 2006 in equal numbers across race, BMI, and menopausal status 
categories.    
Data collection 
Trained study interviewers conducted structured baseline interviews with participants using a 
computer-assisted interview which elicited information including demographics, 
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anthropometrics, and several aspects of health and behavior.  Height and weight at the time 
of the baseline interview were self-reported by participants and used to calculate BMI as 
[weight (kg)] / [height (m)2].  For the 20% of women who were patients in the CHC on the 
day of the baseline interview, measured height and weight were abstracted from medical 
records for validation purposes. 
A convenience blood sample was collected at the time of recruitment using one 
EDTA-containing plasma tube and one serum BD Vacutainer® tube.  For this study, the 
median time between the last reported meal and blood collection was 6.0 hours for blacks 
and 6.3 hours for whites (p=0.07).  Fasting blood, defined as at least 8 hours since last meal, 
was collected for 44% of the participants.  Blood samples were shipped cold to Vanderbilt 
University in Nashville, TN, where they were processed for storage at -80° C.  84% of the 
blood samples were received the day after the blood draw and 98% were received within two 
days.  The samples were frozen for an average of 2.6 years (range 3 months to 5 years) prior 
to analysis. 
Adiponectin measurement 
Adiponectin was measured in serum by immunoassay using the LINCOplex kit (Luminex® 
xMAPTM Technology, St. Louis, MO) in the Vanderbilt Hormone Assay and Analytical 
Services Core Laboratory in duplicate for each woman.  The average of the two 
measurements was used in all analyses.  Duplicate sets of samples for five randomly selected 
women as well as five repeat samples from each of two pooled samples were measured to 
assess the reliability and validity of the assay.  Adiponectin was successfully measured in 
1,992 of the 2,000 samples (eight samples failed due to a filter plate error or low sample 
volume).  The intra-assay coefficient of variation was 9.4%.   
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Genotyping of SNPs 
Candidate genes were selected for genotyping based on their relevance to cancer-related 
pathways and obesity, including the genes encoding for adiponectin and its receptors, 
ADIPOQ, ADIPOR1, and ADIPOR2.  SNP selection was based on a haplotype tagging 
approach to select SNPs that represent common variation in the genes of interest.  The 
International HapMap project was the primary data source for the selection of the SNPs (10).  
Using the Tagger pairwise method implemented in Haploview, tag-SNPs were selected based 
on a minor allele frequency (MAF) greater than 5% in either the Caucasian (CEU) or West 
African (Yoruban, YRI) populations and an r2 cut-off of 0.8 (where r2 is a measure of the 
correlation between alleles at two markers) as determined from the HapMap Project.  All 
SNPs were scored for their ability to perform well on the Illumina GoldenGate genotyping 
platform using an Illumina in-house algorithm (Illumina Inc., San Diego, CA).  Twenty-five 
SNPs were selected for ADIPOQ, 19 for ADIPOR1, and 27 for ADIPOR2.   
 An additional 292 SNPs were selected as ancestry informative markers (AIM) (11). 
AIMs were required to pass the Illumina scoring algorithm, be at least 5 Mb from the 
candidate genes, have a MAF > 0.05 in both the CEU and YRI populations, and have an 
allele frequency difference between the CEU and YRI populations > 0.6.   
Genomic DNA was extracted from buffy coat using Puregene’s DNA Purification 
kits (Gentra Systems, Minneapolis, MN) or Qiagen’s DNA Purification kits (Qiagen, 
Valencia, CA) according to manufacturers’ instructions.  Genotyping took place at 
Vanderbilt University.  The SNPs included in this project were grouped with those from a 
larger study of obesity to facilitate the use of the Illumina GoldenGate genotyping platform 
(Illumina Inc., San Diego, CA).  Blinded QC samples (N=29) and another 171 pairs of 
duplicated samples were included and the consistency rate was 99.9%.   
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Statistical Methods 
Of the 2,000 women selected for analysis, genotyping was successful for 1,990.  Individuals 
were assigned admixture estimates (called ancestry allelic clusters or AAC) using the 292 
genotyped AIMs and STRUCTURE Version 2.2.3 software (12).  Given that the participants 
in this project were selected for inclusion based on self-reported race being only black or 
white (and the number of Asian and Hispanic participants in the SCCS overall is very low), 
the number of ancestral populations to be estimated was a priori specified to be 2. Thus two 
AACs were generated for each individual: one for African ancestry and one for European 
ancestry.   Twenty-three women were excluded from analysis because of discrepancies 
between self-reported race and ancestry estimates derived from STRUCTURE leaving 1,967 
women for study (N=990 black and N=977 white).  For analyses with adiponectin as the 
outcome, 1,959 women were examined after excluding eight for whom adiponectin could not 
be measured.  
We tested for Hardy-Weinberg equilibrium in race-stratified samples and found one 
SNP in ADIPOQ (rs1648707) that showed significant deviation from Hardy-Weinberg 
equilibrium in both white (p=8.6x10-16) and black (p=1.3x10-16) women.  This SNP was 
excluded from all further analyses. 
Linkage disequilibrium was calculated and displayed between each of the genotyped 
SNPs, stratified by race, using the r2 metric and Haploview software (Supplementary Figure 
4.1). 
Associations between individual SNPs and adiponectin levels were examined using 
race-stratified multiple linear regression models with log-transformed adiponectin as the 
outcome.  Similar models were constructed with BMI as the outcome variable.  SNPs were 
generally examined using a codominant inheritance model (with 2 degree of freedom) with 
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the referent genotype selected to be the most common race-specific homozygous genotype.  
For SNPs in which less than 10 women had the rare homozygous genotype, a dominant 
model was used that combined women with the rare homozygous genotype with those with 
the heterozygous genotype.  Each regression model included adjustment for age at baseline 
SCCS interview as well as percentage of African ancestry as estimated by STRUCTURE.  
Adjusted mean adiponectin levels for each genotype were back-transformed for presentation.  
Models including adjustment for the first five principal components derived using 
EIGENSTRAT software (13) in place of the AAC derived from STRUCTURE were also 
examined and found to have very similar results.  SAS version 9.2 (SAS Institute) was used 
for all modeling.   
A Bonferroni correction was applied to the a priori alpha level of 0.05 and was 
calculated based on examination of individual models for each SNP over the three genes of 
interest.  Alpha values of 0.00096 and 0.00075 were used for white and black women, 
respectively, based on the analysis of 52 and 67 SNPs. 
Results 
Consistent with the stratified sampling design for this study, equal numbers of black and 
white women were post-menopausal, and women in both race groups had a mean BMI (BMI) 
of approximately 30 kg/m2 (Table 4.1).  Income and education distributions between the race 
groups were also similar.  Adiponectin levels were lower in black women than in white 
women (15.4 v 19.9, mg/ml).  There were no differences in adiponectin levels by fasting 
blood status (black fasting v. non-fasting mean=14.9 v. 15.9, p=0.25; white fasting v. non-
fasting mean=20.2 v. 19.6, p=0.6).      
The location and genotype frequencies of the SNPs selected for the three genes of 
interest are described in Tables 4.2a, 4.2b, and 4.2c.  Genotyping was successful for all 1,967 
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women for 58 (84%) of the SNPs and over 96% complete for the other 11 SNPs.  More tag-
SNPs were needed to provide adequate gene coverage for the black sample compared to the 
white sample.  SNPs that were found to have a MAF < 0.001 within a race group were 
omitted from further analyses in that race group.   
 Adjusted mean adiponectin levels by genotype are shown by race in Figure 4.1 for 
ADIPOQ, ADIPOR1, and ADIPOR2.  One SNP, rs17366568 in white women (p=0.00036), 
met the Bonferroni p-value threshold for significance.  This SNP was not in LD with any of 
the other genotyped SNPs and thus haplotype analyses were not conducted (Supplementary 
Table 4.1).  Otherwise, we observed no significant associations between adiponectin levels 
and individual SNPs.  Figure 4.2 shows adjusted mean BMI values by genotype for the three 
genes of interest.  There was little variation by BMI across genotypes in any of the SNPs and 
none met the Bonferroni p-value threshold for significance.  
For the single SNP meeting the Bonferroni p-value threshold (rs17366568 in 
ADIPOQ in white women), the additive genetic model was also examined.  rs17366568 was 
found to be significantly associated with adiponectin using this model form with little 
difference seen compared to the co-dominant model (additive model p-value=0.0002 versus 
p=0.00036 for co-dominant model).  BMI was added as a covariate to the linear regression 
model for rs17366568 in ADIPOQ in relation to adiponectin levels, and while it was found to 
be a very strongly associated with adiponectin itself, its inclusion did not alter the association 
between the SNP and the adiponectin levels (data not shown). 
Interactions between SNP rs17366568 and BMI, diabetes status, and menopausal 
status were examined.  Of these factors, only BMI was found to be a significant effect 
modifier of the SNP-adiponectin association (likelihood ratio p-value < 0.0001 for 
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interaction).  A strong positive association was seen for adiponectin levels among individuals 
of non-obese BMI (<25 kg/m2) (adiponectin=8.1, 19.3, and 23.7 ug/ml for A/A, A/G, and 
G/G genotypes, respectively; p=0.004); this marked increase in adiponectin levels across 
genotype was not as clear in the other strata of BMI (25-29, 30-34, and 35+) (Figure 4.3).  
However, these interaction models should be considered exploratory as the number of 
individuals in some cells was very small (for example, N=3 for individuals with BMI <25 
kg/m2 and genotype A/A). 
The percentage of African ancestry covariate was found to be non-significant in white 
women but borderline significant in black women (p=0.1) for SNP rs17366568 in ADIPOQ.  
Race-combined models were also examined for each SNP-outcome association in order to 
increase statistical power to detect associations.  In these models adjusted for age and 
percentage of African ancestry, SNP rs17366568 in ADIPOQ remained significantly 
associated with adiponectin and no additional SNPs were found to meet the Bonferroni 
corrected p-value for statistical significance in relation to either adiponectin or BMI.    
Discussion 
This study examined effects of variation in the adiponectin-related genes on adiponectin 
levels and BMI in a large, population-based sample using a pathway-based approach.  We 
observed a significant association between adiponectin levels and SNP rs17366568 in 
ADIPOQ among white women, a finding also recently reported by two recent genome-wide 
association studies (GWAS) of European whites (7, 14).  This SNP was not found to be 
associated with adiponectin levels among black women in our study which was the first, to 
our knowledge, to examine the adiponectin-related genes in blacks.  Determining relevant 
SNPs affecting adiponectin levels and BMI, and whether these SNPs differ across racial 
groups, is an important step in our understanding of the roles played by adiponectin and 
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obesity in the complex mechanisms underlying racial disparities for major chronic disease 
such as diabetes, cardiovascular disease, and many cancers.   
Our pathway-based results for SNP rs17366568 in ADIPOQ were very similar to 
those seen in the two GWAS studies (7, 14) that also found significant associations with this 
SNP and adiponectin levels.  The A/A genotype was relatively rare in our study (MAF=0.14, 
N=19 white women had the A/A genotype) as it was in the two GWAS (MAF=0.11 and 
0.13) (7, 14).  The effect size (using log-transformed adiponectin, ug/ml, as the outcome) for 
an additive model was 0.20 for each addition of the G allele in the KORA portion of the Heid 
study (7), which was very close to our effect estimate of 0.18 for a similar model.  The 
proportion of variance explained by this SNP was 1.7% in our pathway-based study, slightly 
lower than the 5.3% reported for women in one GWAS (7) but close to the <2% reported in 
the other GWAS (14) 
In our study, we found no additional SNPs beyond rs17366568 that were associated 
with adiponectin in black or white women.  Adiponectin levels have been examined in 
relation to variants in ADIPOQ in more than a dozen association studies of white and Asian 
individuals but few specific SNPs or haplotypes have been replicated in multiple populations.  
Four common ADIPOQ polymorphisms (rs2241766 (commonly called 45TÆG), rs1501299 
(commonly called 276GÆT), -11391GÆG, and -11377CÆG) were genotyped in early 
candidate gene studies for association with adiponectin with inconsistent results (15-25).  
Several of these studies were examined in a 2007 meta-analysis of genetic variants in 
ADIPOQ in relation to adiponectin levels.  Menzaghi et al. reported that two of the most 
commonly typed SNPs on ADIPOQ, rs17300539 and rs1501299, were significantly 
associated with adiponectin levels in the meta-analysis of five and twelve studies, 
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respectively (6). Neither of these SNPs was genotyped in our study but each was in strong 
linkage disequilibrium (LD) with selected tag SNPs that we did genotype.  In the HapMAP 
CEU population (release 22), both rs822387 and rs16861210 had a pairwise r2 value of 0.82 
with rs17300539, but neither was found to be significantly associated with adiponectin levels 
in white women in our study (p=0.2 for rs822387 and p=0.1 for rs16861210).  SNP 
rs6444175 in ADIPOQ has a pairwise r2 value of 0.92 in the CEU population and an r2 of 
0.53 in the YRI population with rs1501299, but, again, neither of these SNPs was found to be 
significantly associated with adiponectin levels in our study (p=0.5 for white women and 
p=0.6 for black women).  As genotyping larger numbers of SNPs has become easier and 
more cost-efficient, additional SNPs in ADIPOQ  have been typed and examined in relation 
to adiponectin levels but still little consistency has been observed in association with 
adiponectin across studies (4, 26-29).   
Regarding BMI, several studies have reported positive associations between BMI and 
ADIPOQ variants (30-33) while others have not found any significant effects (16, 20, 25, 28, 
34).  No significant associations with BMI were found with SNPs in ADIPOQ in the 
Menzaghi 2007 meta-analysis (6).  Positive associations in past reports were found for 
several different SNPs in ADIPOQ with little replication across studies.  Only rs182052, 
found to be associated with BMI in a group of over 800 Hispanic individuals (32), was also 
genotyped in our study but we did not find any association with BMI in black (p=0.95) or 
white women (p=0.14).   
Very few studies have examined polymorphisms in ADIPOR1 and ADIPOR2 in 
relation to adiponectin or BMI.  No genome-wide significant associations between 
adiponectin levels and SNPs in either ADIPOR1 or ADIPOR2 were found in a GWAS of 
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Europeans (14).  Loos et al. investigated two SNPs in ADIPOR1 (rs1539355 and rs2275737) 
and two in ADIPOR2 (rs0773982 and rs2058112) in relation to BMI in French-Canadians 
and found no statistically significant associations (25); we also observed no association with 
BMI for these four SNPs in black or white women.   
High heritability estimates for both adiponectin levels and obesity as well as linkage 
studies showing the adiponectin-related genes to be strongly related to these phenotypes  
indicate that while the data have been inconsistent, polymorphisms in the genes encoding 
adiponectin and the two known adiponectin receptors remain promising avenues for 
explaining variation in adiponectin levels as well as obesity.  Conflicting results to date may 
be due to a myriad of differences across studies including sample size, analysis methodology 
(including the examination of single-SNPs versus haplotypes, differing approaches to 
confounding, control for population stratification, and multiple comparisons), genetic 
background, and possibly environmental or gene-gene influences across populations.  Studies 
of other adipokines in relation to genetic variation in the protein-encoding or receptor-
encoding genes have been similarly inconsistent.  For leptin, perhaps the best studied of the 
adipokines, relatively scant data are available examining polymorphisms in the LEP or LEPR 
genes in relation to circulating leptin levels and conflicting evidence exists for associations 
with specific SNPs (35-38).  
It remains possible that there are unknown rare variants that have a strong effect on 
adiponectin levels, and few studies to date, including ours, have been well-powered to detect 
rare variants.  There may also be many as-yet unidentified common loci with small 
individual effects on adiponectin levels.  Additionally, genetic contribution to adiponectin 
variation may be influenced by interactions between multiple loci or between loci and 
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environmental factors or perhaps by epigenetic factors, none of which have been carefully 
examined yet. 
Individuals of African descent display, on average, more variation in allele frequency 
than do people of European descent, indicating that the frequency of etiologically important 
SNPs may differ by race.  The difference in the association with adiponectin levels and SNP 
rs17366568 between black and white women seems at least in part due to allele frequency 
differences with the MAF=0.14 for the white women and only 0.015 for black women.  This 
is consistent with the results of the HapMap project in which all of the YRI samples were 
found to have the G/G genotype (and thus this SNP is not shown on the LD plot for the 
HapMap YRI population, Figure 4.4, top panel).   
LD plots for ADIPOQ for the HapMap YRI and CEU populations are shown in 
Figure 4.4 (top and bottom panels, respectively) and demonstrate the importance of 
examining genetic correlates of adiponectin and obesity in racially diverse populations.  
However, to date, polymorphisms in ADIPOQ, ADIPOR1, and ADIPOR2 have been 
examined almost exclusively in populations that did not include individuals of African 
descent.  One genome-wide linkage scan which included both 89 Hispanic families and 42 
black families reported heritability estimates of 71% and 64% in Hispanics and blacks, 
respectively, for adiponectin but the region of the genome where ADIPOQ is located was 
identified as a major quantitative trait loci only in the Hispanic sample (39).  The 
HERITAGE study included 276 black participants and found two variants in ADIPOQ that 
were associated with measures of body fat in blacks but not whites (34).  Beyond these two 
reports with only limited numbers of black participants, our study is the first to examine 
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either adiponectin levels or BMI in relation to adiponectin-related genes in a large group of 
comparable black and white participants.   
The major strength of this study was the use of participants from the SCCS which 
allowed for the examination of adiponectin levels and BMI in relation to genetic variation in 
adiponectin-related genes in a large, population-based sample of black and white women.  
SNPs were selected to provide coverage across the genes using both the HapMap CEU and 
YRI populations which resulted in similar precision in estimating sequence variation in both 
the black and white participants.  Study limitations include the potential for measurement 
error in either of the outcome variables of adiponectin and BMI.  As is common in large 
population-based studies, we measured total adiponectin rather than high-molecular weight 
adiponectin.  Additionally, we only measured adiponectin at one point in time;  however, 
adiponectin levels measured one year apart have been reported to be highly correlated and 
likely sufficient for large epidemiologic studies (40, 41).  It has also been suggested that 
serum adiponectin levels, as we and others have measured, may not reflect the overall 
amount of adiponectin in the body or adiponectin concentrations in areas that are targets for 
this protein but much work remains to determine how to more meaningfully measure 
adiponectin (6).  We also did not require participants to provide fasting blood samples 
although we found no differences in the mean adiponectin levels by fasting status.  For BMI, 
we used self-reported height and weight measures to calculate BMI.  While there is evidence 
to indicate that women tend to over-report height while under-reporting weight (42), BMI 
values calculated from self-reported height and weight in the SCCS were very highly 
correlated with BMI values calculated from medical record data overall (Pearson correlation 
coefficient > 0.95) as well as across strata of race and BMI, indicating that the self-reported 
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values are generally of good quality.  A further limitation of this study is the lack of 
information regarding central obesity which may be a stronger correlate of disease risk than 
BMI and has been observed to vary across race groups for a given BMI (43).  
In this first-ever study of genetic variation in adiponectin-related genes in relation to 
adiponectin and BMI among both black and white women, we demonstrated that there may 
be different genetic variants that contribute to variation in adiponectin levels by race.  We 
confirmed an association observed recently in two GWAS between SNP rs17366568 located 
in ADIPOQ and adiponectin levels in white women, but we did not find any association with 
this SNP in black women.  Additionally, we found no other SNPs that were associated with 
adiponectin levels or with BMI in black or white women.  Future discovery of additional 
variants that affect adiponectin levels (and particularly rare variants that may occur only in 
certain race groups) as well as detection of gene-gene and gene-environment interactions 
related to adiponectin levels and BMI will require future studies with large sample sizes from 
multiple racial groups.  
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Table 4.1.  Characteristics of black and white women genotyped for ADIPOQ, ADIPOR1, 
and ADIPOR2 from the Southern Community Cohort Study, 2002-2006 
 
 Black women 
(N=996) 
White women 
(N=994) 
 Mean [std] Mean [std] 
Age at baseline interview (years) 50.1 [8.9] 49.9 [8.6] 
Body mass index (kg/m2) 30.4 [6.4] 30.3 [6.6] 
Adiponectin (ug/ml) 15.4 [13.4] 19.9 [16.1] 
     
 N (%) N (%) 
Education     
    <9 years 78 (7.8) 86 (8.7) 
      9-11 years 243 (24.4) 221 (22.2) 
      Completed high school 411 (41.3) 411 (41.4) 
      More than high school 264 (26.5) 276 (27.8) 
Annual Household Income    
      < $15,000 621 (62.9) 597 (60.3) 
         $15,000 – 24,999 233 (23.6) 199 (20.1) 
         $25,000 – 49,999 116 (11.8) 130 (13.1) 
         $50,000+ 17 (1.7) 64 (6.5) 
        Missing 9  4  
Menopausal status    
      Pre  497 (49.9) 497 (50.0) 
      Post 499 (50.1) 497 (50.0) 
Diabetes1    
      Yes 218 (21.9) 162 (16.3) 
       No 778 (78.1) 832 (83.7) 
 
1 Self-reported from the question “Has a doctor ever told you that you have diabetes?”
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Table 4.2a.  Characteristics of ADIPOQ SNPs genotyped in black and white women in the Southern Community Cohort Study 
 
      Genotype frequency 
      Black women (N=990) White women (N=977) 
 
 
SNP 
 
 
Gene region 
 
Tagging 
popn 
 
Coded 
allele 
Non-
coded 
allele 
 
N 
 
C/C 
 
C/NC 
 
NC/NC 
 
C/C 
 
C/NC 
 
NC/NC 
rs864265 5' near gene YRI, CEU C A 1,967 0.75 0.23 0.02 0.70 0.27 0.03 
rs822387 5' near gene YRI A G 1,967 0.45 0.44 0.11 0.83 0.16 0.008 
rs16861194 5' near gene YRI, CEU A G 1,967 0.57 0.38 0.05 0.84 0.16 0.006 
rs182052 5' near gene YRI G A 1,967 0.41 0.48 0.11 0.44 0.44 0.12 
rs16861205 5' near gene YRI G A 1,967 0.65 0.33 0.04 0.85 0.14 0.006 
rs822391 Intron 1 CEU A G 1,967 0.92 0.08 0 0.62 0.32 0.06 
rs16861210 Intron 1 YRI, CEU G A 1,967 0.68 0.29 0.03 0.82 0.17 0.01 
rs822396 Intron 1 CEU A G 1,967 0.63 0.32 0.05 0.65 0.31 0.05 
rs12495941 Intron 1 YRI, CEU C A 1,967 0.40 0.46 0.14 0.43 0.46 0.11 
rs7649121 Intron 1 CEU A T 1,967 0.79 0.20 0.01 0.68 0.29 0.02 
rs9877202 Intron 1 YRI A G 1,967 0.71 0.26 0.03 0.99 0.002 0 
rs17366568 Intron 1 CEU G A 1,967 0.97 0.03 0.001 0.75 0.23 0.02 
rs3821799 Intron 1 CEU G A 1,967 0.18 0.49 0.33 0.33 0.47 0.20 
rs3774261 Intron 1 YRI, CEU G A 1,967 0.18 0.50 0.31 0.41 0.45 0.15 
rs17366743 Intron 2 CEU A G 1,967 0.99 0.01 0 0.95 0.05 0.003 
rs6444174 Intron 2 YRI A G 1,963 0.70 0.27 0.03 0.99 0.006 0 
rs1063539 Exon 3 CEU C G 1,879 0.62 0.38 0.002 0.75 0.23 0.02 
rs9842733 3' UTR YRI T A 1,967 0.83 0.16 0.008 0.99 0.003 0 
rs1403697 3' UTR YRI A G 1,967 0.77 0.22 0.02 0.99 0.003 0 
rs7641507 3’ near gene YRI G A 1,967 0.85 0.15 0.005 0.99 0.004 0 
rs1403696 3’ near gene YRI G A 1,967 0.62 0.33 0.05 0.99 0.007 0 
rs6444175 3’ near gene YRI, CEU G A 1,967 0.46 0.46 0.08 0.56 0.36 0.08 
rs7628649 3’ near gene YRI, CEU G A 1,967 0.46 0.46 0.11 0.79 0.19 0.01 
rs17373414 3’ near gene CEU G A 1,967 0.98 0.02 0.001 0.78 0.20 0.02 
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Table 4.2b.  Characteristics of ADIPOR1 SNPs genotyped in black and white women in the Southern Community Cohort Study 
 
      Genotype frequency 
      Black women (N=990) White women (N=977) 
 
 
SNP 
 
Gene region 
 
Tagging 
popn 
 
Coded 
allele 
Non-
coded 
allele 
 
N 
 
C/C 
 
C/NC 
 
NC/NC 
 
C/C 
 
C/NC 
 
NC/NC 
rs6672643 5' near gene YRI, CEU A G 1965 0.56 0.37 0.07 0.75 0.22 0.03 
rs2185781 5' near gene YRI, CEU G A 1967 0.66 0.30 0.04 0.65 0.30 0.04 
rs4336908 5' near gene YRI G A 1967 0.86 0.13 0.01 0.65 0.30 0.04 
rs10920531 5' near gene YRI, CEU C A 1967 0.24 0.46 0.30 0.43 0.42 0.15 
rs7539542 Exon 8 CEU G C 1967 0.16 0.44 0.40 0.49 0.40 0.10 
rs1342387 Intron 4 YRI G A 1966 0.25 0.49 0.26 0.32 0.45 0.23 
rs7518457 Intron 4 YRI A G 1967 0.88 0.11 0.01 0.99 0.004 0 
rs12045862 Intron 3 YRI, CEU G A 1967 0.83 0.16 0.01 0.55 0.38 0.07 
rs2275737 Intron 1 YRI, CEU C A 1967 0.31 0.49 0.20 0.35 0.44 0.21 
rs12733285 Intron 1 CEU G A 1967 0.62 0.33 0.05 0.49 0.41 0.09 
rs10753929 Intron 1 YRI, CEU G A 1967 0.65 0.31 0.04 0.76 0.21 0.02 
rs1539355 Intron 1 YRI, CEU A G 1967 0.29 0.50 0.21 0.49 0.41 0.10 
rs10800888 3’ Near gene YRI G A 1967 0.76 0.23 0.01 0.99 0.002 0 
rs6666089 3’ Near gene YRI G A 1967 0.75 0.23 0.02 0.49 0.41 0.10 
rs7523903 3’ Near gene YRI G C 1963 0.59 0.40 0.01 0.98 0.02 0 
rs2232849 3’ Near gene YRI G A 1967 0.83 0.16 0.009 0.99 0.004 0 
rs2232844 3’ Near gene YRI A G 1967 0.83 0.16 0.009 1.00 0 0 
rs2232842 3’ Near gene YRI A G 1967 0.71 0.27 0.02 0.94 0.05 0.002 
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Table 4.2c.  Characteristics of ADIPOR2 SNPs genotyped in black and white women in the Southern Community Cohort Study 
 
      Genotype frequency 
      Black women (N=990) White women (N=977) 
 
 
SNP 
 
Gene region 
 
Tagging 
popn 
 
Coded 
allele 
Non-
coded 
allele 
 
N 
 
C/C 
 
C/NC 
 
NC/NC 
 
C/C 
 
C/NC 
 
NC/NC 
rs758027 5' near gene YRI A G 1966 0.81 0.18 0.01 0.99 0.001 0 
rs1029629 5' near gene YRI A C 1966 0.56 0.39 0.05 0.50 0.40 0.09 
rs7304096 Intron 1 TRI A G 1967 0.93 0.07 0.001 0.99 0.001 0 
rs2058033 Intron 1 CEU A C 1967 0.95 0.05 0.001 0.76 0.21 0.02 
rs7975600 Intron 1 YRI, CEU T A 1967 0.75 0.23 0.01 0.73 0.24 0.02 
rs11832817 Intron 1 CEU G A 1967 0.70 0.28 0.02 0.52 0.40 0.08 
rs12826079 Intron 1 CEU G A 1966 0.98 0.02 0 0.87 0.12 0.006 
rs10773982 Intron 1 YRI, CEU A G 1967 0.39 0.47 0.14 0.46 0.43 0.11 
rs11061946 Intron 1 CEU G A 1966 0.98 0.02 0.001 0.86 0.13 0.004 
rs10773983 Intron 1 CEU G A 1966 0.07 0.38 0.56 0.49 0.40 0.11 
rs12316367 Intron 1 YRI A G 1967 0.02 0.26 0.72 0.29 0.49 0.22 
rs10773989 Intron 1 YRI A G 1967 0.54 0.40 0.06 0.24 0.52 0.25 
rs2058112 Intron 1 CEU G A 1967 0.62 0.33 0.05 0.75 0.24 0.01 
rs12298275 Exon 2 YRI A G 1967 0.92 0.08 0.001 1.00 0 0 
rs7134070 Intron 2 YRI A G 1967 0.74 0.24 0.02 0.99 0.01 0 
rs7967137 Intron 2 YRI A G 1967 0.51 0.41 0.09 0.75 0.24 0.01 
rs7138701 Intron 2 YRI G A 1967 0.66 0.31 0.04 0.99 0.01 0 
rs11614639 Intron 3 YRI A C 1967 0.30 0.51 0.19 0.32 0.49 0.20 
rs10773991 Intron 3 YRI A G 1967 0.03 0.33 0.64 0.29 0.49 0.22 
rs4140993 Intron 4 YRI A C 1967 0.70 0.27 0.03 0.99 0.01 0 
rs16928751 Exon 6 YRI, CEU G A 1967 0.61 0.35 0.05 0.75 0.24 0.01 
rs2286384 Intron 6 YRI, CEU C G 1967 0.08 0.46 0.46 0.29 0.49 0.22 
rs12342 3' UTR YRI G A 1967 0.65 0.32 0.03 0.49 0.41 0.10 
rs1044471 3' UTR YRI, CEU G A 1967 0.63 0.33 0.04 0.26 0.51 0.23 
rs7294540 3’ Near gene YRI A C 1967 0.74 0.25 0.02 0.18 0.49 0.34 
rs13219 3’ Near gene YRI, CEU A G 1967 0.02 0.27 0.71 0.33 0.48 0.19 
rs2058111 3’ Near gene YRI A C 1963 0.65 0.32 0.03 0.19 0.48 0.34 
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Tables 4.2a, b, and c abbreviations: 
 
C/C = coded allele/coded allele;  C/NC = coded allele/non-coded allele;  NC/NC = non-coded allele/non-coded allele 
UTR = untranslated region 
YRI = Yoruban population from HapMap; CEU = Caucasian population from HapMap 
C/C = Common/Common genotype; C/r = Common/rare genotype; r/r = rare/rare genotype
  
166 
   ADIPOQ     ADIPOR1         ADIPOR2 
 
 
Figure 4.1.  Adjusted mean adiponectin levels (ug/ml) and associated p-values from race-stratified linear regression models for 
SNPs in ADIPOQ (left panel), ADIPOR1 (center panel), and ADIPOR2 (right panel) among 990 black women and 977 white 
women, Southern Community Cohort Study, 2002-2006 
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   ADIPOQ     ADIPOR1         ADIPOR2 
 
 
Figure 4.2.  Adjusted mean body mass index (kg/m2) values and associated p-values from race-stratified linear regression models 
for SNPs in ADIPOQ (left panel), ADIPOR1 (center panel), and ADIPOR2 (right panel) among 990 black women and 977 white 
women, Southern Community Cohort Study, 2002-2006 
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Figure 4.3.  Adjusted mean adiponectin levels (ug/ml) for genotypes in SNP rs17366568 in 
ADIPOQ among white women from linear regression models stratified by body mass index 
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Figure 4.4.  Linkage disequilibrium (LD) plots showing r2 values for the Yoruban (YRI) 
(top panel) and Caucasian/CEPH (CEU) (bottom panel) populations from HapMap phase II 
data, NCBI build 36 including the gene region for ADIPOQ plus 10 kb downstream and 
upstream.
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Supplementary Figure 4.1.  Linkage disequilibrium (LD) plots for ADIPOQ showing r2 
values between genotyped SNPs in 990 black women (top panel) and 977 white women 
(bottom panel), Southern Community Cohort Study, 2002-2006  
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CHAPTER 5: DISCUSSION 
 
Summary 
Using interview data and blood samples collected at baseline from the Southern 
Community Cohort Study, this cross-sectional study examined serum adiponectin levels in 
relation to a variety of environmental and behavioral factors as well as several single 
nucleotide polymorphisms (SNPs) in three adiponectin-related genes (ADIPOQ, ADIPOR1, 
and ADIPOR2).   This study was the largest to-date to measure adiponectin in both black and 
white women.  The results showed that black women have lower adiponectin levels 
compared to whites even after adjustment for body mass index (BMI).  These results expand 
upon previous studies that were limited by small sample sizes (1-4) or narrow age ranges (5-
7) and demonstrate that racial differences in adiponectin exist across the spectrum of adult 
age and body size.  In an examination of predictors of adiponectin levels, age, HDL-
cholesterol, and hypertension were found to be strong correlates of adiponectin in both race 
groups.  In the genetic analyses, one SNP (rs17366568) on ADIPOQ was found to be 
significantly associated with adiponectin levels in white women but not in black women.  
This finding is supported by similar observations in two recent genome-wide association 
studies (GWAS) in European whites which found differences in adiponectin levels across 
genotypes of this SNP (8, 9).  Further, for the first time, this study examined SNP 
rs17366568 in blacks.  Different results compared to white women were found for this SNP; 
among the black women in this study, no association was observed with rs173665368 and 
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adiponectin levels.  No significant associations were observed between any of the SNPs in 
the three adiponectin-related genes and BMI. 
Study Strengths 
Study design 
This study was a cross-sectional design using data from 2,000 women enrolled in the 
SCCS.  From the larger SCCS population, women were randomly selected for inclusion in 
this study sample within strata of race, menopausal status, and BMI category.  This design 
ensured that sufficient numbers of women in each race group were included which allowed 
this study to overcome problems with small sample sizes of blacks in previous studies of 
adiponectin across race groups.  Further, by including women in equal numbers across 
categories of BMI, the study was amply powered to quantify differences in adiponectin levels 
across a wide range of body size. 
Biologic plausibility and novelty of research questions 
 A large number of potential correlates were selected for examination in relation to 
adiponectin levels including age, BMI, HDL-cholesterol, socioeconomic status (education 
and income), cigarette smoking, physical activity, macronutrient intakes (total calories, fat, 
carbohydrate, protein, as well as fiber), reproductive measures, and several co-morbidities 
(diabetes, heart attack or coronary artery bypass surgery, hypertension, high cholesterol, and 
depression).  These factors were selected because reports in the literature indicated possible 
links to adiponectin or because they were known to be associated with body size and thus 
were hypothesized to be possible correlates of adiponectin as well. 
Linkage studies (10, 11) as well as genome-wide association studies (8, 9) have 
indicated that the adiponectin locus (ADIPOQ) is strongly associated with adiponectin levels, 
supporting one of the major hypotheses of this study which was to examine polymorphisms 
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in this gene in relation to circulating adiponectin levels.  The genes for the adiponectin 
receptors, ADIPOR1 and ADIPOR2, were also selected because these receptors are known 
binding sites throughout the body for adiponectin, and it seemed plausible that variation in 
the receptor-encoding genes might affect their structure and thus their affinity for adiponectin 
leading to differences in circulating levels.   
The comparison of adiponectin levels, predictors, and genetic polymorphisms in 
women of different race groups was an important component of this research.  It has been 
well-established that black women are heavier than white women (12) and that black women 
have a higher burden of many chronic diseases (13, 14).  There has been much debate about 
the root causes of these differences, but it seems likely that at least some of the racial 
disparities in incident disease and mortality may be due to differences in biologic factors.  
The adipokines, and adiponectin in particular, are strong candidates for exploration because 
they appear to play a major role in several of the metabolic pathways related to diseases such 
as cancer, type 2 diabetes, and CVD, and a small body of emerging evidence has indicated 
that there may be racial differences in protein levels in circulation.  This study allowed for 
the largest-ever comparison of adiponectin levels and correlates in both black and white 
women across a wide range of age and body size.   
SNP selection and Genotyping 
A tag-SNP approach was employed for this study that included the selection of tag-
SNPs based on both the African (YRI) and white (CEU) study samples in HapMap.  The use 
of both data sources for tag-SNP selection ensured adequate coverage across the three genes 
of interest to account for the possibility that LD block sizes might be smaller among the 
women of African versus European descent. 
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The genotyping for this study was conducted as part of a larger genotyping effort, 
allowing the use of the Illumina GoldenGate platform, a high-throughput method with very 
high call rates and reproducibility.   
Adjustment for population stratification 
 Eligibilty for this study included self-report of race/ethnicity as only “White” or 
“Black/African-American”.  However, as has been much discussed in the literature, self-
reported race in such broad categories may be insufficient for dealing with the issue of 
population stratification which refers to substructures that may exist within race/ethnic 
groups that can create biased associations between genetic variants and phenotypic outcomes 
(15, 16).  Several methodologies have been developed to adjust for population stratification 
and two of these were examined in this study and found to have very similar effects.  Using 
292 ancestry informative markers (AIM), two ancestry allelic clusters were determined using 
a Bayesian clustering approach implemented in the STRUCTURE software package (17).  
The percentage of African ancestry estimated from this method was included as a covariate 
in the models examining SNP-adiponectin and SNP-BMI associations.  Principal components 
were also derived from the AIMs (18) and the first five principal components were examined 
as covariates.  Effect estimates were essentially unchanged in models comparing the two 
different methods of adjustment for population stratification and thus the STRUCTURE 
method was selected because of the smaller degrees of freedom required in the statistical 
models. 
 Population substructure was also examined by running unadjusted linear regression 
models including only the black women in this sample (N=986) with log-adiponectin as the 
outcome variable and percentage of European ancestry (continuous) as the exposure variable.  
European ancestry was not significantly associated with log-adiponectin in either a crude 
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model (p=0.12) or in a multivariate linear regression model including age, BMI, HDL 
cholesterol and hypertension (p=0.36).  Re-running of these models using percentage 
European ancestry as estimated from the entire set of 1,420 SNPs genotyped in the Komen 
Obesity Project resulted in nearly identical effect estimates and measures of variability.  
These results are somewhat in contrast with the report by Wassel Fyr et al. (19) in which the 
authors observed a significant association between European ancestry and log-adiponectin 
levels in both unadjusted models and after multivariate adjustment in 1,241 adults in the 
Health ABS study who self-reported their race as Black Americans.  One major difference 
between our study and the Health ABC is the mean individual European ancestry which was 
22.1% in the Health ABC study (25.1% at their Pittsburgh site and 18.7% at their Memphis 
site) but only 7.5% in our study (as estimated by the 276 AIM SNPs; mean European 
ancestry was estimated at 8.4% using the entire set of 1,420 genotyped SNPs).  In this study, 
while broad race categories (as defined by self-reported black or white race) were clearly a 
major factor related to adiponectin levels, within groups of self-reported race, admixture was 
relatively low and not strongly associated with adiponectin levels. 
These results are somewhat in contrast with the report by Wassel Fyr et al (19) in 
which the authors observed a significant association between European ancestry and log-
adiponectin levels in both unadjusted models and after multivariate adjustment in 1,241 
adults in the Health ABS study who self-reported their race as black.  One major difference 
between our study and the Health ABC is the mean individual European ancestry which was 
22.1% in the Health ABC study (25.1% at their Pittsburgh site and 18.7% at their Memphis 
site) but only 7.5% in our study (as estimated by the 276 AIM SNPs; mean European 
ancestry was estimated at 8.4% using the entire set of 1,420 genotyped SNPs).  These results 
  181 
 
in conjunction with our observation of strong differences in adiponectin levels by self-
reported race groups (black v. white) indicate that while self-reported race is clearly a major 
factor related to adiponectin level, within groups of self-reported race, limited additional 
variability in racial substructure may not be strongly related to adiponectin levels. 
Study Limitations 
Measurement of adiponectin 
The measurement of adiponectin had a coefficient of variation (CV) of 9.4%, indicating 
some intra-individual variation in the measurement; however, this CV is in line with CVs 
reported from other studies using the same assay (CV range 1.8% to 13.3%) (2, 3, 6).  
Variability in the adiponectin levels related to the assay itself, thus, could account for some 
of the effects observed in this study although it is reassuring that our results are generally in-
line in both direction and magnitude with most previously published reports. 
Adiponectin circulates in blood in several isoforms including a trimer, a hexamer and 
as a high molecular weight-form (HMW).  Designed in 2005, the current study used a 
measurement of total adiponectin, a decision made based on the state of the science and the 
lack of availability of commercial assays for measurement of HMW adiponectin at the time.  
However, some recent work has indicated that the HMW form may be the more biologically 
active.  In vitro, HMW adiponectin, compared to the lower order forms, was shown to have 
the highest binding affinity to its receptors as well as be the most potent activator of AMP 
kinase which plays a crucial role in the metabolic activities of adiponectin (20).   
Determining which measure of adiponectin to use in epidemiologic studies includes 
consideration of the strength of the evidence demonstrating superiority of one isoform over 
the other in relation to relevant outcomes (such as glucose tolerance or chronic disease such 
as diabetes, cancer, or CVD) as well as the feasibility of measuring the different forms.  
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Some groups suggest that studies of adiponectin focus on the HMW isoform (21) while 
others recommend analysis of the ratio of HMW to total adiponectin or to lower order forms 
(22, 23).  The general body of evidence evaluating HMW adiponectin is relatively small, and 
to date remains unclear regarding a clear preference for measurement of one isoform over 
another.  In terms of drug efficacy, the HMW form of adiponectin appears to be the best 
indicator of improvements in liver insulin sensitivity after treatment with PPAR-γ agonists 
(24).  Evidence for differences in association between total, HMW, and ratios of adiponectin 
forms and various disease states is less clear; in a few studies, HMW adiponectin was found 
to be better correlated with measure of glucose tolerance than total adiponectin (21-23).  A 
small case-control study of Greek women reported similar odds ratios between breast cancer 
and total and HMW adiponectin (25).  In Japanese patients, both total and HMW 
adiponectin, but not their ratio, were found to be positively correlated with severity of 
retinopathy and neuropathy in type 2 diabetics (26).  HMW adiponectin but not total 
adiponectin was found to be associated with fruit intake in healthy Greek women (27).   
As for feasibility, measurements of HMW adiponectin as recently as five years ago 
were labor-intensive and not suitable for large studies such as the SCCS (21).  Soon after, a 
novel ELISA assay was developed to measure both total and HMW adiponectin (28) and this 
assay has very recently begun to be used in larger-scale epidemiology studies.   Future work 
in the SCCS will likely include the measurement of multiple isoforms of adiponectin as the 
evidence is accumulating that these distinctions may be relevant. 
A further limitation of this study related to the adiponectin measurement is the use of 
a single, convenience blood sample.  The single blood sample provided at baseline entry into 
the SCCS was utilized for the measurement of adiponectin for each participant which did not 
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allow for the examination of inter-individual variation in adiponectin levels.  Reports in the 
literature, however, show remarkably high correlations between adiponectin measurements 
across time showing that single measurements are likely sufficient for large epidemiologic 
studies, especially when balanced against the effort and costs that would be involved in the 
collection of multiple blood samples in a study as large as the SCCS (29, 30).   
Additionally, SCCS participants were not required to be fasting when blood samples 
were taken, and thus, in this study, only 44% of the samples were collected at least 8 hours 
since the last meal.  Most reports have showed that adiponectin does not exhibit strong 
variability throughout the day or in relation to meal composition (31) indicating that fasting 
status is not crucial in the measurement of adiponectin.  In this study, analyses limited to 
fasting samples showed similar results to those conducted in the entire study sample. 
Measurement of body size 
Self-reported height and weight:  Measures of height and weight used to calculate BMI 
were self-reported by participants during the baseline SCCS interview and represent a 
potential limitation of this study.  Self-reported values can be unreliable and lead to biased 
effect estimates;  indeed a recent review indicates that among women, height does tend to be 
over-reported while weight tends to be under-reported (32).  However, in many large-scale 
epidemiologic studies including the SCCS during the time period of the current study, self-
reported height and weight values are collected due to the higher monetary and time costs 
associated with collecting measured values in a consistent manner.  Supporting the use of 
self-reported measures is a recent report using 1999-2004 National Health and Examination 
Survey data which showed that despite errors in self-report, BMI categories based on self-
reported values still generally demonstrate good agreement with BMI categories from 
measured values (33).  These data also showed that under-reporting was more common in 
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whites and among well-educated women (33) which suggests that the BMI values calculated 
from self-report in the SCCS may be less vulnerable to bias than in other studies of more 
educated, white participants.  Furthermore, the self-reported height and weight data in the 
SCCS baseline interview are believed to be generally of high quality.  First, it is expected 
that the in-person nature of the interview is a deterrent for gross under- or over-reporting of 
weight by the participants.  Second, many patients have just been weighed as part of their 
medical visit at the Community Health Center.  Finally, BMI values calculated from self-
reported height and weight in the SCCS were very highly correlated with BMI values 
calculated from medical record data collected for approximately 25% of the participants, 
overall (Pearson correlation coefficient > 0.95) as well as across strata of race and BMI. 
Limitations of BMI:  BMI has excellent validity as a measure of absolute fat mass adjusted 
for height (34), but, the calculation of BMI [weight (kg)/height (m)2] involves body weight 
which is made up of both lean body mass and fat tissue.  This makes BMI a less valid 
measure for percent body fat than other measures that are able to account for differences in 
the proportion of each type of body tissue such as under-water weighing or DEXA (34). 
Lack of measure of central obesity:  There was no measure of central obesity (either via 
waist circumference or imaging techniques such as MRI/CT in this sample of women.  It has 
been shown that the amount of centrally-deposited adipose tissue differs between black and 
white women at the same level of BMI (35) and further, that there are differences in the 
proportion of the various isoforms of adiponectin in relation to measures of central obesity 
across race groups (36).  Given these findings, lack of measurement of central obesity is a 
primary limitation of this research and should be given more attention in future work. 
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Measurement of potential adiponectin correlates  
In this study, age, BMI, HDL-cholesterol and hypertension were found to be strong 
predictors of adiponectin levels but other factors including socioeconomic status (education 
and income), cigarette smoking, physical activity, and dietary, reproductive, and co-
morbidity indices were not correlated with adiponectin.  Imprecise measurement of some of 
these factors could explain the inability to detect some associations.  These factors were 
assessed via questionnaire including a food frequency questionnaire (FFQ) and a physical 
activity questionnaire (PAQ).  Both the FFQ and the PAQ were designed specifically for the 
target study population, but, by their very nature, neither was entirely comprehensive.  Many 
of the factors were assessed as of the time of the baseline interview and thus may not reflect 
past levels which may have been more influential on adiponectin levels.  For physical 
activity, levels were low overall, which may have resulted in a lack of power to detect 
modest associations.  Difficulty with recall by participants may have also contributed to 
imprecise measurement of some of these factors.  Additionally, some of these factors may be 
more strongly correlated with HMW adiponectin which was not measured in this study.   
It may also be the case that once age, BMI, HDL-cholesterol and hypertension were 
included in the prediction models for adiponectin, other factors (for example, diabetes and 
physical activity), which might have been expected to be predictive of adiponectin but are 
also strongly associated with age, BMI, HDL-cholesterol and hypertension, added minimal 
additional predictive value.   
Multiple comparisons 
As is common in many association studies examining multiple genes and SNPs, this 
study used several statistical models to assess associations between adiponectin, BMI and the 
genotyped SNPs.  A Bonferroni correction was applied to the commonly-used type I error 
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rate of 0.05 to account for the multiple testing.  The Bonferroni correction was selected 
because it is a simple, easily understood, and relatively common type of correction for these 
circumstances but it is not without its drawbacks.  It is a conservative approach in that it is 
unable to account for the correlation structure inherent among a group of SNPs.  A less 
conservative alternative might have been the use of permutation testing in order to maintain a 
test with appropriate type I error.  However, the methodology of permutation testing has not 
yet been extended to allow for simultaneous adjustment for population stratification which 
was deemed potentially important in this study population of blacks and whites.      
While the Bonferroni approach is conservative, its application did not drastically alter 
the interpretation of these results.  There were few SNPs that were significantly associated 
with adiponectin or BMI at an alpha level of 0.05 (5 total for adiponectin and 9 total for BMI, 
out of 119 total associations examined).  Further, there was no evidence of clustering of 
SNPs with lower p-values in any specific regions of the genes examined (Figures A.1a, A.1b, 
and A.1c for adiponectin and Figures A.2a, A.2b, and A2.c for BMI).  None of these 14 
SNPs are known to be functional variants nor have they been found in previous studies to be 
associated with these outcomes.  They may, however, represent areas of the genes worthy of 
further exploration in future studies.   
Future directions 
 These results show clear differences in adiponectin levels between black and white 
women after adjustment for BMI.  However, while BMI is highly correlated with total body 
fat overall (37), there are known differences in body composition between black and white 
women at the same level of BMI.  Several studies have shown that blacks have less visceral 
adipose tissue than do whites at the same BMI (35, 38-40).  Thus, the measurement of 
visceral fat will be important in future studies attempting to determine the etiology of 
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differences in adiponectin levels across race groups.  Sex hormones such as estrogen and 
androgens may also affect adiponectin expression (31) and thus their measurement may also 
be a useful addition to future studies examining levels and correlates of adiponectin. 
 With differences in adiponectin levels shown between black and white women, an 
exciting next step will be assessing relationships between adiponectin and incident disease in 
these two groups of women.  In the Southern Community Cohort Study (SCCS), nested case-
control studies of major cancer sites (including breast, lung, and colon) will be conducted in 
the near future.  Measurement of adiponectin in blood samples collected at baseline entry 
into the SCCS (i.e. before cancer diagnosis) in these studies will be an important step in 
assessing the role played by adiponectin in the development of these cancers.  Future studies 
of incident diabetes and heart disease will also be conducted shortly within the SCCS and 
measures of adiponectin in both the black and white participants are expected to be useful 
factors in untangling differences in disease rates by race.  Examination of adiponectin in 
relation to these diseases is not limited to the SCCS, of course.  The results from this study 
and the resulting need for future analyses highlight the importance of the continued funding 
of large, well-defined cohorts of individuals of diverse populations with available 
biospecimans for measurement of biomarkers and genetic polymorphisms.   
 Replication of effects observed in genetic association studies is emerging as an 
important research objective.  In this study, SNP rs17366568 was found to be associated with 
adiponectin levels in white women, a finding that was recently reported by two GWAS 
studies of white European women.  Notably, this finding was not observed in the black 
women in this study.  Additionally, one group has found evidence to indicate that this SNP 
may not be functionally responsible for changes in adiponectin levels but simply in linkage 
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disequilibrium (LD) with an as-yet undetermined functional SNP (8).  This could potentially 
explain why no association with adiponectin was seen in the black women in this study; if the 
causal allele lies elsewhere in this region, it is possible that rs17366568 did not sufficiently 
tag the true causal allele in the black women who, in general, would be expected to have 
smaller LD blocks.  However, the LD patterns in our study, at least, do not support this 
theory as SNP rs17366568 was in a block all on its own (i.e. r2 between SNP rs17366568 and 
all other genotyped SNPs was very low).  Examination of this SNP, as well as sequencing in 
this region, in additional populations of black and white women will be important to 
determine whether this polymorphism or other variants nearby represent important racial 
differences in the genetic underpinnings of adiponectin levels.   
 Debate is intensifying regarding the utility of tag-SNPs (such as those used in this 
study) to identify important variants because this approach is unlikely to be useful for the 
identification of rare variants.  If the common disease/rare variant (CD/RV) paradigm holds 
for conditions such as obesity (meaning that disease risk is due to loci with low population 
frequency) (31, 41), research approaches that include adequate study power for the 
identification of rare variants will be important in future studies.   As the cost of genotyping 
decreases drastically with each passing year, studies in the not-too-distant future will likely 
consider the sequencing of entire genomes which would include both common and rare 
variants.  The tools to meaningfully analyze large quantities of genetic data, though, are 
already insufficient for the current state of the science, and thus, work in this area will be 
successful only if the development of adequate methods is a major concurrent focus. 
Conclusion 
In this study, differences in adiponectin levels were observed between black and 
white women after adjustment for BMI.  Future studies which include additional 
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measurements of body size and composition may help refine the magnitude of these 
differences.  Adiponectin levels were shown to be strongly related to age, HDL-cholesterol, 
and hypertension but few genetic polymorphisms in three adiponectin-related genes were 
found with the exception of a single SNP among white women on ADIPOQ (rs17366568).  
Larger study samples or pooled studies will likely be required to detect additional variants 
that may have small but important cumulative effects on adiponectin levels.  Observed racial 
differences in adiponectin levels in this study will be utilized in the design of future studies 
of this adipokine in racially diverse populations in relation to diseases affected by 
adiponectin-mediated pathways such as cancer, CVD, and type 2 diabetes.  Additionally, the 
development of therapeutics that increase adiponectin levels for the purpose of disease 
prevention may be guided by the predictors of adiponectin and racial differences observed in 
this study.
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APPENDIX 
Additional Tables and Figures 
Table A.1a.  Comparison of p-values for association between adiponectin and genotypes for 
SNPs in ADIPOQ by method of adjustment for population stratification 
 
 White women Black women 
ADIPOQ SNP1 
STRUCTURE
2 
Principal 
components3 STRUCTURE2 
Principal 
components3 
rs864265 0.076 0.10 0.14 0.16 
rs822387 0.22 0.48 0.13 0.12 
rs16861194 0.73 0.91 0.50 0.51 
rs182052 0.10 0.081 0.49 0.53 
rs16861205 0.76 0.92 0.64 0.63 
rs822391 0.47 0.46 0.85 0.92 
rs16861210 0.11 0.11 0.60 0.67 
rs822396 0.40 0.41 0.44 0.42 
rs12495941 0.057 0.043 0.28 0.27 
rs7649121 0.69 0.67 0.76 0.76 
rs9877202 -- -- 0.54 0.57 
rs17366568 0.00036 0.00030 0.92 0.91 
rs3821799 0.95 0.97 0.94 0.95 
rs3774261 0.20 0.19 0.96 0.95 
rs17366743 0.57 0.17 -- -- 
rs6444174 -- -- 0.63 0.66 
rs1063539 0.20 0.21 0.83 0.19 
rs9842733 -- -- 0.47 0.13 
rs1403697 -- -- 0.44 0.39 
rs7641507 -- -- 0.51 0.74 
rs1403696 -- -- 0.79 0.70 
rs6444175 0.51 0.49 0.63 0.80 
rs7628649 0.34 0.32 0.73 0.76 
rs17373414 0.12 0.10 0.96 0.18 
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Table A.1b.  Comparison of p-values for association between adiponectin and genotypes for 
SNPs in ADIPOR1 by method of adjustment for population stratification 
 
 White women Black women 
ADIPOR1 
SNP1 STRUCTURE2 
Principal 
components3 STRUCTURE2 
Principal 
components3 
rs6672643 0.71 0.75 0.60 0.63 
rs2185781 0.51 0.51 0.57 0.59 
rs4336908 0.53 0.54 0.60 0.47 
rs10920531 0.84 0.88 0.087 0.10 
rs7539542 0.74 0.80 0.10 0.10 
rs1342387 0.38 0.39 0.58 0.58 
rs7518457 -- -- 0.63 0.60 
rs12045862 0.68 0.74 0.27 0.49 
rs2275737 0.32 0.34 0.61 0.61 
rs12733285 0.51 0.56 0.99 0.98 
rs10753929 0.34 0.34 0.76 0.75 
rs1539355 0.88 0.89 0.81 0.81 
rs10800888 -- -- 0.87 0.89 
rs6666089 0.89 0.92 0.30 0.32 
rs7523903 -- -- 0.16 0.16 
rs2232849 -- -- 0.73 0.68 
rs2232844 -- -- 0.73 0.37 
rs2232842 0.25 0.42 0.024 0.028 
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Table A.1c.  Comparison of p-values for association between adiponectin and genotypes for 
SNPs in ADIPOR2 by method of adjustment for population stratification 
 
 White women Black women 
ADIPOR2 
SNP1 STRUCTURE2 
Principal 
components3 STRUCTURE2 
Principal 
components3 
rs758027 -- -- 0.13 0.12 
rs1029629 0.60 0.61 0.57 0.60 
rs7304096 -- -- 0.69 0.59 
rs2058033 0.47 0.49 0.069 0.13 
rs7975600 0.83 0.81 0.47 0.51 
rs11832817 0.31 0.31 0.16 0.17 
rs12826079 0.85 0.94 -- -- 
rs10773982 0.72 0.71 0.45 0.43 
rs11061946 0.10 0.11 0.19 0.27 
rs10773983 0.0035 0.0039 0.37 0.34 
rs12316367 0.054 0.071 0.72 0.68 
rs10773989 0.10 0.11 0.29 0.32 
rs2058112 0.17 0.17 0.94 0.94 
rs12298275 -- -- 0.87 0.62 
rs7134070 -- -- 0.60 0.56 
rs7967137 0.22 0.23 0.97 0.95 
rs7138701 -- -- 0.77 0.80 
rs11614639 0.082 0.10 0.41 0.41 
rs10773991 0.067 0.083 0.76 0.73 
rs4140993 -- -- 0.076 0.08 
rs16928751 0.22 0.23 0.96 0.96 
rs2286384 0.076 0.094 0.23 0.23 
rs12342 0.65 0.68 0.021 0.02 
rs1044471 0.016 0.016 0.47 0.47 
rs7294540 0.067 0.081 0.76 0.79 
rs13219 0.071 0.089 0.45 0.46 
rs2058111 0.067 0.082 0.47 0.49 
 
Note:  All models adjusted for age at baseline SCCS interview. Missing values indicate SNPs 
for which the minor allele frequency (MAF) was <0.01. 
 
1 SNPs are ordered from 5’ to 3’ along ADIPOQ 
 
2 STRUCTURE method included adjustment for percentage African ancestry as estimated by 
STRUCTURE 
 
3 Principal components method included adjustment for five principal components derived 
separately for white and black women using EIGENSTRAT
  197
Table A.2a.  Comparison of p-values for association between body mass index (BMI) and 
genotypes for SNPs in ADIPOQ by method of adjustment for population stratification 
 
 White women Black women 
ADIPOQ SNP1 
STRUCTURE
2 
Principal 
components3 STRUCTURE2 
Principal 
components3 
rs864265 0.42 0.48 0.070 0.071 
rs822387 0.23 0.22 0.014 0.014 
rs16861194 0.75 0.95 0.86 0.86 
rs182052 0.14 0.13 0.95 0.95 
rs16861205 0.59 0.88 0.93 0.92 
rs822391 0.073 0.08 0.21 0.23 
rs16861210 0.28 0.34 0.36 0.36 
rs822396 0.068 0.089 0.33 0.32 
rs12495941 0.31 0.29 0.68 0.65 
rs7649121 0.18 0.21 0.65 0.66 
rs9877202 -- -- 0.04 0.035 
rs17366568 0.68 0.73 0.53 0.53 
rs3821799 0.48 0.54 0.76 0.74 
rs3774261 0.74 0.80 0.81 0.79 
rs17366743 0.64 0.87 -- -- 
rs6444174 -- -- 0.74 0.75 
rs1063539 0.39 0.40 0.46 0.57 
rs9842733 -- -- 0.16 0.079 
rs1403697 -- -- 0.45 0.46 
rs7641507 -- -- 0.42 0.69 
rs1403696 -- -- 0.21 0.21 
rs6444175 0.85 0.57 0.22 0.21 
rs7628649 0.31 0.38 0.026 0.025 
rs17373414 0.35 0.33 0.41 0.55 
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Table A.2b.  Comparison of p-values for association between body mass index (BMI) and 
genotypes for SNPs in ADIPOR1 by method of adjustment for population stratification 
 
 White women Black women 
ADIPOR1 
SNP1 STRUCTURE2 
Principal 
components3 STRUCTURE2 
Principal 
components3 
rs6672643 0.42 0.33 0.028 0.023 
rs2185781 0.30 0.27 0.63 0.62 
rs4336908 0.39 0.35 0.72 0.70 
rs10920531 0.15 0.17 0.23 0.23 
rs7539542 0.019 0.028 0.10 0.10 
rs1342387 0.76 0.77 0.69 0.72 
rs7518457  -- 0.71 0.15 
rs12045862 0.86 0.90 0.77 0.68 
rs2275737 0.88 0.87 0.34 0.40 
rs12733285 0.74 0.77 0.44 0.43 
rs10753929 0.82 0.78 0.59 0.63 
rs1539355 0.75 0.80 0.34 0.37 
rs10800888  -- 0.80 0.81 
rs6666089 0.64 0.68 0.86 0.82 
rs7523903  -- 0.86 0.85 
rs2232849  -- 0.70 0.12 
rs2232844  -- 0.50 0.75 
rs2232842 0.44 0.70 0.10 0.093 
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Table A.2c.  Comparison of p-values for association between body mass index (BMI) and 
genotypes for SNPs in ADIPOR2 by method of adjustment for population stratification 
 
 White women Black women 
ADIPOR2 
SNP1 STRUCTURE2 
Principal 
components3 STRUCTURE2 
Principal 
components3 
rs758027 -- -- 0.23 0.26 
rs1029629 0.55 0.25 0.96 0.95 
rs7304096 -- -- 0.59 0.83 
rs2058033 0.51 0.55 0.77 0.96 
rs7975600 0.62 0.65 0.0085 0.009 
rs11832817 0.91 0.95 0.0062 0.006 
rs12826079 0.42 0.47 -- -- 
rs10773982 0.56 0.61 0.22 0.23 
rs11061946 0.68 0.76 0.87 0.98 
rs10773983 0.068 0.090 0.55 0.55 
rs12316367 0.27 0.33 0.03 0.038 
rs10773989 0.38 0.44 0.28 0.27 
rs2058112 0.20 0.21 0.79 0.77 
rs12298275 -- -- 0.90 0.97 
rs7134070 -- -- 0.96 0.96 
rs7967137 0.28 0.31 0.063 0.063 
rs7138701 -- -- 0.92 0.89 
rs11614639 0.24 0.29 0.34 0.35 
rs10773991 0.20 0.25 0.21 0.22 
rs4140993 -- 0.60 0.55 0.52 
rs16928751 0.28 0.31 0.53 0.50 
rs2286384 0.20 0.25 0.11 0.12 
rs12342 0.57 0.61 0.040 0.04 
rs1044471 0.48 0.55 0.0040 0.0046 
rs7294540 0.12 0.14 0.23 0.26 
rs13219 0.15 0.18 0.15 0.16 
rs2058111 0.17 0.19 0.34 0.34 
 
Note:  All models adjusted for age at baseline SCCS interview. Missing values indicate SNPs 
for which the minor allele frequency (MAF) was <0.01. 
 
1 SNPs are ordered from 5’ to 3’ along ADIPOQ 
 
2 STRUCTURE method included adjustment for percentage African ancestry as estimated by 
STRUCTURE 
 
3 Principal components method included adjustment for five principal components derived 
separately for white and black women using EIGENSTRAT
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Table A.3.  Counts and unadjusted geometric means for adiponectin levels (ug/ml) by 
genotypes of SNPs in ADIPOQ among black and white women 
 
  Black Women White Women 
 Genotype N 
Geometric 
Mean N 
Geometric 
Mean 
rs864265 A/A 20 14.61 27 11.74 
 A/C 221 12.49 261 16.04 
 C/C 745 11.43 684 15.06 
      
rs822387 A/A 446 11.96 810 15.03 
 A/G 436 11.22 154 16.07 
 G/G 104 12.90 8 17.95 
      
rs16861194 A/A 566 11.88 813 15.24 
 A/G 372 11.62 153 15.04 
 G/G 48 10.59 6 15.58 
      
rs182052 A/A 111 11.31 121 13.56 
 A/G 474 11.56 429 15.92 
 G/G 401 12.02 422 15.01 
      
rs16861205 A/A 37 11.15 6 15.58 
 A/G 321 11.50 139 15.10 
 G/G 628 11.87 827 15.23 
      
rs822391 A/A 905 11.70 607 14.85 
 A/G 81 11.87 309 15.94 
 G/G   56 15.30 
      
rs16861210 A/A 28 12.61 11 19.07 
 A/G 287 11.89 164 16.68 
 G/G 671 11.61 797 14.88 
      
rs822396 A/A 619 11.77 628 14.85 
 A/G 320 11.43 296 16.05 
 G/G 47 13.09 48 14.91 
      
rs12495941 A/A 143 12.14 104 14.00 
 A/C 451 11.23 448 15.95 
 C/C 392 12.15 420 14.76 
      
rs7649121 A/A 779 11.72 663 15.38 
 A/T 196 11.65 287 14.94 
 T/T 11 13.09 22 13.75 
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Table A.3. (continued)  Counts and unadjusted geometric means for adiponectin levels 
(ug/ml) by genotypes of SNPs in ADIPOQ among black and white women 
 
  Black Women White Women 
 Genotype N 
Geometric 
Mean N 
Geometric 
Mean 
rs9877202 A/A 701 11.70   
 A/G 252 12.00   
 G/G 33 10.12   
      
rs17366568 A/A 1 7.64 19 9.22 
 A/G 28 11.82 225 13.63 
 G/G 957 11.72 728 15.95 
      
rs3821799 A/A 324 11.82 194 15.08 
 A/G 486 11.63 456 15.00 
 G/G 176 11.77 322 15.60 
      
rs3774261 A/A 309 11.62 145 16.06 
 A/G 495 11.79 431 15.47 
 G/G 182 11.69 396 14.64 
      
rs17366743 A/A   921 15.20 
 A/G   48 16.22 
 G/G   3 7.42 
      
rs6444174 A/A 691 11.85   
 A/G 262 11.30   
 G/G 33 12.43   
      
rs1063539 C/C 583 11.62 693 14.93 
 C/G 362 11.74 215 16.21 
 G/G 2 28.83 15 15.79 
      
rs9842733 A/A 8 19.09   
 A/T 161 11.11   
 T/T 817 11.79   
      
rs1403697 A/A 756 11.71   
 A/G 215 11.54   
 G/G 15 15.03   
      
rs7641507 A/A 5 10.69   
 A/G 144 11.28   
 G/G 837 11.80   
  202
Table A.3. (continued)  Counts and unadjusted geometric means for adiponectin levels 
(ug/ml) by genotypes of SNPs in ADIPOQ among black and white women 
 
  Black Women White Women 
 Genotype N 
Geometric 
Mean  Genotype 
rs1403696 A/A 45 12.72   
 A/G 326 11.44   
 G/G 615 11.80   
      
rs6444175 A/A 76 12.74 75 16.02 
 A/G 454 11.57 352 15.39 
 G/G 456 11.71 545 14.99 
      
rs7628649 A/A 105 12.13 14 16.53 
 A/G 452 11.48 186 16.07 
 G/G 429 11.87 772 14.99 
      
rs17373414 A/A 1 46.30 15 21.42 
 A/G 20 11.01 199 14.77 
 G/G 965 11.72 758 15.23 
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Table A.4.  Counts and unadjusted geometric means for adiponectin levels (ug/ml) by 
genotypes of SNPs in ADIPOR1 among black and white women 
 
  Black women White women 
SNP Genotype N 
Geometric 
Mean N 
Geometric 
Mean 
rs6672643 A/A 546 11.56 732 15.25 
 A/G 366 11.84 213 15.36 
 G/G 73 12.39 26 13.09 
      
rs2185781 A/A 41 12.13 43 15.04 
 A/G 291 12.11 295 14.62 
 G/G 654 11.52 634 15.51 
      
rs4336908 A/A 8 15.29 43 15.04 
 A/G 129 11.23 293 14.65 
 G/G 849 11.77 636 15.49 
      
rs10920531 A/A 297 11.82 146 15.20 
 A/C 456 12.16 409 15.00 
 C/C 233 10.79 417 15.43 
      
rs7539542 C/C 394 11.87 101 15.93 
 C/G 435 12.02 393 15.18 
 G/G 157 10.57 478 15.09 
      
rs1342387 A/A 256 12.08 219 14.62 
 A/G 479 11.72 441 15.84 
 G/G 250 11.36 312 14.77 
      
rs7518457 A/A 873 11.68   
 A/G 108 12.17   
 G/G 5 8.69   
      
rs12045862 A/A 9 10.70 72 15.75 
 A/G 159 11.20 366 15.57 
 G/G 818 11.83 534 14.90 
      
rs2275737 A/A 195 12.18 206 14.36 
 A/C 484 11.41 424 15.80 
 C/C 307 11.92 342 15.02 
      
rs12733285 A/A 50 12.18 91 14.18 
 A/G 321 11.70 400 15.50 
 G/G 615 11.69 481 15.17 
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Table A.4. (continued)  Counts and unadjusted geometric means for adiponectin levels 
(ug/ml) by genotypes of SNPs in ADIPOR1 among black and white women 
 
  Black women White women 
SNP Genotype N 
Geometric 
Mean N 
Geometric 
Mean 
rs10753929 A/A 41 12.17 21 18.62 
 A/G 304 11.86 207 14.56 
 G/G 641 11.62 744 15.31 
      
rs1539355 A/A 290 11.53 475 15.36 
 A/G 491 11.67 397 15.06 
 G/G 205 12.11 100 15.09 
      
rs10800888 A/A 12 12.31   
 A/G 224 11.79   
 G/G 750 11.69   
      
rs6666089 A/A 19 11.14 96 14.94 
 A/G 229 11.05 395 15.13 
 G/G 738 11.95 481 15.33 
      
rs7523903 C/C 13 12.12   
 C/G 391 12.38   
 G/G 582 11.28   
      
rs2232849 A/A 9 9.62   
 A/G 162 12.03   
 G/G 815 11.68   
      
rs2232844 A/A 816 11.68   
 A/G 161 12.10   
 G/G 9 8.95   
      
rs2232842 A/A 694 11.39 917 15.10 
 A/G 269 12.23 53 16.88 
 G/G 23 16.68 2 32.82 
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Table A.5  Counts and unadjusted geometric means for adiponectin levels (ug/ml) by 
genotypes of SNPs in ADIPOR2 among black and white women 
 
  Black women White women 
SNP Genotype N 
Geometric 
mean N 
Geometric 
mean 
rs758027 A/A 800 11.95   
 A/G 174 10.97   
 G/G 11 8.34   
      
rs1029629 A/A 553 11.43 489 14.99 
 A/C 383 12.21 391 15.20 
 C/C 50 11.25 91 16.51 
      
rs7304096 A/A 913 11.74   
 A/G 72 11.52   
 G/G 1 5.82   
      
rs2058033 A/A 935 11.59 743 14.99 
 A/C 50 14.50 206 15.70 
 C/C 1 6.45 23 18.49 
      
rs7975600 A/A 11 10.13 21 16.04 
 A/T 230 12.36 237 15.22 
 T/T 745 11.55 714 15.19 
      
rs11832817 A/A 15 10.15 79 17.24 
 A/G 278 12.67 382 15.31 
 G/G 693 11.39 511 14.85 
      
rs12826079 A/A   6 14.27 
 A/G   115 15.44 
 G/G   851 15.19 
      
rs10773982 A/A 387 11.43 451 14.97 
 A/G 465 12.10 413 15.22 
 G/G 134 11.28 108 16.23 
      
rs11061946 A/A 1 6.45 4 29.74 
 A/G 21 15.51 126 16.86 
 G/G 964 11.65 841 14.91 
      
rs10773983 A/A 547 11.60 105 16.03 
 A/G 374 11.63 391 16.69 
 G/G 65 13.36 475 13.90 
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Table A.5 (continued)  Counts and unadjusted geometric means for adiponectin levels 
(ug/ml) by genotypes of SNPs in ADIPOR2 among black and white women 
 
  Black women White women 
SNP Genotype N 
Geometric 
mean N 
Geometric 
mean 
rs12316367 A/A 20 10.69 279 13.88 
 A/G 257 11.96 480 15.44 
 G/G 709 11.66 213 16.59 
      
rs10773989 A/A 529 11.55 228 16.82 
 A/G 395 12.19 502 14.83 
 G/G 62 10.37 242 14.60 
      
rs2058112 A/A 46 11.76 12 20.49 
 A/G 330 11.53 232 16.19 
 G/G 610 11.82 728 14.84 
      
rs12298275 A/A 908 11.72   
 A/G 77 11.83   
 G/G 1 5.82   
      
rs7134070 A/A 729 11.89   
 A/G 238 11.24   
 G/G 19 11.16   
      
rs7967137 A/A 498 11.80 728 14.84 
 A/G 403 11.61 231 16.22 
 G/G 85 11.76 13 19.35 
      
rs7138701 A/A 38 10.45   
 A/G 301 11.76   
 G/G 647 11.78   
      
rs11614639 A/A 296 11.15 309 14.06 
 A/C 504 11.81 473 15.47 
 C/C 186 12.42 190 16.58 
      
rs10773991 A/A 34 10.97 279 13.98 
 A/G 322 11.97 476 15.33 
 G/G 630 11.63 217 16.66 
      
rs4140993 A/A 691 11.50   
 A/C 266 12.58   
 C/C 29 9.57   
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Table A.5 (continued)  Counts and unadjusted geometric means for adiponectin levels 
(ug/ml) by genotypes of SNPs in ADIPOR2 among black and white women 
 
  Black women White women 
SNP Genotype N 
Geometric 
mean N 
Geometric 
mean 
rs16928751 A/A 48 11.88 13 19.35 
 A/G 341 11.57 231 16.22 
 G/G 597 11.79 728 14.84 
      
rs2286384 C/C 82 10.47 280 14.02 
 C/G 451 11.57 475 15.31 
 G/G 453 12.11 217 16.66 
      
rs12342 A/A 29 12.17 101 16.21 
 A/G 313 12.99 392 15.37 
 G/G 644 11.13 479 14.88 
      
rs1044471 A/A 37 10.20 225 13.40 
 A/G 327 11.91 497 15.48 
 G/G 622 11.72 250 16.47 
      
rs7294540 A/A 724 11.72 173 16.42 
 A/C 247 11.79 471 15.71 
 C/C 15 10.38 328 13.95 
      
rs13219 A/A 22 10.07 327 14.06 
 A/G 268 12.12 464 15.47 
 G/G 696 11.62 181 16.81 
      
rs2058111 A/A 640 11.64 180 16.84 
 A/C 314 12.02 461 15.47 
 C/C 30 10.24 329 14.07 
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Table A.6  Counts and unadjusted means for body mass index (kg/m2) by genotypes of 
SNPs in ADIPOQ  among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs864265 A/A 20 32.05 27 31.79 
 A/C 223 31.09 263 30.54 
 C/C 747 30.17 687 30.21 
      
rs822387 A/A 448 30.32 815 30.23 
 A/G 438 30.87 154 31.05 
 G/G 104 28.89 8 28.18 
      
rs16861194 A/A 567 30.41 817 30.31 
 A/G 375 30.49 154 30.50 
 G/G 48 29.93 6 30.74 
      
rs182052 A/A 111 30.54 121 30.52 
 A/G 477 30.32 431 29.88 
 G/G 402 30.49 425 30.76 
      
rs16861205 A/A 37 30.38 6 30.74 
 A/G 324 30.54 140 30.62 
 G/G 629 30.35 831 30.29 
      
rs822391 A/A 909 30.36 610 30.47 
 A/G 81 30.97 311 29.81 
 G/G   56 31.91 
      
rs16861210 A/A 28 31.50 11 31.13 
 A/G 290 30.79 164 31.05 
 G/G 672 30.21 802 30.19 
      
rs822396 A/A 622 30.64 631 30.45 
 A/G 321 30.12 298 29.83 
 G/G 47 29.47 48 32.14 
      
rs12495941 A/A 143 30.00 104 30.93 
 A/C 453 30.47 452 30.01 
 C/C 394 30.50 421 30.56 
      
rs7649121 A/A 783 30.35 667 30.57 
 A/T 196 30.58 288 29.96 
 T/T 11 31.74 22 28.52 
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Table A.6 (continued)  Counts and unadjusted means for body mass index (kg/m2) by 
genotypes of SNPs in ADIPOQ  among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs9877202 A/A 704 30.71   
 A/G 253 29.59   
 G/G 33 30.39   
      
rs17366568 A/A 1 34.70 19 31.31 
 A/G 28 29.26 226 30.09 
 G/G 961 30.44 732 30.39 
      
rs3821799 A/A 324 30.37 195 30.65 
 A/G 489 30.34 460 30.44 
 G/G 177 30.70 322 30.01 
      
rs3774261 A/A 309 30.47 146 30.26 
 A/G 498 30.31 435 30.51 
 G/G 183 30.61 396 30.18 
      
rs17366743 A/A   926 30.37 
 A/G   48 29.97 
 G/G   3 28.68 
      
rs6444174 A/A 693 30.51   
 A/G 264 30.25   
 G/G 33 29.79   
      
rs1063539 C/C 585 30.59 697 30.15 
 C/G 364 30.28 216 30.82 
 G/G 2 26.84 15 30.61 
      
rs9842733 A/A 8 25.66   
 A/T 162 29.98   
 T/T 820 30.55   
      
rs1403697 A/A 758 30.55   
 A/G 217 29.94   
 G/G 15 30.39   
      
rs7641507 A/A 5 31.67   
 A/G 144 30.82   
 G/G 841 30.34   
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Table A.6 (continued)  Counts and unadjusted means for body mass index (kg/m2) by 
genotypes of SNPs in ADIPOQ  among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs1403696 A/A 46 30.03   
 A/G 328 29.98   
 G/G 616 30.68   
      
rs6444175 A/A 76 30.58 75 30.25 
 A/G 454 30.81 356 30.19 
 G/G 460 30.00 546 30.46 
      
rs7628649 A/A 106 29.61 14 29.43 
 A/G 454 30.03 187 30.97 
 G/G 430 31.02 776 30.21 
      
rs17373414 A/A 1 24.14 15 27.91 
 A/G 20 29.37 199 30.49 
 G/G 969 30.44 763 30.35 
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Table A.7.  Counts and unadjusted means for body mass index (kg/m2) by genotypes of 
SNPs in ADIPOR1 among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs6672643 A/A 550 29.94 735 30.42 
 A/G 366 30.84 215 29.90 
 G/G 73 31.80 26 31.38 
      
rs2185781 A/A 41 30.81 43 29.86 
 A/G 293 30.15 297 30.84 
 G/G 656 30.51 637 30.14 
      
rs4336908 A/A 8 31.62 43 29.86 
 A/G 130 30.09 295 30.78 
 G/G 852 30.45 639 30.17 
      
rs10920531 A/A 297 30.71 148 29.77 
 A/C 458 30.55 409 30.82 
 C/C 235 29.78 420 30.08 
      
rs7539542 C/C 395 30.78 102 28.87 
 C/G 436 30.45 394 30.89 
 G/G 159 29.42 481 30.21 
      
rs1342387 A/A 257 30.40 221 30.24 
 A/G 480 30.57 443 30.23 
 G/G 252 30.08 313 30.57 
      
rs7518457 A/A 876 30.38   
 A/G 109 30.43   
 G/G 5 36.13   
      
rs12045862 A/A 9 31.62 72 29.93 
 A/G 160 30.17 368 30.41 
 G/G 821 30.45 537 30.35 
      
rs2275737 A/A 196 30.08 208 30.20 
 A/C 485 30.74 426 30.30 
 C/C 309 30.11 343 30.48 
      
rs12733285 A/A 51 30.52 91 30.64 
 A/G 322 30.77 403 30.16 
 G/G 617 30.22 483 30.44 
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Table A.7. (continued)  Counts and unadjusted means for body mass index (kg/m2) by 
genotypes of SNPs in ADIPOR1 among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs10753929 A/A 41 29.51 21 29.58 
 A/G 304 30.41 210 30.21 
 G/G 645 30.47 746 30.40 
      
rs1539355 A/A 292 30.24 478 30.19 
 A/G 492 30.71 399 30.43 
 G/G 206 29.97 100 30.69 
      
rs10800888 A/A 12 30.65   
 A/G 224 30.69   
 G/G 754 30.33   
      
rs6666089 A/A 19 30.79 96 30.95 
 A/G 231 30.21 397 30.30 
 G/G 740 30.47 484 30.26 
      
rs7523903 C/C 13 30.46   
 C/G 392 30.28   
 G/G 585 30.50   
      
rs2232849 A/A 9 34.65   
 A/G 163 30.04   
 G/G 818 30.44   
      
rs2232844 A/A 820 30.35   
 A/G 161 30.77   
 G/G 9 29.99   
      
rs2232842 A/A 698 30.51 922 30.38 
 A/G 269 30.41 53 29.78 
 G/G 23 27.68 2 27.52 
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Table A.8. Counts and unadjusted means for body mass index (kg/m2) by genotypes of 
SNPs in ADIPOR2 among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs758027 A/A 804 30.24   
 A/G 174 31.20   
 G/G 11 30.99   
      
rs1029629 A/A 555 30.43 490 30.58 
 A/C 385 30.35 394 30.11 
 C/C 50 30.68 92 30.18 
      
rs7304096 A/A 917 30.38   
 A/G 72 30.82   
 G/G 1 30.90   
      
rs2058033 A/A 939 30.41 744 30.47 
 A/C 50 30.58 209 29.88 
 C/C 1 30.18 24 30.29 
      
rs7975600 A/A 11 33.11 21 29.58 
 A/T 232 29.36 238 30.67 
 T/T 747 30.70 718 30.26 
      
rs11832817 A/A 15 33.19 80 30.24 
 A/G 280 29.46 386 30.25 
 G/G 695 30.74 511 30.43 
      
rs12826079 A/A   6 27.59 
 A/G   117 30.01 
 G/G   854 30.41 
      
rs10773982 A/A 389 30.57 451 30.57 
 A/G 466 30.10 417 30.09 
 G/G 135 31.08 109 30.38 
      
rs11061946 A/A 1 30.18 4 31.86 
 A/G 21 29.99 129 30.10 
 G/G 968 30.42 843 30.38 
      
rs10773983 A/A 550 30.61 106 29.56 
 A/G 375 30.10 395 29.99 
 G/G 65 30.58 475 30.82 
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Table A.8. (continued) Counts and unadjusted means for body mass index (kg/m2) by 
genotypes of SNPs in ADIPOR2 among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs12316367 A/A 20 33.80 279 30.78 
 A/G 257 30.11 483 30.31 
 G/G 713 30.43 215 29.84 
      
rs10773989 A/A 533 30.27 230 29.92 
 A/G 395 30.43 505 30.34 
 G/G 62 31.56 242 30.76 
      
rs2058112 A/A 46 30.92 12 27.20 
 A/G 331 30.30 233 30.13 
 G/G 613 30.44 732 30.46 
      
rs12298275 A/A 912 30.41   
 A/G 77 30.50   
 G/G 1 30.90   
      
rs7134070 A/A 731 30.41   
 A/G 239 30.44   
 G/G 20 30.20   
      
rs7967137 A/A 500 30.61 732 30.46 
 A/G 405 29.94 232 30.11 
 G/G 85 31.52 13 27.80 
      
rs7138701 A/A 39 30.65   
 A/G 302 30.30   
 G/G 649 30.45   
      
rs11614639 A/A 297 30.81 309 30.65 
 A/C 505 30.37 476 30.42 
 C/C 188 29.90 192 29.67 
      
rs10773991 A/A 34 32.24 279 30.77 
 A/G 322 30.19 479 30.37 
 G/G 634 30.43 219 29.73 
      
rs4140993 A/A 692 30.51   
 A/C 269 30.06   
 C/C 29 31.30   
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Table A.8. (continued) Counts and unadjusted means for body mass index (kg/m2) by 
genotypes of SNPs in ADIPOR2 among black and white women 
 
  Black women White women 
SNP Genotype N Mean N Mean 
rs16928751 A/A 48 31.10 13 27.80 
 A/G 343 30.17 232 30.11 
 G/G 599 30.50 732 30.46 
      
rs2286384 C/C 82 31.29 280 30.78 
 C/G 451 30.68 478 30.37 
 G/G 457 30.00 219 29.73 
      
rs12342 A/A 29 29.03 102 30.34 
 A/G 315 29.72 396 30.08 
 G/G 646 30.81 479 30.56 
      
rs1044471 A/A 37 33.61 225 30.57 
 A/G 327 30.52 500 30.44 
 G/G 626 30.17 252 29.93 
      
rs7294540 A/A 728 30.44 175 29.54 
 A/C 247 30.19 474 30.33 
 C/C 15 32.87 328 30.79 
      
rs13219 A/A 22 32.80 327 30.73 
 A/G 268 30.15 467 30.37 
 G/G 700 30.44 183 29.58 
      
rs2058111 A/A 644 30.39 182 29.61 
 A/C 314 30.31 464 30.36 
 C/C 30 31.98 329 30.73 
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Table A.9.  Step-by-step confounding assessment for creation of a linear regression model 
using backwards model selection with log-adiponectin as outcome and BMI as primary 
exposure among white women. 
 
 
 
Covariate 
BMI Change-
in-estimate 
(%) 
 
 
Model action 
BMI -- Forced 
Age at interview -- Forced 
Sample selection (pilot/Komen) -- Forced 
Current PA recommendation met (Yes/No) 0.02 Dropped (step 1) 
Menopause (Pre/Post) 0.01 Dropped (step 2) 
Education 0.01 Dropped (step 3) 
Total protein intake 0.02 Dropped (step 4) 
Number of live births 0.1 Dropped (step 5) 
Alcohol consumption 0.04 Dropped (step 6) 
Total energy intake 0.09 Dropped (step 7) 
Depression (Yes/No) 0.1 Dropped (step 8) 
Total physical activity 0.02 Dropped (step 9) 
Age at first menstrual period 0.03 Dropped (step 10) 
Diabetes 0.3 Dropped (step 11) 
Total fat intake 0.06 Dropped (step 12) 
Cigarette smoking status 0.3 Dropped (step 13) 
High cholesterol (Yes/No) 0.2 Dropped (step 14) 
Total carbohydrate intake 0.7 Dropped (step 15) 
Income 1.5 Dropped (step 16) 
Heart disease (Yes/No) 2.6 Dropped (step 17) 
Hypertension (Yes/No) 1.4 Dropped (step 18) 
HDL cholesterol 37.0 Retained 
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Table A.10.  Step-by-step confounding assessment for creation of a linear regression model 
using backwards model selection with log-adiponectin as outcome and BMI as primary 
exposure among black women.   
 
 
 
Covariate 
BMI Change- 
in-estimate  
(%) 
 
 
Model action 
BMI -- Forced 
Age at interview -- Forced 
Sample selection (pilot/Komen) -- Forced 
Total energy intake 0.04 Dropped (step 1) 
Menopause (Pre/Post) 0.04 Dropped (step 2) 
Depression (Yes/No) 0.04 Dropped (step 3) 
Total fat intake 0.01 Dropped (step 4) 
High cholesterol (Yes/No) 0.1 Dropped (step 5) 
Total physical activity 0.01 Dropped (step 6) 
Current PA recommendation met (Yes/No) 0.004 Dropped (step 7) 
Total protein intake 0.4 Dropped (step 8) 
Heart disease (Yes/No) 0.3 Dropped (step 9) 
Education 0.7 Dropped (step 10) 
Total carbohydrate intake 0.08 Dropped (step 11) 
Number of live births 1.7 Dropped (step 12) 
Income 0.1 Dropped (step 13) 
Diabetes (Yes/No) 2.9 Dropped (step 14) 
Hypertension (Yes/No) 4.8 Dropped (step 15) 
Age at first menstrual period 1.3 Dropped (step 16) 
Alcohol consumption 2.9 Dropped (step 17) 
Cigarette smoking status 3.5 Dropped (step 18) 
HDL cholesterol 56.1 Retained 
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Table A.11.  Step-by-step modeling decisions for 992 white women using Akaike 
Information Criteria (AIC) for multiple linear regression model fit evaluation of prediction 
model for log-adiponectin as outcome.  
  
Model Model covariates in model with lowest AIC AIC (Δ AIC) 
1 Sample selection 
BMI 
 
-694.0 
2 Sample selection 
BMI 
HDL cholesterol 
 
-812.1 (118.1) 
3 Sample selection 
BMI 
HDL cholesterol 
Age 
 
-835.1 (23.0) 
4 Sample selection 
BMI 
HDL cholesterol 
Age 
Hypertension 
 
-836.2 (1.1) 
STOP: No other covariates change AIC > 1 unit 
 
Δ AIC = change in AIC from previous model 
 
Sample selection = Participant selected from SCCS Biospeciman pilot versus Komen Obesity 
Project
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Table A.12.  Step-by-step modeling decisions for 992 black women using Akaike 
Information Criteria (AIC) for multiple linear regression model fit evaluation of prediction 
model for log-adiponectin as outcome.  
  
Model Model covariates in model with lowest AIC AIC (Δ AIC) 
1 Sample selection 
BMI 
 
-629.2 
2 Sample selection 
BMI 
HDL cholesterol 
 
-730.6 (101.3) 
3 Sample selection 
BMI 
HDL cholesterol 
Age 
 
-740.7 (10.8) 
4 Sample selection 
BMI 
HDL cholesterol 
Age 
Hypertension 
 
-743.2 (2.5) 
STOP: No other covariates change AIC > 1 unit 
 
Δ AIC = change in AIC from previous model 
 
Sample selection = Participant selected from SCCS Biospeciman pilot versus Komen Obesity 
Project
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Table A.13.  Beta coefficients and standard errors for body mass index (BMI) term in race-
stratified linear regression models with log-adiponectin as the outcome and adjustment for 
HDL cholesterol and hypertension, by categories of year of birth.  
 
 Black women White women 
   Year of birth N Beta (se) N Beta (se) 
   1924 – 1939      100 -0.031 (0.014) 72 -0.016 (0.011) 
   1940 – 1949 166 -0.015 (0.008) 204 -0.012 (0.009) 
   1950 – 1959 419 -0.034 (0.005) 389 -0.018 (0.006) 
   1960 – 1966 310  -0.028 (0.006) 331 -0.017 (0.006) 
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Table A.14.  Adjusted geometric means for adiponectin levels (ug/ml) and p-values from 
race-stratified linear regression models examining associations between adiponectin and 
ADIPOQ SNPs.  
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p-
value 
Adiponectin  
geometric 
mean df 
p- 
value 
rs864265 A/A 14.44 2 0.14 11.38 2 0.076 
 A/C 12.43   15.88   
 C/C 11.45   15.14   
        
rs822387 A/A 11.87 2 0.13 15.02 1 0.22 
 A/G 11.25   16.23   
 G/G 13.12      
        
rs16861194 A/A 11.91 2 0.50 15.27 1 0.73 
 A/G 11.60   14.93   
 G/G 10.54      
        
rs182052 A/A 11.42 2 0.49 13.54 2 0.10 
 A/G 11.46   15.87   
 G/G 12.11   15.06   
        
rs16861205 A/A 11.15 2 0.64 14.95 1 0.76 
 A/G 11.42      
 G/G 11.91   15.26   
        
rs822391 A/A 11.73 1 0.85 14.99 2 0.47 
 A/G 11.54   15.83   
 G/G    14.34   
        
rs16861210 A/A 12.94 2 0.60 17.64 2 0.11 
 A/G 11.97   16.84   
 G/G 11.56   14.87   
        
rs822396 A/A 11.80 2 0.44 14.99   
 A/G 11.38   15.89   
 G/G 13.06   14.04 2 0.40 
        
rs12495941 A/A 12.14 2 0.28 13.99 2 0.057 
 A/C 11.26   16.14   
 C/C 12.12   14.58   
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Table A.14. (continued)  Adjusted geometric means for adiponectin levels (ug/ml) and p-
values from race-stratified linear regression models examining associations between 
adiponectin and ADIPOQ SNPs. 
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p-
value 
Adiponectin  
geometric 
mean df 
p- 
value 
rs7649121 A/A 11.74 2 0.76 15.36 2 0.69 
 A/T 11.52   14.99   
 T/T 13.52   13.58   
        
rs9877202 A/A 11.69 2 0.54    
 A/G 11.99      
 G/G 10.35      
        
rs17366568 A/A 11.55 1 0.92 9.30 2 0.00036 
 A/G    13.72   
 G/G 11.72   15.91   
        
rs3821799 A/A 11.85 2 0.94 15.21 2 0.95 
 A/G 11.64   15.11   
 G/G 11.70   15.36   
        
rs3774261 A/A 11.65 2 0.96 16.21 2 0.20 
 A/G 11.80   15.57   
 G/G 11.61   14.49   
        
rs17366743 A/A    15.16 1 0.57 
 A/G    16.10   
        
rs6444174 A/A 11.86 2 0.63    
 A/G 11.30      
 G/G 12.19      
        
rs1063539 C/C 11.64 1 0.83 14.87 2 0.20 
 C/G 11.76   16.49   
 G/G    15.06   
        
rs9842733 A/A 11.29 1 0.47    
 T/T 11.81      
        
rs1403697 A/A 11.73 2 0.44    
 A/G 11.48      
 G/G 14.72      
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Table A.14. (continued)  Adjusted geometric means for adiponectin levels (ug/ml) and p-
values from race-stratified linear regression models examining associations between 
adiponectin and ADIPOQ SNPs. 
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p-
value 
Adiponectin 
geometric 
mean df 
p- 
value 
rs7641507 A/A 11.31 1 0.51    
 G/G 11.79      
        
rs1403696 A/A 12.29 2 0.79    
 A/G 11.50      
 G/G 11.80      
        
rs6444175 A/A 12.64 2 0.63 15.85 2 0.51 
 A/G 11.68   15.65   
 G/G 11.61   14.85   
        
rs7628649 A/A 12.00 2 0.73 16.01 2 0.34 
 A/G 11.49   16.30   
 G/G 11.89   14.95   
        
rs17373414 A/A 11.81 1 0.96 22.25 2 0.12 
 A/G    14.82   
 G/G 11.72   15.20   
 
Note: Models include adjustment for age at baseline SCCS interview (continuous) and 
percentage African ancestry (continuous)
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Table A.15.  Adjusted geometric means for adiponectin levels (ug/ml) and p-values from 
race-stratified linear regression models examining associations between adiponectin and 
ADIPOR1 SNPs.   
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df p-value 
Adiponectin  
geometric 
mean df p-value 
rs6672643 G/G 12.50 2 0.60 13.52 2 0.71 
 A/A 11.51   15.24   
 A/G 11.89   15.33   
        
rs2185781 A/A 11.97 2 0.57 15.67 2 0.51 
 A/G 12.14   14.60   
 G/G 11.52   15.48   
        
rs4336908 A/A 11.37 1 0.60 15.67 2 0.53 
 A/G    14.62   
 G/G 11.78   15.46   
        
rs10920531 A/A 11.83 2 0.087 15.37 2 0.84 
 A/C 12.19   14.96   
 C/C 10.73   15.40   
        
rs7539542 C/C 11.90 2 0.10 16.05 2 0.74 
 C/G 12.04   15.11   
 G/G 10.46   15.12   
        
rs1342387 A/A 12.06 2 0.58 14.70 2 0.38 
 A/G 11.77   15.77   
 G/G 11.28   14.81   
        
rs7518457 A/A 11.67 1 0.63    
 A/G 12.09      
        
rs12045862 A/A 11.08 1 0.27 15.87 2 0.68 
 A/G    15.48   
 G/G 11.85   14.94   
        
rs2275737 A/A 12.18 2 0.61 14.44 2 0.32 
 A/C 11.48   15.79   
 C/C 11.81   14.98   
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Table A.15. (continued)  Adjusted geometric means for adiponectin levels (ug/ml) and p-
values from race-stratified linear regression models examining associations between 
adiponectin and ADIPOR1 SNPs.   
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p- 
value 
Adiponectin  
geometric 
mean df 
p- 
value 
rs12733285 A/A 11.92 2 0.99 14.05 2 0.51 
 A/G 11.71   15.51   
 G/G 11.70   15.20   
        
rs10753929 A/A 12.31 2 0.76 18.82 2 0.34 
 A/G 11.94   14.76   
 G/G 11.58   15.25   
        
rs1539355 G/G 12.05 2 0.81 15.11 2 0.88 
 A/A 11.55   15.40   
 A/G 11.68   15.02   
        
rs10800888 A/A 12.86 2 0.87    
 A/G 11.84      
 G/G 11.67      
        
rs6666089 A/A 10.73 2 0.30 14.90 2 0.89 
 A/G 11.05   15.09   
 G/G 11.96   15.38   
        
rs7523903 C/C 12.15 2 0.16    
 C/G 12.36      
 G/G 11.30      
        
rs2232849 A/A 11.92 1 0.73    
 G/G 11.68      
        
rs2232844 A/A 11.68 1 0.73    
 A/G 11.92      
        
rs2232842 A/G 12.13 2 0.024 16.99 1 0.25 
 A/A 11.42   15.11   
 G/G 16.92      
 
Note: Models include adjustment for age at baseline SCCS interview (continuous) and 
percentage African ancestry (continuous)
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Table A.16.  Adjusted geometric means for adiponectin levels (ug/ml) and p-values from 
race-stratified linear regression models examining associations between adiponectin and 
ADIPOR2 SNPs. 
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p- 
value 
Adiponectin 
geometric 
mean df 
p- 
value 
rs758027 G/G 8.46 2 0.13    
 A/G 11.02      
 A/A 11.94      
        
rs1029629 C/C 11.13 2 0.57 16.32 2 0.60 
 A/C 12.06   15.24   
 A/A 11.54   15.00   
        
rs7304096 A/A 11.75 1 0.69    
 A/G 11.34      
        
rs2058033 A/A 11.60 1 0.069 15.04 2 0.47 
 A/C 14.02   15.58   
 C/C    17.86   
        
rs7975600 A/A 9.79 2 0.47 16.73 2 0.83 
 A/T 12.20   15.19   
 T/T 11.60   15.17   
        
rs11832817 A/A 9.87 2 0.16 17.02 2 0.31 
 A/G 12.50   15.30   
 G/G 11.46   14.88   
        
rs12826079 A/A    15.39 1 0.85 
 G/G    15.19   
        
rs10773982 G/G 11.08 2 0.45 16.00 2 0.72 
 A/G 12.05   15.23   
 A/A 11.56   15.01   
        
rs11061946 A/A 14.30 1 0.19 16.76 1 0.10 
 G/G 11.67   14.97   
        
rs10773983 G/G 13.25 2 0.37 14.05 2 0.0035 
 A/G 11.57   16.60   
 A/A 11.65   15.61   
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Table A.16. (continued)  Adjusted geometric means for adiponectin levels (ug/ml) and p-
values from race-stratified linear regression models examining associations between 
adiponectin and ADIPOR2 SNPs.   
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p- 
value 
Adiponectin 
geometric 
mean df 
p- 
value 
rs12316367 A/A 10.58 2 0.72 13.99 2 0.054 
 A/G 11.97   15.49   
 G/G 11.66   16.30   
        
rs10773989 G/G 10.49 2 0.29 14.63 2 0.10 
 A/G 12.13   14.88   
 A/A 11.57   16.65   
        
rs2058112 A/A 11.82 2 0.94 19.68 2 0.17 
 A/G 11.58   16.09   
 G/G 11.78   14.88   
        
rs12298275 A/A 11.73 1 0.87    
 A/G 11.57      
        
rs7134070 G/G 11.55 2 0.60    
 A/G 11.25      
 A/A 11.88      
        
rs7967137 G/G 11.72 2 0.97 18.42 2 0.22 
 A/G 11.64   16.13   
 A/A 11.78   14.88   
        
rs7138701 A/A 10.80 2 0.77    
 A/G 11.83      
 G/G 11.72      
        
rs11614639 C/C 12.35 2 0.41 16.25 2 0.082 
 A/C 11.75   15.54   
 A/A 11.29   14.14   
        
rs10773991 A/A 11.15 2 0.76 14.09 2 0.067 
 A/G 11.98   15.37   
 G/G 11.62   16.40   
        
rs4140993 C/C 9.83 2 0.076    
 A/C 12.63      
 A/A 11.47      
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Table A.16. (continued)  Adjusted geometric means for adiponectin levels (ug/ml) and p-
values from race-stratified linear regression models examining associations between 
adiponectin and ADIPOR2 SNPs.   
 
  Black women White women 
SNP Genotype 
Adiponectin 
geometric 
mean df 
p- 
value 
Adiponectin 
geometric 
mean df 
p- 
value 
rs16928751 A/A 11.92 2 0.96 18.42 2 0.22 
 A/G 11.62   16.13   
 G/G 11.76   14.88   
        
rs2286384 C/C 10.51 2 0.23 14.14 2 0.076 
 C/G 11.57   15.35   
 G/G 12.10   16.40   
        
rs12342 A/A 12.15 2 0.021 15.99 2 0.65 
 A/G 12.85   15.37   
 G/G 11.19   14.93   
        
rs1044471 A/A 10.21 2 0.47 13.50 2 0.016 
 A/G 11.92   15.56   
 G/G 11.71   16.20   
        
rs7294540 C/C 10.23 2 0.76 14.10 2 0.067 
 A/C 11.76   15.73   
 A/A 11.74   16.04   
        
rs13219 A/A 10.13 2 0.45 14.18 2 0.071 
 A/G 12.13   15.51   
 G/G 11.62   16.42   
        
rs2058111 C/C 10.27 2 0.47 14.19 2 0.067 
 A/C 12.05   15.51   
 A/A 11.63   16.48   
 
Note: Models include adjustment for age at baseline SCCS interview (continuous) and 
percentage African ancestry (continuous)
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Table A.17. Adjusted means for body mass index (BMI, kg/m2) and p-values from race 
stratified linear regression models examining BMI and ADIPOQ SNPs. 
 
  Black women White women 
SNP Genotype BMI mean df 
p-
value BMI mean df 
p-
value 
rs864265 A/A 32.10 2 0.070 31.77 2 0.42 
 A/C 31.12   30.53   
 C/C 30.16   30.21   
        
rs822387 A/A 30.38 2 0.014 30.23 1 0.23 
 A/G 30.83   30.91   
 G/G 28.81      
        
rs16861194 A/A 30.42 2 0.86 30.31   
 A/G 30.46   30.50 1 0.75 
 G/G 29.93      
        
rs182052 A/A 30.52 2 0.95 30.52 2 0.14 
 A/G 30.35   29.87   
 G/G 30.46   30.77   
        
rs16861205 A/A 30.32 2 0.93 30.61 1 0.59 
 A/G 30.52      
 G/G 30.36   30.29   
        
rs822391 A/A 30.34 1 0.21 30.48 2 0.073 
 A/G 31.27   29.80   
 G/G    31.86   
        
rs16861210 A/A 31.33 2 0.36 31.07 2 0.28 
 A/G 30.76   31.06   
 G/G 30.23   30.18   
        
rs822396 A/A 30.63 2 0.33 30.45 2 0.068 
 A/G 30.13   29.82   
 G/G 29.54   32.10   
        
rs12495941 A/A 29.98 2 0.68 30.94 2 0.31 
 A/C 30.46   30.01   
 C/C 30.51   30.55   
        
rs7649121 A/A 30.34 2 0.65 30.57 2 0.18 
 A/T 30.66   29.96   
 T/T 31.71   28.50   
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Table A.17. (continued) Adjusted means for body mass index (BMI, kg/m2) and p-values 
from race stratified linear regression models examining BMI and ADIPOQ  SNPs. 
 
  Black women White women 
SNP Genotype BMI mean df 
p-
value BMI mean df 
p-
value 
rs9877202 A/A 30.74 2 0.037    
 A/G 29.54      
 G/G 30.28      
rs17366568 A/A 29.67 1 0.53 31.32 2 0.68 
 A/G    30.10   
 G/G 30.44   30.39   
        
rs3821799 A/A 30.34 2 0.76 30.66 2 0.48 
 A/G 30.35   30.45   
 G/G 30.74   30.00   
        
rs3774261 A/A 30.43 2 0.81 30.27 2 0.74 
 A/G 30.31   30.52   
 G/G 30.66   30.17   
        
rs17366743 A/A    30.37 1 0.64 
 A/G    29.92   
        
rs6444174 A/A 30.51 2 0.74    
 A/G 30.24      
 G/G 29.86      
        
rs1063539 C/C 30.59 1 0.46 30.14 2 0.39 
 C/G 30.27   30.84   
 G/G    30.56   
        
rs9842733 A/A 29.80 1 0.16    
 T/T 30.54      
        
rs1403697 A/A 30.55 2 0.45    
 A/G 29.93      
 G/G 30.65      
        
rs7641507 A/A 30.80 1 0.42    
 G/G 30.35      
        
rs1403696 A/A 30.18 2 0.21    
 A/G 29.93      
 G/G 30.69      
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Table A.17. (continued) Adjusted means for body mass index (BMI, kg/m2) and p-values 
from race stratified linear regression models examining BMI and ADIPOQ  SNPs. 
 
  Black women White women 
SNP Genotype BMI mean df 
p-
value BMI mean df 
p-
value 
rs6444175 A/A 30.55 2 0.22 30.24 2 0.85 
 A/G 30.77   30.20   
 G/G 30.04   30.45   
        
rs7628649 A/A 29.62 2 0.026 29.40 2 0.31 
 A/G 30.03   30.98   
 G/G 31.02   30.20   
        
        
rs17373414 A/A 29.28 1 0.41 27.94 2 0.35 
 A/G    30.50   
 G/G 30.44   30.35   
 
Note: Models include adjustment for age at baseline SCCS interview (continuous) and 
percentage African ancestry (continuous)
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Table A.18. Adjusted means for body mass index (BMI, kg/m2) and p-values from race 
stratified linear regression models examining BMI and ADIPOR1 SNPs.  
 
  Black women White women 
SNP Genotype BMI mean df 
p- 
value BMI mean df 
p- 
value 
rs6672643 A/A 29.97 2 0.028 30.42 2 0.42 
 A/G 30.80   29.90   
 G/G 31.74   31.41   
        
rs2185781 A/A 30.89 2 0.63 29.89 2 0.30 
 A/G 30.14   30.83   
 G/G 30.51   30.14   
        
rs4336908 A/A 30.23 1 0.72 29.89 2 0.39 
 A/G    30.78   
 G/G 30.44   30.17   
        
rs10920531 A/A 30.69 2 0.23 29.78 2 0.15 
 A/C 30.55   30.82   
 C/C 29.80   30.08   
        
rs7539542 C/C 30.74 2 0.10 28.85 2 0.019 
 C/G 30.46   30.89   
 G/G 29.47   30.21   
        
rs1342387 A/A 30.41 2 0.69 30.25 2 0.76 
 A/G 30.54   30.23   
 G/G 30.12   30.57   
        
rs7518457 A/A 30.39      
 A/G 30.62 1 0.71    
        
rs12045862 A/A 30.29 1 0.77 29.93 2 0.86 
 A/G    30.41   
 G/G 30.44   30.35   
        
rs2275737 A/A 30.09 2 0.34 30.21 2 0.88 
 A/C 30.72   30.29   
 C/C 30.15   30.48   
        
rs12733285 A/A 30.63 2 0.44 30.63 2 0.74 
 A/G 30.76   30.16   
 G/G 30.21   30.44   
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Table A.18. (continued) Adjusted means for body mass index (BMI, kg/m2) and p-values 
from race stratified linear regression models examining BMI and ADIPOR1  SNPs. 
 
  Black women White women 
SNP Genotype BMI mean df 
p- 
value BMI mean df 
p- 
value 
rs10753929 A/A 29.44 2 0.59 29.59 2 0.82 
 A/G 30.38   30.22   
 G/G 30.49   30.40   
        
rs1539355 A/A 30.24 2 0.34 30.20 2 0.75 
 A/G 30.70   30.43   
 G/G 29.99   30.69   
        
rs10800888 A/A 30.39 2 0.80    
 A/G 30.66      
 G/G 30.34      
        
rs6666089 A/A 30.91 2 0.86 30.95 2 0.64 
 A/G 30.24   30.30   
 G/G 30.45   30.26   
        
rs7523903 C/C 30.41 2 0.86    
 C/G 30.28      
 G/G 30.51      
        
rs2232849 A/A 30.24 1 0.70    
 G/G 30.45      
        
rs2232844 A/A 30.35 1 0.50    
 A/G 30.71      
        
rs2232842 A/A 30.50 2 0.10 30.38 1 0.44 
 A/G 30.42   29.68   
 G/G 27.58      
 
Note: Models include adjustment for age at baseline SCCS interview (continuous) and 
percentage African ancestry (continuous)
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Table A.19. Adjusted means for body mass index (BMI, kg/m2) and p-values from race 
stratified linear regression models examining BMI and SNPs in ADIPOR2.  
 
  Black women White women 
SNP Genotype BMI mean df 
p- 
value BMI mean df 
p- 
value 
rs758027 A/A 30.25 2 0.23    
 A/G 31.15      
 G/G 30.89      
        
rs1029629 A/A 30.39 2 0.96 30.58 2 0.55 
 A/C 30.41   30.11   
 C/C 30.67   30.17   
   1 0.59    
rs7304096 A/A 30.38      
 A/G 30.80      
        
rs2058033 A/A 30.40 1 0.77 30.48 2 0.51 
 A/C 30.67   29.88   
 C/C    30.27   
        
rs7975600 A/A 33.36 2 0.0085 29.61 2 0.62 
 A/T 29.41   30.66   
 T/T 30.68   30.26   
        
rs11832817 A/A 33.35 2 0.0062 30.23 2 0.91 
 A/G 29.53   30.25   
 G/G 30.71   30.43   
        
rs12826079 A/A    29.89 1 0.42 
 G/G    30.41   
        
rs10773982 A/A 30.52 2 0.22 30.57 2 0.56 
 A/G 30.11   30.09   
 G/G 31.16   30.37   
        
rs11061946 A/A 30.20 1 0.87 30.13 1 0.68 
 G/G 30.42   30.38   
        
rs10773983 A/A 30.57 2 0.55 29.53 2 0.068 
 A/G 30.13   29.98   
 G/G 30.72   30.84   
        
rs12316367 A/A 34.01 2 0.033 30.79 2 0.27 
 A/G 30.16   30.31   
 G/G 30.40   29.82   
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Table A.19. (continued) Adjusted means for body mass index (BMI, kg/m2) and p-values 
from race stratified linear regression models examining BMI and ADIPOR2  SNPs. 
 
  Black women White women 
SNP Genotype BMI mean df 
p- 
value BMI mean df 
p- 
value 
rs10773989 A/A 30.25 2 0.28 29.91 2 0.38 
 A/G 30.45   30.34   
 G/G 31.60   30.76   
        
rs2058112 A/A 30.83 2 0.79 27.16 2 0.20 
 A/G 30.25   30.12   
 G/G 30.47   30.46   
        
rs12298275 A/A 30.41 1 0.90    
 A/G 30.50      
        
rs7134070 A/A 30.41 2 0.96    
 A/G 30.45      
 G/G 30.02      
        
rs7967137 A/A 30.65 2 0.063 30.46 2 0.28 
 A/G 29.91   30.10   
 G/G 31.46   27.75   
        
rs7138701 A/A 30.47 2 0.92    
 A/G 30.29      
 G/G 30.47      
        
rs11614639 A/A 30.76 2 0.34 30.65 2 0.24 
 A/C 30.40   30.42   
 C/C 29.89   29.65   
        
rs10773991 A/A 32.26 2 0.21 30.78 2 0.20 
 A/G 30.23   30.38   
 G/G 30.41   29.71   
        
rs4140993 A/A 30.51 2 0.55    
 A/C 30.09      
 C/C 31.11      
        
rs16928751 A/A 31.02 2 0.53 27.75 2 0.28 
 A/G 30.13   30.10   
 G/G 30.53   30.46   
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Table A.19. (continued) Adjusted means for body mass index (BMI, kg/m2) and p-values 
from race stratified linear regression models examining BMI and SNPs in ADIPOR2. 
 
  Black women White women 
SNP Genotype BMI mean df 
p- 
value BMI mean df 
p- 
value 
rs2286384 C/C 31.28 2 0.11 30.79 2 0.20 
 C/G 30.69   30.37   
 G/G 29.98   29.71   
        
rs12342 A/A 29.05 2 0.040 30.33 2 0.57 
 A/G 29.79   30.08   
 G/G 30.78   30.56   
        
rs1044471 A/A 33.71 2 0.0040 30.58 2 0.48 
 A/G 30.53   30.45   
 G/G 30.16   29.92   
        
rs7294540 A/A 30.41 2 0.23 29.51 2 0.12 
 A/C 30.25   30.33   
 C/C 33.16   30.80   
        
rs13219 A/A 32.96 2 0.15 30.74 2 0.15 
 A/G 30.20   30.37   
 G/G 30.42   29.56   
        
rs2058111 A/A 30.37 2 0.34 29.58 2 0.17 
 A/C 30.33   30.36   
 C/C 32.10   30.74   
 
Note: Models include adjustment for age at baseline SCCS interview (continuous) and 
percentage African ancestry (continuous).
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Table A.20.  Final multiple linear regression model results for adiponectin-BMI model after confounder adjustment for entire 
study sample (N=1,992) and subset of women who gave a fasting blood sample (N=870). 
 
 Entire sample Fasting subset 
 Βeta Std err p-value Βeta Std err p-value 
WHITE WOMEN 
    Body Mass Index (kg/m2) -0.030 0.003 <.0001 -0.030 0.005 <.0001 
    Age at interview (years) 0.014 0.002 <.0001 0.018 0.004 <.0001 
    HDL-cholesterol (mg/dl)       
        Q1 (<43) Referent      
        Q2  (43-50) 0.30 0.053 <.0001 0.22 0.083 0.009 
        Q3  (51-60) 0.42 0.057 <.0001 0.39 0.086 <.0001 
        Q4  (>60) 0.68 0.062 <.0001 0.75 0.10 <.0001 
       
BLACK WOMEN       
    Body Mass Index (kg/m2) -0.018 0.004 <.0001 -0.012 0.005 0.02 
    Age at interview (years) 0.009 0.002 0.0003 0.006 0.004 0.13 
    HDL-cholesterol (mg/dl)       
        Q1 (<43) Referent      
        Q2  (43-50) 0.17 0.067 0.01 0.20 0.10 0.045 
        Q3  (51-60) 0.53 0.067 <.0001 0.61 0.10 <.0001 
        Q4  (>60) 0.59 0.064 <.0001 0.59 0.10 <.0001 
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Figure A.1a. - log10(p-value) from linear regression models with log-adiponectin as 
outcome and SNPs in ADIPOQ as exposure of interest among black and white women.  
Models were adjusted for age at interview and percentage of African ancestry. 
 
  239
 
(p=0.05)
(p=0.10)
(p=0.0007)*
* Bonferroni p-value
5’
0
0.5
1
1.5
2
2.5
3
3.5
4
rs6
67
26
43
rs2
18
57
81
rs4
33
69
08
rs1
09
20
53
1
rs7
53
95
42
rs1
34
23
87
rs7
51
84
57
rs1
20
45
86
2
rs2
27
57
37
rs1
27
33
28
5
rs1
07
53
92
9
rs1
53
93
55
rs1
08
00
88
8
rs6
66
60
89
rs7
52
39
03
rs2
23
28
49
rs2
23
28
44
rs2
23
28
42
-lo
g1
0(
p-
va
lu
e)
Black women White women
5’ 3’
 
Figure A.1b. - log10(p-value) from linear regression models with log-adiponectin as 
outcome and SNPs in ADIPOR1 as exposure of interest among black and white women.  
Models were adjusted for age at interview and percentage of African ancestry. 
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Figure A.1c. - log10(p-value) from linear regression models with log-adiponectin as 
outcome and SNPs in ADIPOR2 as exposure of interest among black and white women.  
Models were adjusted for age at interview and percentage of African ancestry. 
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Figure A.2a. - log10(p-value) from linear regression models with body mass index (BMI) as 
outcome and SNPs in ADIPOQ as exposure of interest among black and white women.  
Models were adjusted for age at interview and percentage of African ancestry.  
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Figure A.2b. - log10(p-value) from linear regression models with body mass index (BMI) as 
outcome and SNPs in ADIPOR1 as exposure of interest among black and white women.  
Models were adjusted for age at interview and percentage of African ancestry. 
  243
 
(p=0.05)
(p=0.10)
(p=0.0007)*
* Bonferroni p-value
0
0.5
1
1.5
2
2.5
3
3.5
4
rs7
58
02
7
rs1
02
96
29
rs7
30
40
96
rs2
05
80
33
rs7
97
56
00
rs1
18
32
81
7
rs1
28
26
07
9
rs1
07
73
98
2
rs1
10
61
94
6
rs1
07
73
98
3
rs1
23
16
36
7
rs1
07
73
98
9
rs2
05
81
12
rs1
22
98
27
5
rs7
13
40
70
rs7
96
71
37
rs7
13
87
01
rs1
16
14
63
9
rs1
07
73
99
1
rs4
14
09
93
rs1
69
28
75
1
rs2
28
63
84
rs1
23
42
rs1
04
44
71
rs7
29
45
40
rs1
32
19
rs2
05
81
11
-lo
g1
0(
pv
al
ue
)
Black women White women
5’ 3’
 
 
Figure A.2c. - log10(p-value) from linear regression models with body mass index (BMI) as 
outcome and SNPs in ADIPOR2 as exposure of interest among black and white women.  
Models were adjusted for age at interview and percentage of African ancestry 
